<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001535" GROUP_ID="RENAL" ID="842099081714110126" MERGED_FROM="" MODIFIED="2008-05-15 00:23:19 +0200" MODIFIED_BY="Narelle Willis" REVIEW_NO="034" REVMAN_SUB_VERSION="5.0.8" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2008-05-15 00:23:19 +0200" MODIFIED_BY="Narelle Willis">
<TITLE>Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women</TITLE>
<CONTACT MODIFIED="2008-05-15 00:23:19 +0200" MODIFIED_BY="Narelle Willis"><PERSON ID="9193" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Monika</FIRST_NAME><LAST_NAME>Lutters</LAST_NAME><POSITION>Stellvertretende Leiterin</POSITION><EMAIL_1>Monika.Lutters@ksb.ch</EMAIL_1><ADDRESS><DEPARTMENT>Apotheke</DEPARTMENT><ORGANISATION>Kantonsspital Baden</ORGANISATION><CITY>Baden</CITY><ZIP>CH-5404</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 56 4863943</PHONE_1><FAX_1>+41 56 4863949</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-05-15 00:23:19 +0200" MODIFIED_BY="Narelle Willis"><PERSON ID="9193" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Monika</FIRST_NAME><LAST_NAME>Lutters</LAST_NAME><POSITION>Stellvertretende Leiterin</POSITION><EMAIL_1>Monika.Lutters@ksb.ch</EMAIL_1><ADDRESS><DEPARTMENT>Apotheke</DEPARTMENT><ORGANISATION>Kantonsspital Baden</ORGANISATION><CITY>Baden</CITY><ZIP>CH-5404</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 56 4863943</PHONE_1><FAX_1>+41 56 4863949</FAX_1></ADDRESS></PERSON><PERSON ID="16157" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nicole</FIRST_NAME><MIDDLE_INITIALS>B</MIDDLE_INITIALS><LAST_NAME>Vogt-Ferrier</LAST_NAME><POSITION>Médecin Associé</POSITION><EMAIL_1>Nicole-B.Vogt-Ferrier@hcuge.ch</EMAIL_1><ADDRESS><DEPARTMENT>Unité de Gérontopharmacologie Clinique</DEPARTMENT><ORGANISATION>Hôpitaux Universitaires de Genève</ORGANISATION><ADDRESS_1>3, Chemin Pont-Bochet</ADDRESS_1><CITY>Thônex</CITY><ZIP>CH-1226</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 22 3056518</PHONE_1><FAX_1>+41 22 3056115</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-05-07 13:06:59 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="7" MONTH="5" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="5" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="18" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2008-05-15 08:18:21 +1000" MODIFIED_BY="Narelle S Willis">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-05-15 08:18:21 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="7" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>2 new studies added, new outcomes.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="27" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-05-15 08:17:58 +1000" MODIFIED_BY="Narelle S Willis">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-05-15 08:17:58 +1000" MODIFIED_BY="Narelle S Willis">
<DATE DAY="8" MONTH="1" YEAR="2004"/>
<DESCRIPTION>
<P>New search, no new trials</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-05-09 15:22:15 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-05-09 15:18:35 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-05-06 16:05:29 +1000" MODIFIED_BY="Narelle S Willis">Antibiotic duration for treating uncomplicated symptomatic lower urinary tract infection in elderly women</TITLE>
<SUMMARY_BODY MODIFIED="2008-05-09 15:18:35 +1000" MODIFIED_BY="[Empty name]">
<P>As people age (especially women), they become more prone to infections in the bladder (UTI - urinary tract infections). Older people are more likely to have adverse reactions to drugs. Up to the present time older women with uncomplicated UTI were treated longer than younger patients - without any scientific evidence and with an increased risk of adverse drug reactions. We defined three groups of treatment durations: single-dose, short (3 to 6 days) and longer courses (7 to 14 days).</P>
<P>We identified 15 studies (1644 elderly women) comparing single dose, short-course (3 to 6 days) and long course (7 to 14 days) antibiotic treatment for uncomplicated symptomatic UTI in elderly women. Our review suggests that single dose treatments are less effective than short or long courses, but better accepted by the patients. On the other hand longer courses may have more side effects. On the basis of the evidence available at present, an antibiotic treatment of 3 to 6 days could be sufficient for treating uncomplicated UTIs in elderly women, although more studies on specific, commonly prescribed antibiotics are needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-05-09 15:18:39 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-05-06 15:57:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Urinary tract infections (UTI) are common in elderly patients. Authors of non systematic literature reviews often recommend longer treatment durations (7 to 14 days) for older women, but the evidence for such recommendations is unclear.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the optimal duration of antibiotic treatment for uncomplicated symptomatic lower UTI in elderly women.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-05-07 15:52:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>We contacted known investigators and pharmaceutical companies, screened reference lists of identified articles, reviews and books, and searched MEDLINE, EMBASE, CINAHL, Healthstar, Popline, Gerolit, Bioethics Line, <I>The Cochrane Library</I>, Dissertation Abstracts International and Index to Scientific &amp; Technical Proceedings without language restriction.<BR/>
<I>Date of most recent search: 7 May 2008.</I>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-05-07 15:52:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>All randomised controlled trials (RCTs) comparing different treatment durations of oral antibiotics for uncomplicated symptomatic lower UTIs in elderly women were included. Whenever possible we obtained outcome data for older women included in studies with a broader age range<I>. </I>We excluded patients with fever, flank pain or complicating factors; studies with treatment durations longer than 14 days and prevention studies.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-05-07 15:53:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>The two authors independently assessed study quality and extracted data. Statistical analyses were performed using the random effects model and results expressed as risk ratio (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-05-09 15:18:39 +1000" MODIFIED_BY="[Empty name]">
<P>Fifteen studies (1644 elderly women) were included. Three studies compared single dose with short-course treatment (3 to 6 days), six compared single dose with long-course treatment (7 to 14 days) and six compared short- with long-course treatment. Methodological quality of all studies was low except for a more recent geriatric study. There was a significant difference for persistent UTI between single dose and short-course treatment (RR 2.01, 95% CI 1.05 to 3.84) and single versus long-course treatment (RR 1.93, 1.01 to 3.70 95% CI), in the short-term (&lt; 2 weeks post-treatment) but not at long-term follow-up or on clinical outcomes. Patients preferred single dose treatment (RR 0.73, 95% CI 0.60 to 0.88) to long-course treatments, but this was based on one study comparing different antibiotics. Short versus longer treatments showed no significant difference in efficacy. Rate of adverse drug reactions increased significantly with longer treatment durations<I> </I>in only one study.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-05-08 13:02:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>Short-course treatment (3 to 6 days) could be sufficient for treating uncomplicated UTIs in elderly women, although more studies on specific commonly prescribed antibiotics are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-05-09 15:22:15 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-05-09 15:17:25 +1000" MODIFIED_BY="[Empty name]">
<P>Urinary tract infections (UTIs) are very common in older people. It is the most frequent bacterial infection recorded in older people, followed by pneumonia and skin/soft tissue infections (<LINK REF="REF-Emori-1991" TYPE="REFERENCE">Emori 1991</LINK>; <LINK REF="REF-Michel-1991" TYPE="REFERENCE">Michel 1991</LINK>; <LINK REF="REF-Smith-1994" TYPE="REFERENCE">Smith 1994</LINK>). Bacteriuria is present in less than 5% of women and less than 0.1% of men in the young to middle-age age range (<LINK REF="REF-Kaye-1980" TYPE="REFERENCE">Kaye 1980</LINK>), compared with at least 20% of women and 10% of men over the age of 65 (<LINK REF="REF-Sobel-1990" TYPE="REFERENCE">Sobel 1990</LINK>). The prevalence of bacteriuria depends on where a person is living and is very high in institutionalised women with functional disability (25% to 50%) (<LINK REF="REF-Abrutyn-1991" TYPE="REFERENCE">Abrutyn 1991</LINK>; <LINK REF="REF-Nicolle-1993" TYPE="REFERENCE">Nicolle 1993</LINK>).</P>
<P>The causes of the increased susceptibility to UTI in older people are multiple: decline in cell-mediated immunity, altered bladder defences due to obstructive uropathy, neurogenic bladder dysfunction, increased bacterial receptivity of uroepithelial cells (<LINK REF="REF-Reid-1984" TYPE="REFERENCE">Reid 1984</LINK>), increased risk of contamination due to faecal and urinary incontinence as well as urethral instrumentation and catheterization, and decrease in prostatic and vaginal antibacterial factors associated with changes in zinc levels, urinary and vaginal pH, and hormones, especially lack of estrogens (<LINK REF="REF-Sant-1987" TYPE="REFERENCE">Sant 1987</LINK>).</P>
<P>The bacteriological features of UTI also differ between elderly and young patients. <I>Escherichia coli </I>and <I>Staphylococcus saprophyticus</I> are the most common causative organisms of UTI in young adults, accounting for 80% to 90% of all cases (<LINK REF="REF-Winickoff-1981" TYPE="REFERENCE">Winickoff 1981</LINK>). <I>E. coli </I>is also the most common pathogen in elderly women, varying from 90% in outpatients to 45% in hospitalised patients. In contrast with younger people, <I>Proteus</I>, <I>Klebsiella</I>, <I>Enterobacter</I>, <I>Serratia</I>, <I>Pseudomonas</I> spp., and other gram-negative bacteria as well as enterococci are also frequently encountered (<LINK REF="REF-Kunin-1987" TYPE="REFERENCE">Kunin 1987</LINK>). <I>S. saprophyticus</I> is very rarely isolated in older people. In addition, elderly patients often show a different response to treatment (<LINK REF="REF-Harding-1991" TYPE="REFERENCE">Harding 1991</LINK>; <LINK REF="REF-Nolan-1988" TYPE="REFERENCE">Nolan 1988</LINK>). The most important factors that affect pharmacokinetic and pharmacodynamic drug response in elderly patients are a decline in renal function, reduced body weight, decreased response to homeostatic changes, presence of multiple underlying disease, and polypharmacy, which lead to an increased risk of drug interactions and toxicity (<LINK REF="REF-Borrego-1997" TYPE="REFERENCE">Borrego 1997</LINK>). All these differences suggest that older patients with UTI need a different treatment approach than younger patients.</P>
<P>UTIs are classified as either asymptomatic or symptomatic UTIs. Symptomatic UTI include uncomplicated lower (cystitis) and upper UTI (pyelonephritis) and complicated infections of the lower or upper urinary tract (<LINK REF="REF-Stamm-1992" TYPE="REFERENCE">Stamm 1992</LINK>; <LINK REF="REF-Wood-1996" TYPE="REFERENCE">Wood 1996</LINK>). UTIs in men are considered as complicated infections.</P>
<P>In young women with uncomplicated lower UTI, many studies have shown that short-term treatments with antibiotics (1 to 3 days) are as effective as the traditional longer treatments (7 to 14 days), are less expensive, associated with fewer side effects and result in better compliance. However, the results from several studies and two systematic reviews have shown that single-dose treatment is less effective than longer treatments (<LINK REF="REF-Norrby-1990" TYPE="REFERENCE">Norrby 1990</LINK>; <LINK REF="REF-Warren-1999" TYPE="REFERENCE">Warren 1999</LINK>). Most authors, including the Infectious Diseases Society of America, recommend a 3-day treatment for lower, uncomplicated UTI in young women (<LINK REF="REF-Norrby-1990" TYPE="REFERENCE">Norrby 1990</LINK>; <LINK REF="REF-Warren-1999" TYPE="REFERENCE">Warren 1999</LINK>). In elderly women, the situation is less clear. Excessively long antimicrobial therapy may have negative implications with respect to community levels of antimicrobial resistance<I> </I>(<LINK REF="REF-Goessens-2007" TYPE="REFERENCE">Goessens 2007</LINK>; <LINK REF="REF-Tam-2007" TYPE="REFERENCE">Tam 2007</LINK>).<I>

<BR/>

</I>
<BR/>We performed a critical quality assessment of the many published review articles on UTIs in older people (<LINK REF="REF-Lutters-2000" TYPE="REFERENCE">Lutters 2000</LINK>). The overall methodological quality was low (mean score 2.0 ± 1.1 on a scale of 9). In particular, none of the identified reviews specified the methods of identifying, selecting and validating the included information. The resulting treatment recommendations varied enormously, especially for the treatment duration for uncomplicated lower UTI in elderly women, which differed from 3 to 10 days (<LINK REF="REF-Wood-1996" TYPE="REFERENCE">Wood 1996</LINK>). Many authors did not recommend short treatment (1 to 3 days) in elderly women because it is said to be less effective than in younger women (<LINK REF="REF-Baldassarre-1991" TYPE="REFERENCE">Baldassarre 1991</LINK>; <LINK REF="REF-Humbert-1992" TYPE="REFERENCE">Humbert 1992</LINK>; <LINK REF="REF-Nicolle-1992" TYPE="REFERENCE">Nicolle 1992</LINK>; <LINK REF="REF-Nygaard-1996" TYPE="REFERENCE">Nygaard 1996</LINK>; <LINK REF="REF-Stamm-1993" TYPE="REFERENCE">Stamm 1993</LINK>). However, this recommendation was based either on previous review articles or on results from three studies which did not specifically assess efficacy in elderly women. Indeed, two of these studies compared women over and under 40 years old (<LINK REF="STD-Pfau-1984" TYPE="STUDY">Pfau 1984</LINK>; <LINK REF="STD-Saginur-1992" TYPE="STUDY">Saginur 1992</LINK>). The participants mean age was 26 in one study and 36 years in the other (<LINK REF="STD-Pfau-1984" TYPE="STUDY">Pfau 1984</LINK>; <LINK REF="STD-Saginur-1992" TYPE="STUDY">Saginur 1992</LINK>). The third study included only women with urinary catheters, i.e. complicated UTI (<LINK REF="REF-Harding-1991" TYPE="REFERENCE">Harding 1991</LINK>).</P>
<P>Since this survey, the Infectious Diseases Society of America published guidelines on the treatment of UTI based on an extensive review of the literature using meta-analytical techniques (<LINK REF="REF-Warren-1999" TYPE="REFERENCE">Warren 1999</LINK>). However their findings applied primarily to younger women and did not include clinical outcomes like improvement of urinary symptoms.</P>
<P>We performed this systematic review to determine the optimal treatment duration of uncomplicated symptomatic lower UTIs in elderly women. Men and patients with upper or complicated UTI were excluded from this review because they usually require longer and more aggressive treatment (<LINK REF="REF-Baldassarre-1991" TYPE="REFERENCE">Baldassarre 1991</LINK>; <LINK REF="REF-Childs-1996" TYPE="REFERENCE">Childs 1996</LINK>; <LINK REF="REF-Nicolle-1994" TYPE="REFERENCE">Nicolle 1994</LINK>; <LINK REF="REF-Wood-1996" TYPE="REFERENCE">Wood 1996</LINK>) Patients with asymptomatic UTI werealso be excluded, because there is consensus in the medical literature that elderly patients without symptoms should not be treated (<LINK REF="REF-Humbert-1992" TYPE="REFERENCE">Humbert 1992</LINK>).</P>
<P>First published in 2002, our objective is to update this review as new studies appear.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-05-07 13:12:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>To determine the benefits (clinical and bacteriological efficacy) and harms (adverse drug reactions) of different durations of antibiotic treatment for uncomplicated symptomatic lower UTIs in elderly women.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials (RCTs) comparing different treatment durations of oral antibiotics for uncomplicated lower UTIs in elderly women. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-05-08 13:09:29 +1000" MODIFIED_BY="Narelle S Willis">
<P>Elderly women (over 60 years old or as defined by the study), with acute uncomplicated lower UTI, (i.e. symptoms of dysuria, urgency, frequency or suprapubic pain) and a significant positive urine culture (&#8805; 10³ colony forming units (cfu)/mL) and pyuria (&#8805; 5 leukocytes/mm³) (<LINK REF="REF-Naber-1990" TYPE="REFERENCE">Naber 1990</LINK>; <LINK REF="REF-Rubin-1992" TYPE="REFERENCE">Rubin 1992</LINK>; <LINK REF="REF-Stamm-1992" TYPE="REFERENCE">Stamm 1992</LINK>). Studies including other persons (e.g. men, younger persons, patients with asymptomatic bacteriuria) were included if those patients made up &#8804; 20% of all participants or if separate data for elderly women were available. If a study included such a mixed population without giving details on subgroups, we contacted the authors of the study to ask for separate data for the group of elderly women with acute uncomplicated lower UTI.</P>
<P>Patients with pyelonephritis (symptoms of fever or flank pain) and those with complicating factors such as indwelling or intermittent urinary catheters, &gt; 100 mL post-void residual urine, obstructive uropathy, vesicoureteral reflux and other urological abnormalities, azotaemia due to intrinsic kidney disease or kidney transplantation, were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-08 13:10:02 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Treatment group</HEADING>
<P>Any oral antibiotic treatment used for the treatment of UTI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Control group</HEADING>
<P>Any oral antibiotic treatment with a different treatment duration.</P>
<P>We preferred studies comparing the same antibiotic with the same dosage (except when a single dose is used), but a different treatment duration. We included only antibiotic treatments used at a dose recommended in an official pharmacopoeia for the treatment of lower uncomplicated UTI.<BR/>We also included studies comparing a different antibiotic with a different treatment duration, because they provided more information, especially on clinical outcomes. However, these studies are confounded by the different antibiotics used (see discussion).</P>
<P>To anticipate large variations in durations, we defined the following categories of duration and made comparisons between these:</P>
<OL>
<LI>Single dose</LI>
<LI>Short-course (3 to 6 days)</LI>
<LI>Long-course (7 to 14 days)</LI>
<LI>3 to 14 days (combination of group 2 and 3)</LI>
</OL>
<P>Longer as well as prophylactic treatments were excluded.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-05-07 13:12:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Studies which measured at least one of the following outcomes (as defined in the study report):<BR/>
</P>
<UL>
<LI>clinical treatment failure: persistence of urinary symptoms (i.e. dysuria, frequency, urgency and suprapubic pain), as study defined</LI>
<LI>mental and functional status (e.g. confusion, weakness, falls)</LI>
<LI>incidence of new symptoms of cystitis (after initial clinical cure)</LI>
<LI>development of pyelonephritis, urosepsis or other renal complications</LI>
<LI>long-term mortality, all cause and related to UTI</LI>
<LI>total rate of adverse drug reactions (as study defined)</LI>
<LI>discontinuations of treatment due to adverse drug reactions</LI>
<LI>quality of life</LI>
<LI>convenience for the patient (e.g. compliance, satisfaction with the treatment)</LI>
<LI>persistent UTI (significant positive urine culture at follow-up: &#8805; 10³ cfu/mL)</LI>
<LI>recurrence of bacterial infection after initial eradication of bacteria (i.e. relapse with the same organism or reinfection with a different one)</LI>
</UL>
<P>We anticipated that studies would report outcomes at different time points. If possible, outcomes were to be recalculated for common time points from the raw data. As this was not possible, outcomes were pooled for short-term effects (i.e. during, immediately after or up to two weeks post-treatment) and long-term effects (&gt; two weeks post-treatment).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-05-08 13:15:11 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Initial search</HEADING>
<P>We searched the following databases: MEDLINE, EMBASE, CINAHL, Healthstar, Popline, Gerolit, Bioethics Line, <I>The Cochrane Library</I>, the trial register of the Cochrane Renal Group, Dissertation Abstracts International (1991-95), Index to Scientific &amp; Technical Proceedings (1978-85).</P>
<P>In MEDLINE, the first two sections of the optimal MEDLINE search strategy (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) were applied to identify RCTs, and combined with the terms used in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> - <I>Electronic Databases</I>
</P>
<P>EMBASE was searched by a professional librarian.</P>
<P>For the other databases a similar, often simplified search strategy was used.</P>
<P>The reference lists of identified articles, reviews, books and book chapters on the treatment of infections in older people were searched. Available abstracts of conferences in the fields of infectious diseases, geriatric medicine and pharmacology were screened. Unpublished data were sought from known authors working in this field as well as from pharmaceutical companies marketing antibiotics that are used in UTIs.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Review updates</HEADING>
<P>For updates, electronic searches in CENTRAL, the Cochrane Renal Group's specialised register and MEDLINE were performed.</P>
<P>No language restriction was applied. Articles written in languages other than those familiar to the authors have been translated and evaluated by native speakers.</P>
<P>
<I>Date of most recent search: May 2008</I>
</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-05-09 15:19:04 +1000" MODIFIED_BY="[Empty name]">
<P>Study selection and data extraction were independently performed by both authors, using specifically designed forms (available on request from the authors). Authors were not blinded to authors or text source, because a RCT has shown that blinding did not significantly decrease bias when conducting meta-analyses of RCTs (<LINK REF="REF-Berlin-1997" TYPE="REFERENCE">Berlin 1997</LINK>). Discrepancies were resolved by discussion, or, if no consensus could be reached, by seeking advice from a third party. Where important data have not been reported, triallists were contacted to get the necessary information.</P>
<P>The following data were extracted for each included study:<BR/>
</P>
<UL>
<LI>study design</LI>
<LI>method of randomizations</LI>
<LI>blinding</LI>
<LI>number of participants</LI>
<LI>exclusions after randomizations</LI>
<LI>loss-to-follow-up</LI>
<LI>setting (community, long-stay institution, hospital)</LI>
<LI>description of the study population</LI>
<LI>detailed description of the treatments used (substance, galenical form, dosage, duration)</LI>
<LI>description and results of all measured outcomes</LI>
</UL>
<P>The level of allocation concealment was assessed using the criteria described in the Cochrane Handbook (<LINK REF="REF-Mulrow-1994" TYPE="REFERENCE">Mulrow 1994</LINK>). Studies were graded A if the assigned treatment was adequately concealed prior to allocation, B if there was inadequate information to judge concealment, and C if the assigned treatment was clearly not concealed prior to allocation. All data were analysed together, and then a subgroup analysis was performed to determine if the inclusion of lower quality studies (levels B and C) affects the overall result. To further test the robustness of the results, we planned to perform several other subgroup analyses (if enough studies were available):<BR/>
</P>
<UL>
<LI>blinded versus non blinded studies</LI>
<LI>studies with a high versus a low drop-out rate</LI>
<LI>studies including only elderly persons versus studies with a mixed population.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="3">Statistical assessment</HEADING>
<P>Risk ratio (RR) and 95% confidence intervals (CI) were used for dicotomous outcomes and mean difference (MD) for continuous outcomes. Heterogeneity was tested using the I² statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). I² values of 25%, 50% and 75% correspond to low, medium and high levels of heterogeneity. The RR from each study were combined using a random effects model. If enough studies were identified, variables which are likely to influence the outcome of the studies were assessed in subgroup analyses. Such variables include:<BR/>
</P>
<UL>
<LI>studies comparing the same antibiotic</LI>
<LI>different antibiotic classes (e.g. beta-lactams, quinolones) or molecules</LI>
<LI>place of residence (community, long-stay institution, hospital)</LI>
<LI>patients' age (over 75 years old).</LI>
</UL>
<P>We planned to use the funnel plot approach to assess the likelihood of publication bias.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-05-08 13:31:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Our initial literature search identified more than 7000 references (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> - <I>Results of Initial Search</I>). After triage of titles and abstracts, we retained 69 articles (of 56 authors) that could be included in our review. However, most of these articles did not report precise age data of included patients, and a subgroup analysis of elderly patients was often missing. We contacted the authors of all these studies, but we got either no answer, the raw data were no longer available or they only included younger patients. We finally included only those studies which were done in elderly populations or which reported separate outcome data for elderly patients.</P>
<P>In most of the cases, the two authors took the same decision of selection or non-selection of identified references (94%). Although they screened only a part of all identified references two times independently, none of the finally selected studies would have been missed (see <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> - <I>Inter-individual variability of study selection</I>).</P>
<P>We included 15 studies in our review. Only seven of these studies (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) compared the same antibiotic in different treatment durations. We did a separate analysis for those seven studies. The 15 included studies were published between 1981 and 2005. Eleven were discovered by a MEDLINE search, one in EMBASE and one in the Cochrane Renal Group's specialised register. The remaining two studies were found by screening the bibliographies of identified studies and reviews and by contacting pharmaceutical companies (see <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK> -<I>Sources of included studies</I>). We did not find duplicate publications. The majority of the 15 studies were conducted in European countries. Ten studies took place in an outpatient setting, two in hospitals, one in both settings, and two studies did not describe the setting.</P>
<P>Two studies included men (<LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>) and <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK> also included asymptomatic and complicated UTIs. In nine studies (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>) we considered only the outcome results of the subgroup of elderly women. Elderly patients were defined differently throughout the studies (i.e. over 50, 58, 60, 63 or 65 years), so seven studies (or analysed subgroups) also included patients under 60 years. All these studies compared different antibiotics.</P>
<P>The presence of resistant organisms in the urine was handled differently throughout the studies. <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK> did not use one specific antibiotic/treatment group but chose the treatment from four antibiotics according to the sensitivity of urinary pathogens. <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK> and <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK> stated that all initially isolated bacteria were sensitive to the study antibiotic. Two studies (<LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>) excluded all patients with resistant organisms. <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK> and <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK> excluded these patients only for the evaluation of the bacteriological efficacy, but included them for all other outcomes. <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK> included also resistant uropathogens and gave detailed outcome information of patients with trimethoprim-resistant isolates. The remaining seven studies did not mention how they handled resistant pathogens. However they did not formally exclude resistant uropathogens from the study.</P>
<P>All 15 studies used various antibiotic treatment regimens (e.g. sulfamethizole, trimethoprim, fosfomycin trometamol, cephalexin, and various fluoroquinolones). Six studies compared single dose treatment with short-term (3 to 6 days) treatment (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>), three compared single dose to longer treatment durations (7 to 14 days) (<LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>; <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>) and five studies assessed short-term versus long-term treatment (<LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>). In the last update we identified one study comparing a 3-day with a 5-day treatment (<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>). We included this study in a separate comparison group.</P>
<P>With respect to the seven studies comparing the same antibiotic, three studies compared single dose with short-term treatment (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>), one study compared single dose versus long-term treatment (<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>), two compared 3-day with 7-day treatment (<LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>), and one study 3 days versus 5 days of treatment (<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-05-08 13:35:45 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Allocation concealment</HEADING>
<P>In only five studies (<LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) the assigned treatment was adequately concealed prior to allocation (numbered boxes, by telephone, numbered sealed envelopes). In eight studies (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>) the allocation concealment was not clear or not described, and <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK> used an open random list.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Randomisation method</HEADING>
<P>The method of randomisation was described in 6/15 studies (random tables or computer generator) (<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>In nine studies, neither patients nor outcome assessors were blinded to treatment (<LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>). Of the remaining six studies, four were double-blind (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) and two were single-blind (<LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>). Only two studies provided an intention-to-treat analysis of the results (<LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>). Eleven studies described why patients had been excluded after randomisation (<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>;).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Baseline characteristics</HEADING>
<P>Baseline characteristics of the different treatment groups were described and compared in 11 studies (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>). In 8/15 studies there was no statistically significant difference between the groups (<LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>; <LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>; <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sample size/power calculation</HEADING>
<P>Eight studies described a sample size and power calculation (<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>; <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>; <LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>; <LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>; <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>; <LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>). The total number of patients enrolled in these studies ranged from 60 to 595 patients. Sample size for elderly patients (used for the meta-analysis) ranged from 23 to 482 subjects assessed for outcome analysis, most included &lt; 100 elderly women.</P>
<P>The quality of the seven studies comparing the same antibiotic was not better than the overall quality of studies (2/7 studies were graded A for allocation concealment, 5/7 single- or double-blinded), but overall the most recently published study (<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) showed greater attention to study design quality. See <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> - <I>Quality of included studies.<BR/>
</I>
</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-05-09 15:21:28 +1000" MODIFIED_BY="[Empty name]">
<P>The clinical failure rate (persistence of urinary symptoms), our main outcome parameter, was reported in only 7/15 studies. In contrast, the bacteriological eradication rate was always reported. In three studies, the bacterial eradication rate was not given for the subgroup of elderly patients (in case of studies with mixed populations). Adverse drug reactions were evaluated in most studies, but these data were often missing for the subgroup of elderly patients. Other outcome parameters such as quality of life or the development of complications (e.g. pyelonephritis, urosepsis) were not reported at all. Due to the variety of included studies (i.e. comparison of various treatment durations) and the resulting classification into five comparison groups, the data of only one study were available for many outcome parameters.</P>
<P>Guibert tested in two studies the acceptability of single dose versus 3 days (<LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>) and 10 days of treatment (<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>). Patients were asked if they were "very satisfied," "satisfied", "little satisfied" or "not satisfied" with the treatment.</P>
<SUBSECTION>
<HEADING LEVEL="3">Single dose versus short-course treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Persistent UTI (i.e. significant positive urine culture at follow-up)</HEADING>
<P>The rate of persistent UTI at short-term follow-up (&#8804; two weeks post-treatment) was significantly higher for single dose therapy compared to short-course treatment (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>: RR 2.01, 95% CI 1.05 to 3.84; I² = 36%). At long-term follow-up (&gt; two weeks), the rate of bacteriological persistence was similar in both groups (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>: RR 1.18, 95% CI 0.59 to 2.32; I² = 0%). There was no significant heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical failure</HEADING>
<P>One study (<LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>) reported short-term clinical failure and found no difference between single dose and short-course treatment (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>: RR 1.69, 95% CI 0.08 to 37.26).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reinfection rate</HEADING>
<P>
<LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK> reported no significant differences in either short-term (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>: RR 0.67, 95% CI 0.28 to 1.62) and long-term (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>: RR 2.81, 95% CI 0.81 to 9.79) reinfection rates.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment acceptability/dissatisfaction</HEADING>
<P>
<LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK> reported less patients were dissatisfied with single dose compared to short-course treatment, however this was not significant (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>: RR 0.30, 95% CI 0.09 to 1.05).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Single dose versus long-course treatment</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Persistent UTI</HEADING>
<P>There was a significant decrease in persistent UTI for long-course treatment compared to single dose therapy at short-term follow-up (&#8804; 2 weeks post-treatment) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>: RR 1.93, 95% CI 1.01 to 3.70; I² = 31%) but not at long-term follow-up (&gt; 2 weeks) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>: RR 1.28, 95% CI 0.89 to 1.84; I² = 0%). There was no significant heterogeneity between the studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical failure</HEADING>
<P>One study (<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>) reported short-term clinical failure and found no difference between single dose and long-course treatment (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>: RR 1.94, 95% CI 0.68 to 5.57).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse reactions</HEADING>
<P>There were no significant differences in the rate of adverse drug reactions (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>: RR 0.80, 95% CI 0.45 to 1.41; I² = 0%) or discontinuation due to adverse reactions (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>: RR 0.33, 95% CI 0.01 to 7.87) between single dose and long-course treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment acceptability/dissatisfaction</HEADING>
<P>
<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK> reported significantly more patients were satisfied with single dose compared to long-course treatment (<LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>: RR 0.73, 95% CI 0.60 to 0.88).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Short-course versus long-course treatment</HEADING>
<P>
<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK> compared two different antibiotics (ofloxacin for 3 days with cephalexin given for 7 days), <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK> compared 3 days versus 7 days ciprofloxacin in a large population of elderly women and <LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK> compared 3 days versus 7 days norfloxacin in a small subgroup of elderly women. <LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK> compared 3 days temafloxacin versus 7 days ciprofloxacin including a subgroup analysis of patients over 65 years.</P>
<SUBSECTION>
<HEADING LEVEL="4">Persistent UTI</HEADING>
<P>There was no significant difference in the number of persistent UTIs for those on short-course compared to long-course treatment within the first two weeks (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>
<U>.1</U>: RR 0.85, 95% CI 0.29 to 2.47). There was no difference between the two groups at long-term follow-up (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>
<U>.1</U>: RR 0.85, 95% CI 0.54 to 1.32).</P>
<P>Including only studies comparing the same antibiotic (<LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>), there was no significant difference at short (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>
<U>.2</U>; RR 1.00, 95% CI 0.39 to 2.19) and long-term (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>
<U>.2</U>; RR 1.18, 95% CI 0.50 to 2.81) follow-up.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical failure</HEADING>
<P>There was no difference between short-course and long-course treatment for short-term clinical failure (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>
<U>.1</U>: RR 0.98, 95% CI 0.62 to 1.54). One study (<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>) reported no difference between short-course or long-course treatment for long-term clinical failure (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>: RR 0.75, 95% CI 0.49 to 1.13). Excluding <LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK> did not change these results (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>
<U>.2</U>: RR 0.96, 95% CI 0.27 to 3.47).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse reactions</HEADING>
<P>There were no significant differences in the rate of adverse drug reactions (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>: RR 0.87, 95% CI 0.26 to 2.93) or discontinuation due to adverse reactions (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>: RR 0.11, 95% CI 0.01 to 1.97) between short-course and long-course treatment.</P>
<P>
<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK> reported statistically significant decreases in the mean number of adverse events/patient at day 5 (<LINK REF="CMP-003.10" TYPE="ANALYSIS">Analysis 3.10</LINK>: MD -0.70, 95% CI -1.09 to -0.31) and day 9 (<LINK REF="CMP-003.11" TYPE="ANALYSIS">Analysis 3.11</LINK>: MD -0.90, 95% CI -1.33 to -0.47) for short-course treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reinfection rate</HEADING>
<P>
<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK> reported no significant differences in the short-term reinfection rate (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>: RR 4.37, 95% CI 0.98 to 19.49). Two studies reported long-term reinfection rates (<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) and this showed no significant difference between short-course and long-course treatments (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>: RR 1.30, 95% CI 0.42 to 4.01; I² = 72%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment acceptability/dissatisfaction</HEADING>
<P>
<LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK> reported more patients were satisfied with short-course treatment compared to long-course treatment, however this was not significant (<LINK REF="CMP-003.09" TYPE="ANALYSIS">Analysis 3.9</LINK>: RR 0.35, 95% CI 0.07 to 1.72).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Single dose versus short- or long-course treatment (3 to 14 days)</HEADING>
<P>We combined the short-course and long-course treatment groups and compared to single dose treatment.</P>
<SUBSECTION>
<HEADING LEVEL="4">Persistent UTI</HEADING>
<P>The rate of persistent UTI was not significantly different for single dose therapy compared to short-course or long-course treatment at either short-term follow-up (&#8804; 2 weeks post-treatment) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>
<U>.1</U>: RR 1.51, 95% CI 0.92 to 2.49; I² = 28%) or long-term follow-up (&gt; 2 weeks) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>
<U>
<I>.</I>1</U>: RR 1.14, 95% CI 0.80 to 1.63; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical failure</HEADING>
<P>There was no statistical difference between single dose and short- or long-course treatment for short-term clinical failure (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>: RR 1.91, 95% CI 0.70 to 5.19; I² = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse reactions</HEADING>
<P>There were no significant differences in the rate of adverse drug reactions (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>: RR 0.80, 95% CI 0.45 to 1.41; I² = 0%) or discontinuation due to adverse reactions (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>: RR 0.33, 95% CI 0.01 to 7.87) between single dose and short-course or long-course treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Treatment acceptability/dissatisfaction</HEADING>
<P>
<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK> and <LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK> reported less patients were dissatisfied with single dose compared to short-course or long-course treatment, however this was not significant (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>: RR 0.58, 95% CI 0.27 to 1.25; I² = 48%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antibiotics used</HEADING>
<P>When the four studies<B> </B>comparing the same antibiotic in each group were analysed (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>), there was no statistical difference between the single dose group and short-course or long-course treatment group for persistent UTI at short-term follow-up (&#8804; 2 weeks post-treatment) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>
<U>.2</U>: RR 1.87, 95% CI 0.91 to 3.83; I² = 41%) or at long-term follow-up (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>
<U>.2</U>: RR 1.06, 95% CI 0.50 to 2.24; I² = 16%).</P>
<P>Only one of the four studies reported adverse drug reactions (<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>). There was no statistical difference between the single dose group and the short-course or long-course treatment group (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>: RR 0.14, 95% CI 0.01 to 2.85).</P>
<P>Other clinical outcomes were not available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Healthcare settings</HEADING>
<P>Of the four studies comparing the same antibiotic two studies were undertaken in hospitals (<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>; <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>) and two included ambulatory women (<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>; <LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>). There was no significant difference between single dose treatment and short-course or long-course treatment for either hospital patients (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>
<U>.3</U>: RR 2.57, 95% CI 0.64 to 10.37; I² = 67%) or ambulatory women (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>
<U>.4</U>: RR 1.35, 95% CI 0.64 to 2.86; I² = 0%).</P>
<P>There were insufficient studies to analyse clinical cure or adverse drug reactions.<B>
<BR/>
</B>
<BR/>The other subgroup analyses planned in the protocol (e.g. antibiotic classes and patients' age) were not done due to the low number and heterogeneity of included studies. The planned sensitivity analyses were also not undertaken because of the same reasons.</P>
<P>There were insufficient studies to analyse for publication bias.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Three versus 5-day treatment</HEADING>
<P>We included one study identified at our last update in this separate comparison group (<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Persistent UTI</HEADING>
<P>
<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK> found more persistent UTI in the 3-day than in the 5-day treatment group, however this difference was not statistically significant (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>: RR 2.72, 95% CI 0.90 to 8.27). This subgroup analysis of older patients included only 26 patients (12 and 14 in each group). The authors had calculated that they needed 142 patients/treatment regimen to detect a difference in efficacy of 10%. Therefore sample size was too small to detect a significant difference.</P>
<P>The rate of trimethoprim-resistant <I>E. coli</I> reported in this study was high (16%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Clinical failure</HEADING>
<P>The self-reported rate of clinical failure was similar in both treatment regimens (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>: RR 1.17, 95% CI 0.29 to 4.74). Interestingly, it took the same time to recover from symptoms of UTI as the rate of recovery increased from day 1 to day 3 after the end of therapy, regardless of the duration of treatment (<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-05-09 15:22:15 +1000" MODIFIED_BY="[Empty name]">
<P>The discussion will focus on the results and their clinical interpretation but also on important methodological quality issues.</P>
<SUBSECTION>
<HEADING LEVEL="2">Methodological Issues</HEADING>
<P>The methodological quality of most studies was low, as only a few studies reported an adequate method of allocation concealment (five studies) and blinding of patients and outcome assessors (four studies). Only one more recent study (<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) met high methodological quality standards (overall quality ranking A).</P>
<P>While all studies showed results of bacteriological cure rate, clinically important outcomes such as cure of symptoms or kidney complications were rarely described. Again, the more recent studies (<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>; <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) did report on improvement of symptoms such as nocturia, urgency, frequency, burning on micturition and suprapubic pain after treatment.</P>
<P>Other quality issues pertain to the many sources of heterogeneity between included studies. Two studies included men, and one of these also included patients with urinary catheters (<LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>). These patients are usually more difficult to treat and need longer treatment durations (i.e. 10 to 14 days) (<LINK REF="REF-Nicolle-1992" TYPE="REFERENCE">Nicolle 1992</LINK>; <LINK REF="REF-Nygaard-1996" TYPE="REFERENCE">Nygaard 1996</LINK>; <LINK REF="REF-Stamm-1993" TYPE="REFERENCE">Stamm 1993</LINK>; <LINK REF="REF-Wood-1996" TYPE="REFERENCE">Wood 1996</LINK>). <LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK> included patients with asymptomatic bacteriuria. This is a frequent and usually benign infection in elderly patients which often resolves spontaneously and does not need antimicrobial treatment (<LINK REF="REF-Humbert-1992" TYPE="REFERENCE">Humbert 1992</LINK>; <LINK REF="REF-Kasviki_x002d_Charvati1982" TYPE="REFERENCE">Kasviki-Charvati1982</LINK>; <LINK REF="REF-Sourander-1972" TYPE="REFERENCE">Sourander 1972</LINK>).<BR/>
<BR/>Another possible source of heterogeneity between studies is the different handling of patients with organisms resistant to the study drugs. Some studies excluded those patients. In clinical practice, patients with uncomplicated lower UTI are usually treated empirically. <LINK REF="REF-Norrby-1992" TYPE="REFERENCE">Norrby 1992</LINK> recommended in his overview on study design in UTI to continue treatment of cystitis even if the causative organism is reported as being resistant to one or more of the study drugs. Therefore patients with resistant pathogens should be included in studies on UTI and also evaluated for efficacy. In the more recent study by <LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK> none of the identified bacteria were resistant to ciprofloxacin.</P>
<P>In nine studies we were able to do a subgroup analysis of elderly patients. However, not all authors reported the outcomes for elderly patients, and we are unsure if these subgroups were stratified and/or comparable a priori. Most of the studies included relatively young women (e.g. &gt; 50 years), whereas only three studies enrolled older patients (mean age &gt; 78 years) who are often more fragile and present multiple comorbidities.</P>
<P>The setting of studies in elderly patients is very important, because the prevalence of UTI in older people depends on the place of living which may influence the outcome of UTI. Our results suggest that longer treatment durations may be necessary for hospitalised patients. However, the two studies taking place in hospital only included much older patients (mean age 80 and 82) than the other studies. This may also affect the response to treatment. Unfortunately, none of the studies took place in nursing homes where recurrent UTI is a frequent problem (<LINK REF="REF-Nicolle-1983" TYPE="REFERENCE">Nicolle 1983</LINK>; <LINK REF="REF-Nicolle-1993" TYPE="REFERENCE">Nicolle 1993</LINK>). One geriatric study (<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) included elderly women from both ambulatory clinics and hospital acute care units.</P>
<P>Eight of the 15 studies compared different treatment durations and different antibiotics. These may not be necessarily equivalent - neither in their bacterial efficacy nor in half-life or adverse drug reactions. For example, several studies showed that trimethoprim, pivmecillinam, amoxicillin and certain cephalosporins are less effective than fluoroquinolones, co-amoxiclav or cotrimoxazole - given the same treatment duration (<LINK REF="REF-Ewer-1988" TYPE="REFERENCE">Ewer 1988</LINK>; <LINK REF="REF-Gallacher-1986" TYPE="REFERENCE">Gallacher 1986</LINK>; <LINK REF="REF-Hooton-1995" TYPE="REFERENCE">Hooton 1995</LINK>; <LINK REF="REF-Jonsson-1990" TYPE="REFERENCE">Jonsson 1990</LINK>). These findings may explain the better bacterial efficacy of a 3-day course of ofloxacin compared to a 7-day course with cephalexin (<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>).</P>
<P>Some antibiotics may not be appropriate for short-course treatment for pharmacokinetic reasons. Several penicillins and cephalosporins have a relatively short half-life (1 to 2 hours in young people, 2 to 4 hours in older people), whereas the fluoroquinolones, cotrimoxazole and fosfomycin have longer half-lives (4 to 12 hours, 8 to 13 hours, 4 to 50 hours respectively) (<LINK REF="REF-Compendium-1998" TYPE="REFERENCE">Compendium 1998</LINK>; <LINK REF="REF-McCue-1992" TYPE="REFERENCE">McCue 1992</LINK>). Indeed, <LINK REF="REF-Norrby-1990" TYPE="REFERENCE">Norrby 1990</LINK> has shown in his systematic review, that the optimal treatment duration for lower, uncomplicated UTI in women (of all ages) depends on the type of antibiotic: three days for cotrimoxazole and the fluoroquinolones and five days for beta-lactam antibiotics. Due to these findings we included the seven studies comparing the same antibiotic for a different length of time in a separate meta-analysis. Unfortunately, clinical outcomes like persistence of symptoms (our primary outcome) or patients' acceptability were not reported. The other results were similar to the meta-analyses of all 15 studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Discussion of results</HEADING>
<P>There was a significant difference for persistent UTI between single dose and short-course treatment in the short-term (&lt; 2 weeks post-treatment) (RR 2.01, 95% CI 1.05 to 3.84), but not at the long-term follow-up (RR 1.18, 95% CI 0.59 to 2.32) or on clinical outcomes. However sample size of the last two outcome parameters was small.</P>
<P>There was a significant decrease in persistent UTI for long-course treatment compared to single dose for short-term (RR 1.93, 95% CI 1.01 to 3.70) but not long-term follow-up (RR 1.28, 95% CI 0.89 to 1.84).There was no statistically significant difference adverse drug reactions. Patients preferred single dose treatment (RR 0.73, 95% CI 0.60 to 0.88) to longer treatments (7 to 14 days), but this was based on only one study comparing different antibiotics.</P>
<P>Short versus longer treatments showed no significant difference in efficacy. Rate of adverse drug reactions increased significantly with longer treatment durations in only one study (<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>). This study suggested a safety advantage for three day therapy. However ciprofloxacin can cause central side effects in geriatric patients which are rare with antibiotics which do not permeate tissues and remain concentrated in the urine (norfloxacin for example). Other studies in our review with other antibiotics did not cause higher side effects rates in the longer treatment arms.</P>
<P>In one study (which we analysed separately) a three day treatment was compared with a five day regimen of trimethoprim (<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>). There was no statistically significant difference in bacterial and clinical outcomes, but the sample size was very small.</P>
<P>Two other systematic reviews, which mainly included studies with younger patients, found that single dose therapy was less effective than longer treatment durations (<LINK REF="REF-Norrby-1990" TYPE="REFERENCE">Norrby 1990</LINK>; <LINK REF="REF-Warren-1999" TYPE="REFERENCE">Warren 1999</LINK>). The same systematic reviews showed that most antimicrobials given for three days (e.g. trimethoprim, cotrimoxazole or a fluoroquinolone) were as effective as the same antibiotic given for a longer duration. Therefore, a three day course is recommended in younger patients with uncomplicated lower UTI (<LINK REF="REF-Warren-1999" TYPE="REFERENCE">Warren 1999</LINK>). These results seem also to apply to older patients, but further investigations are needed to determine the optimal treatment duration in relation to specific antibiotics.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE MODIFIED="2008-05-08 14:02:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>This review suggests that single dose antibiotic treatment is less effective but may be better accepted by the patients than longer treatment durations (3 to 6 days). In addition, there was no difference between short-course (3 to 6 days) and long-course (7 to 14 days) antibiotics in regards to treatment efficacy. Longer courses may be associated with more adverse drug events. The evidence suggests the optimal treatment duration in elderly women is 3 to 6 days.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-05-07 13:41:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>The more recent ciprofloxacin study (<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>) offers a high quality model for designing new geriatric RCTs with clinically relevant outcomes, testing the efficacy of different treatment durations of a given antibiotic in elderly women. Indeed it would be clinically relevant, to verify the optimal treatment duration of other antibiotics especially those with narrow spectrum antibacterial activity and less systemic side effects.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-05-07 14:50:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>We thank Narelle Willis, Managing Editor of the Cochrane Renal Group, for her great and dedicated help when updating the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-05-06 16:26:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>NV - study selection, data extraction, review writing<BR/>ML - study selection, data extraction, data analysis, review writing</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-05-07 16:06:53 +1000" MODIFIED_BY="Narelle S Willis">
<STUDIES MODIFIED="2008-05-07 15:59:24 +1000" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2008-05-06 17:10:26 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Andersen-1986" MODIFIED="2008-03-28 10:48:49 +1100" MODIFIED_BY="[Empty name]" NAME="Andersen 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-03-28 10:48:49 +1100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Andersen B. Bonderup OK. Tilma A. Urinary tract infection in general practice treated with sulfametizole as single dose or for six days. [Journal] Ugeskrift for Laeger. Vol 148(9) (pp 511-513), 1986. AN: 1986075363&lt;/p&gt;" NOTES_MODIFIED="2008-03-28 10:48:49 +1100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersen B, Bonderup OK, Tilma A</AU>
<TI>Urinary tract infection in general practice treated with sulfametizole in a single dose or for six days</TI>
<TO>Urinvejsinfektion i almen praksis behandlet med sulfametizol som enkeltdosis eller is seks dage</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1986</YR>
<VL>148</VL>
<NO>9</NO>
<PG>511-3</PG>
<IDENTIFIERS MODIFIED="2008-03-28 10:48:49 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-03-28 10:48:49 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1986075363"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferraro-1990" MODIFIED="2008-05-06 15:51:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ferraro 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-05-06 15:51:28 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Ferraro G, Ambrosi G, Bucci L, Palmieri R, Palmieri G. Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly. Chemotherapy 1990;36(Suppl. 1):46-9.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 15:51:28 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferraro G, Ambrosi G, Bucci L, Palmieri R, Palmieri G</AU>
<TI>Fosfomycin trometamol versus norfloxacin in the treatment of uncomplicated lower urinary tract infections of the elderly</TI>
<SO>Chemotherapy</SO>
<YR>1990</YR>
<VL>36</VL>
<NO>Suppl 1</NO>
<PG>46-9</PG>
<IDENTIFIERS MODIFIED="2008-03-28 10:48:29 +1100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-03-28 10:48:29 +1100" MODIFIED_BY="[Empty name]" TYPE="EMBASE" VALUE="1991016672"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flanagan-1991" MODIFIED="2008-05-06 17:02:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Flanagan 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-06 17:02:22 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flanagan PG, Rooney PJ, Davies EA, Stout RW</AU>
<TI>A comparison of single-dose versus conventional-dose antibiotic treatment of bacteriuria in elderly women</TI>
<SO>Age &amp; Ageing</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>3</NO>
<PG>206-11</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:02:22 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:02:22 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1853794"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gellermann-1988" MODIFIED="2008-05-06 17:03:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gellermann 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-05-06 17:03:37 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Gellermann HJ, Grote J, Peters-Haertel W, Verbeek H. Kurzzeit-Therapie von unkomplizierten Harnwegsinfektionen der Frau mit Ciprofloxacin. Med Welt 1988;39:1585-91.&lt;br&gt;Gellermann HJ. Grote J. Peters-Haertel W. Verbeek H. Short-term therapy with ciprofloxacin of uncomplicated infections of the urinary tract in female patients. [Journal] Medizinische Welt. Vol 39(51-52) (pp 1586-1591), 1988. AN: 1989012389 &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:03:37 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gellermann HJ, Grote J, Peters-Haertel W, Verbeek H</AU>
<TI>Short-term therapy with ciprofloxacin of uncomplicated infections of the urinary tract in female patients</TI>
<TO>Kurzzeit-Therapie von unkomplizierten harnwegsinfektionen der frau mit ciprofloxacin</TO>
<SO>Medizinische Welt</SO>
<YR>1988</YR>
<VL>39</VL>
<NO>51-2</NO>
<PG>1585-91</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:03:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:03:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00406885"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guibert-1993" NAME="Guibert 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;no raw data available, no information on patients over 60 (letter from the author)&lt;br&gt;Guibert J, Mazeman E, Colau JC, Delavault P. Cystite aigu&amp;#235; chez la femme de plus de 50 ans. Efficacit&amp;#233; de la p&amp;#233;floxacine en dose unique et de la norfloxacine prescrite pendant 10 jours [Acute cystitis in women over 50 years of age. Efficacy of pefloxacin with single dose and norfloxacin for 10 days]. Presse Medicale 1993;22(7):288-92.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guibert J, Mazeman E, Colau JC, Delavault P</AU>
<TI>Acute cystitis in women over 50 years of age. Efficacy of pefloxacin with single dose and norfloxacin for 10 days</TI>
<TO>Cystite aiguë chez la femme de plus de 50 ans. Efficacité de la péfloxacine en dose unique et de la norfloxacine prescrite pendant 10 jours</TO>
<SO>Presse Medicale</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>7</NO>
<PG>288-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8502627"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guibert-1996" NAME="Guibert 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;no raw data available, no information on patients over 60 (letter from the author)&lt;br&gt;Guibert J, Capron MH, Giacomino A. Traitement de la cystite aigu&amp;#235; non compliqu&amp;#233;e de la femme: lom&amp;#233;floxacine versus p&amp;#233;floxacine [Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin]. Presse Medicale 1996;25(28):1271-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guibert J, Capron MH, Giacomino A</AU>
<TI>Treatment of non-complicated acute cystitis in women: lomefloxacin versus pefloxacin</TI>
<TO>Traitement de la cystite aiguë non compliquée de la femme: loméfloxacine versus péfloxacine</TO>
<SO>Presse Medicale</SO>
<YR>1996</YR>
<VL>25</VL>
<NO>28</NO>
<PG>1271-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8949786"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guibert-1997" NAME="Guibert 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;raw data no more available (according to letter from the author)&lt;br&gt;Guibert J, Herman H, Capron MH. Traitement de la cystite non compliqu&amp;#233;e r&amp;#233;cidivante de la femme: lom&amp;#233;floxacine versus norfloxacine [Treatment of uncomplicated recurrent cystitis in women: lomefloxacin versus norfloxacin]. Contraception, Fertilite, Sexualite1997;25(1):79-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guibert J, Herman H, Capron MH</AU>
<TI>Treatment of uncomplicated recurrent cystitis in women: lomefloxacin versus norfloxacin</TI>
<TO>Traitement de la cystite non compliquée récidivante de la femme: loméfloxacine versus norfloxacine</TO>
<SO>Fertilite Contraception Sexualite</SO>
<YR>1997</YR>
<VL>25</VL>
<NO>1</NO>
<PG>79-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9064058"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jardin-1990" NAME="Jardin 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Jardin A. A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose. Infection 1990;18 (Suppl. 2):S 89-93.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jardin A</AU>
<TI>A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>Suppl 2</NO>
<PG>89-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2286468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacey-1981" MODIFIED="2008-05-06 15:51:22 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lacey 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-05-06 15:51:22 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Lacey RW, Simpson MHC, Lord VL, Fawcett C, Button ES, Luxton DEA, Trotter IS. Comparison of single-dose trimethoprim with a five-day course for the treatment of urinary tract infections. Age &amp;amp; Ageing 1981;10:179-85.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 15:51:22 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacey RW, Simpson MHC, Lord VL, Fawcett C, Button ES, Luxton DE et al</AU>
<TI>Comparison of single-dose trimethoprim with a five-day course for the treatment of urinary tract infections</TI>
<SO>Age &amp; Ageing</SO>
<YR>1981</YR>
<VL>10</VL>
<NO>3</NO>
<PG>179-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7023207"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-1994" NAME="Matsumoto 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;* Matsumoto T, Ogata N, Kumazawa J, Hasegawa Y, Nakamura M, Sakamoto N, Yamaguchi A, Hara S, Nakamuta S, Kano M, Takahashi K, Takayama K, Mihara Y, Miyazaki Y, Funatsu M, Sawae Y. Single-dose therapy of isepamicin for the treatment of acute uncomplicated cystitis - Comparison with a three-day regimen of ofloxacin. Nishihinon Journal of Urology 1994;56:239-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto T, Ogata N, Kumazawa J, Hasegawa Y, Nakamura M, Sakamoto N et al</AU>
<TI>Single-dose therapy of isepamicin for the treatment of acute uncomplicated cystitis - Comparison with a three-day regimen of ofloxacin</TI>
<SO>Nishinihon Journal of Urology</SO>
<YR>1994</YR>
<VL>56</VL>
<NO>3</NO>
<PG>239-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1994124884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piipo-1990" MODIFIED="2008-05-06 17:04:28 +1000" MODIFIED_BY="Narelle S Willis" NAME="Piipo 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-05-06 17:04:28 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Piipo T, Pitk&amp;#228;j&amp;#228;rvi T, Salo SA. Three-day versus seven-day treatment with norfloxacin in acute cystitis. Current Therapeutic Research 1990;47(4):644-53.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:04:28 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piipo T, Pitkäjärvi T, Salo SA</AU>
<TI>Three-day versus seven-day treatment with norfloxacin in acute cystitis</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>4</NO>
<PG>644-53</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:04:28 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:04:28 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1990140005"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raz-1996" MODIFIED="2008-05-06 17:05:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Raz 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-05-06 17:05:37 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Raz R. Rozenfeld S. 3-Day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women. [Journal: Article] Antimicrobial Agents &amp;amp; Chemotherapy. Vol 40(9) (pp 2200-2201), 1996. AN: 1996274077 &lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:05:37 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raz R, Rozenfeld S</AU>
<TI>3-day course of ofloxacin versus cefalexin in the treatment of urinary tract infections in postmenopausal women</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>9</NO>
<PG>2200-1</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:05:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:05:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="8878607"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stein-1992" MODIFIED="2008-05-06 17:06:42 +1000" MODIFIED_BY="Narelle S Willis" NAME="Stein 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-05-06 17:06:42 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein GE, Philip E</AU>
<TI>Comparison of three-day temafloxacin with seven-day ciprofloxacin treatment of urinary tract infections in women</TI>
<SO>Journal of Family Practice</SO>
<YR>1992</YR>
<VL>34</VL>
<NO>2</NO>
<PG>180-4</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:06:42 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:06:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="1310715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-Merode-2005" MODIFIED="2008-05-06 17:08:17 +1000" MODIFIED_BY="Narelle S Willis" NAME="van Merode 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-05-06 17:08:17 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Merode T, Nys S, Stobberingh E</AU>
<TI>Acute uncomplicated lower urinary tract infections in general practice: clinical and microbiological cure rate after three- versus five days treatment</TI>
<SO>European Journal of General Practice</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>2</NO>
<PG>55-8</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:08:17 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:08:17 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="16392777"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogel-2004" MODIFIED="2008-05-06 17:10:26 +1000" MODIFIED_BY="Narelle S Willis" NAME="Vogel 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-06 17:10:26 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogel T, Verreault R, Gourdeau M, Morin M, Grenier-Gosselin L, Rochette L</AU>
<TI>Optimal duration of antibiotic therapy fpr uncomplicated urinary tact infection in older women: a double-blind randomized controlled trial</TI>
<SO>CMAJ</SO>
<YR>2004</YR>
<VL>170</VL>
<NO>4</NO>
<PG>469-73</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:10:13 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:10:13 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="14970093"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-05-07 15:59:24 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-Abadi-1986" NAME="Abadi 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abadi T, Razeto L, Katz E, Pallavicini M</AU>
<TI>Single dose of nitrofurantoin in the treatment of acute uncomplicated urinary tract infection</TI>
<TO>Dosis unica de nitrofurantoina en el tratamiento de la infeccion urinaria aguda no complicada</TO>
<SO>Revista Medica de Chile</SO>
<YR>1986</YR>
<VL>114</VL>
<NO>11</NO>
<PG>1047-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3299592"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abadi-1987" NAME="Abadi 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abadi T, Pino J, Razeto L, Kojchen L, Pallavinci M</AU>
<TI>A single dose of sulfamethoxazole-trimethoprim vs. a 7-day course of nitrofurantoin in the treatment of acute non-complicated urinary tract infection in women</TI>
<TO>Dosis unica de sulfametoxazol-trimetoprin versus nitrofurantoina por siete dias en el tratamiento de la infeccion urinaria aguda no complicada en la mujer</TO>
<SO>Revista Medica de Chile</SO>
<YR>1987</YR>
<VL>115</VL>
<NO>12</NO>
<PG>1166-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3332924"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Abbas-1984" MODIFIED="2008-05-06 17:11:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Abbas 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-05-06 17:11:00 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbas AMA, Goel PK, Venkit N, Gowers E</AU>
<TI>Augmentin therapy in the treatment of urinary tract infections in general practice</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>2</NO>
<PG>49-51</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:11:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:11:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1984077896"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allgulander-1979" NAME="Allgulander 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;* Allgulander S, Holm S, Lundgren C. The use of co-trimazine and co-trimoxazole in elderly patients with urinary tract infections. Infection 1979;7 (Suppl. 4):S 404-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allgulander S, Holm S, Lundgren C</AU>
<TI>The use of co-trimazine and co-trimoxazole in elderly patients with urinary tract infections</TI>
<SO>Infection</SO>
<YR>1979</YR>
<VL>7</VL>
<NO>Suppl 4</NO>
<PG>S404-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="389815"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ancill-1987" MODIFIED="2008-05-06 17:11:08 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ancill 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-05-06 17:11:08 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ancill RJ, Ballard JH, Capewell MA</AU>
<TI>Urinary tract infections in geriatric inpatients: A comparative study of amoxicillin-clavulanic acid and cotrimoxazole</TI>
<SO>Current Therapeutic Research</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>4</NO>
<PG>444-8</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:11:08 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:11:08 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1987132825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1979" NAME="Anderson 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JD, Aird MY, Johnson AM, Ree R, Goresky D, Brumwell CA et al</AU>
<TI>The use of a single 1 g dose of amoxycillin for the treatment of acute urinary tract infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1979</YR>
<VL>5</VL>
<NO>4</NO>
<PG>481-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="385583"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1980" MODIFIED="2008-05-06 17:11:15 +1000" MODIFIED_BY="Narelle S Willis" NAME="Anderson 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-05-06 17:11:15 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Anderson JD. Single dose treatment of acute urinary infections in women. Journal of Antimicrobial Chemotherapy 1980;6:170-2.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:11:15 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson JD</AU>
<TI>Single dose treatment of acute urinary infections in women</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1980</YR>
<VL>6</VL>
<NO>2</NO>
<PG>170-2</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:11:15 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:11:15 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1980100863"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrewes-1981" NAME="Andrewes 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Andrewes DA, Chuter PJ, Dawson MJ, Eden BW, Moore RMA, Freestone DS, Morris CA. Trimethoprim and co-trimoxazole in the treatment of acute urinary tract infections: patient compliance and efficacy. Journal of the Royal College of General Practitioners 1981;31:274-80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrewes DA, Chuter PJ, Dawson MJ, Eden BW, Moore RMA, Freestone DS et al</AU>
<TI>Trimethoprim and co-trimoxazole in the treatment of acute urinary tract infections: patient compliance and efficacy</TI>
<SO>Journal of the Royal College of General Practitioners</SO>
<YR>1981</YR>
<VL>31</VL>
<NO>226</NO>
<PG>274-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6975823"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aragones-1990" NAME="Aragones 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aragones E, Torres M, Sarra N, Marti R</AU>
<TI>Single dose in therapeutic strategy in acute urinary tract infection</TI>
<TO>La monodosis en la estrategia terapeutica de la infeccion aguda del tracto urinario</TO>
<SO>Atencion Primaria</SO>
<YR>1990</YR>
<VL>7</VL>
<NO>5</NO>
<PG>84-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2129709"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arredondo-2004" NAME="Arredondo 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;EMBASE: 2004447332&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arredondo-García JL, Figueroa-Damián R, Rosas A, Jáuregui A, Corral M, Costa A et al</AU>
<TI>Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2004</YR>
<VL>54</VL>
<NO>4</NO>
<PG>840-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15347634"/>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00491170"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auquer-2002" NAME="Auquer 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Auquer F, Cordon F, Gorina E, Caballero JC, Adalid C, Batlle J, the Urinary Tract Infection Study Group</AU>
<TI>Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women</TI>
<SO>Clinical Microbiology &amp; Infection</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>1</NO>
<PG>50-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21904068"/>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00378927"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Backhouse-1989" NAME="Backhouse 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Backhouse CI, Matthews JA</AU>
<TI>Single-dose enoxacin compared with 3-day treatment for urinary tract infection</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>6</NO>
<PG>877-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2764538"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1977" NAME="Bailey 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Bailey RR, Abbott GD. Treatment of urinary-tract infection with a single dose of amoxycillin. Nephron 1977;18:316-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Abbott GD</AU>
<TI>Treatment of urinary-tract infection with a single dose of amoxycillin</TI>
<SO>Nephron</SO>
<YR>1977</YR>
<VL>18</VL>
<NO>6</NO>
<PG>316-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="876437"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1978" NAME="Bailey 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Bailey RR, Abbott GD. Treatment of urinary tract infection with a single dose of trimethoprim-sulfamethoxazole. Canadian Medical Association Journal 1978;118:551-2.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Abbott GD</AU>
<TI>Treatment of urinary tract infection with a single dose of trimethoprim-sulfamethoxazole</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1978</YR>
<VL>118</VL>
<NO>5</NO>
<PG>551-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="630515"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1980" NAME="Bailey 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Bailey RR, Blake E. Treatment of uncomplicated urinary tract infections with a single dose of co-trimoxazole. New Zealand Medical Journal 1980;92(285-6).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Blake E</AU>
<TI>Treatment of uncomplicated urinary tract infections with a single dose of co-trimoxazole</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1980</YR>
<VL>92</VL>
<NO>699</NO>
<PG>285-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7003448"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1982" NAME="Bailey 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Peddie B. Chambers PFM, Crofts HG, Davies PR, Bishop V et al</AU>
<TI>Single dose doxycycline, cefuroxime and pivmecillinam for treatment of bacterial cystitis</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1982</YR>
<VL>95</VL>
<NO>717</NO>
<PG>699-700</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6292803"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1984" NAME="Bailey 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Bailey RR, Blake E, Peddie BA. Comparison of single dose netilmicin with a five-day course of co-trimoxazole for uncomplicated urinary tract infections. New Zealand Medical Journal 1984;97:262-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Blake E, Peddie BA</AU>
<TI>Comparison of single dose netilmicin with a five-day course of co-trimoxazole for uncomplicated urinary tract infections</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1984</YR>
<VL>97</VL>
<NO>754</NO>
<PG>262-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6374533"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1985a" NAME="Bailey 1985a" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Bailey RR. Single-dose therapy for cystitis in women. JAMA 1985;254(8):1034.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Hooton TM, Stamm WE</AU>
<TI>Single-dose therapy for cystitis in women</TI>
<SO>JAMA</SO>
<YR>1985</YR>
<VL>254</VL>
<NO>8</NO>
<PG>1034-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1985212822"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bailey-1985b" NAME="Bailey 1985b" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bailey RR, Keenan TD, Eliott JC, Peddie BA, Bishop V</AU>
<TI>Treatment of bacterial cystitis with a single dose of trimethoprim, co-trimoxazole or amoxycillin compared with a course of trimethoprim</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1985</YR>
<VL>98</VL>
<NO>779</NO>
<PG>387-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3887254"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Basista-1991" NAME="Basista 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Basista MP</AU>
<TI>Randomized study to evaluate efficacy and safety of ofloxacin vs. trimethoprim and sulfamethoxazole in treatment of uncomplicated urinary tract infection</TI>
<SO>Urology</SO>
<YR>1991</YR>
<VL>37 Suppl</VL>
<NO>3</NO>
<PG>21-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2003341"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bergan-1990" MODIFIED="2008-05-06 17:11:31 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bergan 1990" YEAR="1990">
<REFERENCE MODIFIED="2008-05-06 17:11:31 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Bergan T. Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 1990;18 (Suppl. 2):2 65-9.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:11:31 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergan T</AU>
<TI>Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18 Suppl</VL>
<NO>2</NO>
<PG>65-9</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:11:31 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:11:31 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1990344485"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bitsch-1985" NAME="Bitsch 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bitsch M, Hansen PH, Pagh J</AU>
<TI>Treatment of acute urinary infections. Comparison between pivmecillinam for 3 days and sulfamethizole therapy for 6 days</TI>
<TO>Behandling af akut urinvejsinfektion. En sammenligning af 3 dages pivmecillinam- og 6 dages sulfametizolbehandling</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1985</YR>
<VL>147</VL>
<NO>17</NO>
<PG>1392-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4002410"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boerema-1990" NAME="Boerema 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Boerema JBJ, Willems FTC. Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice. Infection 1990;18(Suppl. 2):S 80-88.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boerema JBJ, Willems FTC</AU>
<TI>Fosfomycin trometamol in a single dose versus norfloxacin for seven days in the treatment of uncomplicated urinary infections in general practice</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18 Suppl</VL>
<NO>2</NO>
<PG>80-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2286467"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bordier-1978" NAME="Bordier 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Bordier B, Rosatti P, Junod JP. Traitement des infections urinares chez le vieillard par le cotrimoxazole. Schweizerische Rundschau fur Medizin (Praxis) 1978;67:1003-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bordier B, Rosatti P, Junod JP</AU>
<TI>Cotrimoxazol therapy in urinary tract infection of eldery [author's translation]</TI>
<TO>Traitement des infections urinares chez le vieillard par le cotrimoxazole</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1978</YR>
<VL>67</VL>
<NO>27</NO>
<PG>1003-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="674077"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brosof-1980" NAME="Brosof 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brosof AB</AU>
<TI>Five-day therapy with cephradine capsules, 500 mg BID, for the treatment of acute, uncomplicated urinary tract infections</TI>
<SO>Clinical Therapeutics</SO>
<YR>1980</YR>
<VL>3</VL>
<NO>4</NO>
<PG>285-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7023676"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brouhard-1981" NAME="Brouhard 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Brouhard BH, Cunningham RJ. Single-dose antibiotics for urinary infections. Lancet 1981;1(8215):331.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brouhard BH, Cunningham RJ, Eriksson K et al</AU>
<TI>Single-dose antibiotics for urinary infections</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8215</NO>
<PG>331</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6109972"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brumfitt-1993" MODIFIED="2008-05-06 17:11:42 +1000" MODIFIED_BY="Narelle S Willis" NAME="Brumfitt 1993" YEAR="1993">
<REFERENCE MODIFIED="2008-05-06 17:11:42 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Brumfitt W, Hamilton Miller JM, Walker S. Enoxacin relieves symptoms of recurrent urinary infections more rapidly than cefuroxime axetil. Antimicrobial Agents and Chemotherapy 1993;37(7):1558-9.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:11:42 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brumfitt W, Hamilton Miller JM, Walker S</AU>
<TI>Enoxacin relieves symptoms of recurrent urinary infections more rapidly than cefuroxime axetil</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1993</YR>
<VL>37</VL>
<NO>7</NO>
<PG>1558-9</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:11:42 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:11:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1993202406"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buckwold-1982" NAME="Buckwold 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Buckwold FJ, Ludwig P, Harding GKM, Thompson L, Slutchuk M, Shaw J, Ronald AR. Therapy fo acute cystitis in adult women. Randomized comparison of single-dose sulfisoxazole vs trimethoprim-sulfamethoxazole. JAMA 1982;247(13):1839-42.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buckwold FJ, Ludwig P, Harding GKM, Thompson L, Slutchuk M, Shaw J et al</AU>
<TI>Therapy for acute cystitis in adult women. Randomized comparison of single-dose sulfisoxazole vs trimethoprim-sulfamethoxazole</TI>
<SO>JAMA</SO>
<YR>1982</YR>
<VL>247</VL>
<NO>13</NO>
<PG>1839-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7038165"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capalbi-1987" MODIFIED="2008-05-06 17:11:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Capalbi 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-05-06 17:11:51 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Capalbi A, Buzzi M, Alessandrini A, Allegra E, Mogini C, Di Salvo G. Trattamento delle infezioni urinarie in ginecologia. Minerva Urologica e Nefrologica 1987;39:383-9.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:11:51 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capalbi A, Buzzi M, Alessandrini A, Allegra E, Mogini C, Di Salvo G</AU>
<TI>Treatment of urinary infections in gynecology. Comparative study of norfloxacin, oxolinic acid and pipemidic acid carried out on ambulatory patients</TI>
<TO>Trattamento delle infezioni urinarie in ginecologia</TO>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>1987</YR>
<VL>39</VL>
<PG>383-9</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:11:51 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:11:51 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1988073830"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capri-1991" NAME="Capri 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Capri S, Del Bono GP. Indagine sulla terapia della cistite acuta: analisi cost-efficacia della dosa singola verso la terapia convenzionale. Journal of Chemotherapy 1991;38:163-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capri S, Del Bono GP</AU>
<TI>Treatment of acute cystitis: cost-effectiveness analysis of the single dose versus conventional therapy</TI>
<TO>Indagine sulla terapia della cistite acuta: analisi cost-efficacia della dosa singola verso la terapia convenzionale</TO>
<SO>Giornale Italiano di Chemioterapia</SO>
<YR>1991</YR>
<VL>38</VL>
<NO>1-3</NO>
<PG>163-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1365579"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmignani-2005" NAME="Carmignani 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P</AU>
<TI>Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections</TI>
<SO>Urologia Internationalis</SO>
<YR>2005</YR>
<VL>74</VL>
<NO>4</NO>
<PG>326-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="15897698"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charlton-1976" NAME="Charlton 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Charlton CAC, Crowther A, Davies JG, Dynes J, Haward MWA, Mann PG, Rye S. Three-day and ten-day chemotherapy for urinary tract infections in general practice. BMJ 1976;1:124-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charlton CAC, Crowther A, Davies JG, Dynes J, Haward MWA, Mann PG et al</AU>
<TI>Three-day and ten-day chemotherapy for urinary tract infections in general practice</TI>
<SO>BMJ</SO>
<YR>1976</YR>
<VL>1</VL>
<NO>6002</NO>
<PG>124-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="764915"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Charlton-1981" MODIFIED="2008-05-06 17:12:00 +1000" MODIFIED_BY="Narelle S Willis" NAME="Charlton 1981" YEAR="1981">
<REFERENCE MODIFIED="2008-05-06 17:12:00 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Charlton CAC, Crowther A, Davies JG, Dines J, Jackson GE, Mann PG, Rye S, Valentine JP, White DG. Three-day and one-day chemotherapy for urinary tract infections in general practice. Journal of Antimicrobial Chemotherapy 1981;8:409-12.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:12:00 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Charlton CAC, Crowther A, Davies JG, Dines J, Jackson GE, Mann PG et al</AU>
<TI>Three-day and one-day chemotherapy for urinary tract infections in general practice</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1981</YR>
<VL>8</VL>
<NO>5</NO>
<PG>409-12</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:12:00 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:12:00 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1982064141"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheung-1988" MODIFIED="2008-05-06 17:12:10 +1000" MODIFIED_BY="Narelle S Willis" NAME="Cheung 1988" YEAR="1988">
<REFERENCE MODIFIED="2008-05-06 17:12:10 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Cheung R, Sullens CM, Seal D, Dickins J, Nicholson PW, Seshmukh AA, Denham MJ, Dobbs SM. The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community. British Journal of Clinical Pharmacology 1988;26:391-8.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:12:10 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheung R, Sullens CM, Seal D, Dickins J, Nicholson PW, Seshmukh AA et al</AU>
<TI>The paradox of using a 7 day antibacterial course to treat urinary tract infections in the community</TI>
<SO>British Journal of Clinical Pharmacology</SO>
<YR>1988</YR>
<VL>26</VL>
<NO>4</NO>
<PG>391-8</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:12:10 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:12:10 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1988251668"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Compton-1983" MODIFIED="2008-05-06 17:12:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Compton 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-05-06 17:12:24 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Compton AB. Single dose trimethoprim-sulfamethoxazole in acute cystitis. Military Medicine 1983;148:622-3.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:12:24 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Compton AB</AU>
<TI>Single dose trimethoprim-sulfamethoxazole in acute cystitis</TI>
<SO>Military Medicine</SO>
<YR>1983</YR>
<VL>148</VL>
<NO>7</NO>
<PG>622-3</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:12:24 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:12:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1983246086"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1990a" NAME="Cooper 1990a" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper J, Raeburn A, Brumfitt W, Hamilton-Müller JMT</AU>
<TI>Single dose and conventional treatment for acute bacterial and non-bacterial dysuria and frequency in general practice</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18</VL>
<NO>2</NO>
<PG>65-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2185155"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cooper-1990b" NAME="Cooper 1990b" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cooper J, Raeburn AL, Brumfitt W, Hamilton-Miller JMT</AU>
<TI>General practitioner study: fosfomycin trometamol versus amoxycillin clavulanate in acute urinary tract infections</TI>
<SO>Chemotherapy</SO>
<YR>1990</YR>
<VL>36 Suppl</VL>
<NO>1</NO>
<PG>24-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2085984"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cosmi-1996" NAME="Cosmi 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cosmi EV, Cantini L, Monici Preti PA, Di Renzo GC, Abate F, Balsotti G et al</AU>
<TI>Efficacy and tolerability of brodimoprim at two different dosage schedules in the treatment of acute uncomplicated bacterial cystitis: comparative study vs. pefloxacin</TI>
<SO>European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology</SO>
<YR>1996</YR>
<VL>64</VL>
<NO>2</NO>
<PG>207-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8820004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Counts-1982" NAME="Counts 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Counts GW, Stamm WE, McKevitt M, Running K, Holmes KK, Turck M</AU>
<TI>Treatment of cystitis in women with a single dose of trimethoprim-sulfamethoxazole</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>2</NO>
<PG>484-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6981166"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cox-1992" NAME="Cox 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cox CE, Serfer HS, Mena HR, Briefer C, Childs SJ, Gordon SF et al</AU>
<TI>Ofloxacin versus trimethoprim/sulfamethoxazole in the treatment of uncomplicated urinary tract infection</TI>
<SO>Clinical Therapeutics</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>3</NO>
<PG>446-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1638586"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Craft-1991" MODIFIED="2008-05-06 17:14:44 +1000" MODIFIED_BY="Narelle S Willis" NAME="Craft 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-06 17:14:44 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;double publication, see Craft 1991a&lt;br&gt;abstract presented at the 3rd international Symposium on new quinolones, July 1990, Vancouver, Abstract 236&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:14:44 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Craft JC, Hurley M, Hsu P, Pernet A</AU>
<TI>Efficacy and safety fo three-day temafloxacin versus seven-day ciprofloxacin therapy in the treatment of uncomplicated urinary tract infections [abstract]</TI>
<SO>European Journal Of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>Special Issue</NO>
<PG>195-6</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:14:23 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:14:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00460587"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;double publication&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Craft JC, Hurley M, Hsu P, Pernet A</AU>
<TI>Safety and efficacy of 3 days of temafloxacin vs 7 days of ciprofloxacin in the treatment of females with uncomplicated urinary tract infections</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1991</YR>
<VL>3 Suppl</VL>
<NO>4</NO>
<PG>363-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crocchiolo-1990" NAME="Crocchiolo 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crocchiolo P</AU>
<TI>Single-dose fosfomycin trometamol versus multiple dose cotrimoxazole in the treatment of lower urinary tract infections in general practice</TI>
<SO>Chemotherapy</SO>
<YR>1990</YR>
<VL>36 Suppl</VL>
<NO>1</NO>
<PG>37-40</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2085988"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daengsvang-1990" NAME="Daengsvang 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;no author's address mentionned, no data for subgroup of patients &amp;gt; 60&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Daengssvang P</AU>
<TI>Safety and efficacy of 3 days of temafloxacin vs 7 days of ciprofloxacin in the treatment of females with simple cystitis</TI>
<SO>Infectious Diseases International Congress; 1990 July; Montreal (Canada)</SO>
<YR>1990</YR>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Almeida-1994" MODIFIED="2008-05-06 17:17:07 +1000" MODIFIED_BY="Narelle S Willis" NAME="de Almeida 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-05-06 17:17:07 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Almeida Claro J, Urubatan Reis C, Bandeira S, Lima N, Scafi C, Rodrigues Netto N</AU>
<TI>Single-dose (800 mg) pefloxacin vs. seven-day therapy with norfloxacin and co-trimoxazole in the management of low-tract urinary infection</TI>
<TO>Tratamento dose-unica com 800 mg de prefloxacina versus tratamento de sete dias com norfloxacina e co-trimoxazol na infecçao urinaria baixa</TO>
<SO>Jornal Brasileiro de Ginecologia</SO>
<YR>1994</YR>
<VL>104</VL>
<NO>7</NO>
<PG>235-7</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:17:07 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:17:07 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994282657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Jong-1991" NAME="de Jong 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Jong Z, Pontonnier F, Plante P</AU>
<TI>Single-dose fosfomycin trometamol (Monuril) versus multiple-dose norfloxacin: Results of a multicenter study in females with uncomplicated lower urinary tract infections</TI>
<SO>Urologia Internationalis</SO>
<YR>1991</YR>
<VL>46</VL>
<NO>4</NO>
<PG>344-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1926651"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-del-Rio-1996" NAME="del Rio 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Rio G, Dalet F, Agular L, Caffaratti J, Dal-Ré R</AU>
<TI>Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: Clinical evaluation and pharmacodynamic considerations</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>2</NO>
<PG>408-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8834888"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickie-1986" NAME="Dickie 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Dickie AS, Lang SDR. Pilot study of single dose augmentin for acute bacterial cystitis. New Zealand Medical Journal 1986;99(807):600.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dickie AS, Lang SD</AU>
<TI>Pilot study of single dose augmentin for acute bacterial cystitis</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1986</YR>
<VL>99</VL>
<NO>807</NO>
<PG>600</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3462558"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dickreuter-1984" NAME="Dickreuter 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dickreuter W, Berger C</AU>
<TI>Single-dose versus 5-day cotrimoxazole therapy in acute symptomatic urinary tract infections in the female. A prospective randomized study</TI>
<TO>Einmaldosis versus 5-Tage-Cotrimoxazol-Therapie akuter symptomatischer Harnwegsinfekte bei Frauen</TO>
<SO>Geburtshilfe und Frauenheilkunde</SO>
<YR>1984</YR>
<VL>44</VL>
<NO>12</NO>
<PG>803-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6396153"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dubois-1984" NAME="Dubois 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Dubois J, St.-Pierre C, Auger P, Philips R, Perrier A. Single-dose pefloxacin vs. seven days of trimethoprim-sulfamethoxazole in uncomplicated infection of the lower urinary tract in women.. Reviews of Infectious Diseases 1989;11 (Suppl. 5):S1343-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubois J, St.-Pierre C, Auger P, Philips R, Perrier A</AU>
<TI>Single-dose pefloxacin vs. seven days of trimethoprim-sulfamethoxazole in uncomplicated infection of the lower urinary tract in women</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1989</YR>
<VL>11 Suppl</VL>
<NO>5</NO>
<PG>1343-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elhanan-1994" NAME="Elhanan 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elhanan G, Tabenkin H, Yahalom R, Raz R</AU>
<TI>Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1994</YR>
<VL>38</VL>
<NO>11</NO>
<PG>2612-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7872756"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fair-1980" MODIFIED="2008-05-06 15:51:56 +1000" MODIFIED_BY="Narelle S Willis" NAME="Fair 1980" YEAR="1980">
<REFERENCE MODIFIED="2008-05-06 15:51:56 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fair WR, Crane DB, Peterson LJ, Dahmer C, Tague B, Amos W</AU>
<TI>Three-day treatment of urinary tract infections</TI>
<SO>Journal of Urology</SO>
<YR>1980</YR>
<VL>123</VL>
<NO>5</NO>
<PG>717-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7420563"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fairley-1970" NAME="Fairley 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Fairley KF. Cephalexin in recurrent urinary tract infection. Postgraduate Medical Journal 1970;Suppl 24-7:24 - 27.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fairley KF</AU>
<TI>Cephalexin in recurrent urinary tract infection</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1970</YR>
<VL>Suppl</VL>
<PG>24-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="5488203"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falck-1984" NAME="Falck 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Falck G, Ericsson M, Skjutare-Emmanuelson A, Fellner H. Tredagarsbehandling av nedre urinv&amp;#228;gsinfektion hos kvinnor. L&amp;#228;kartidningen 1984;81(50):4732-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falck G, Ericsson M, Skjutare-Emmanuelson A, Fellner H</AU>
<TI>3-day care of lower urinary tract infection in women</TI>
<TO>Tredagarsbehandling av nedre urinvägsinfektion hos kvinnor</TO>
<SO>Läkartidningen</SO>
<YR>1984</YR>
<VL>81</VL>
<NO>50</NO>
<PG>4732-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6521572"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falck-1988" NAME="Falck 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Anonymous. Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group. [Clinical Trial. Journal Article. Randomized Controlled Trial] Scandinavian Journal of Infectious Diseases. 20(6):619-24, 1988. UI: 2906171&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections. The Inter-Nordic Urinary Tract Infection Study Group</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1988</YR>
<VL>20</VL>
<NO>6</NO>
<PG>619-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2906171"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fang-1978" NAME="Fang 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Fang LST, Tolkoff-Rubin NE, Rubin RH. Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. New England Journal of Medicine 1978;298:413-6.&lt;br&gt;Fang LS. Tolkoff-Rubin NE. Rubin RH. Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic. [Clinical Trial. Journal Article. Randomized Controlled Trial] New England Journal of Medicine. 298(8):413-6, 1978 Feb 23. UI: 340949&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fang LS, Tolkoff-Rubin NE, Rubin RH</AU>
<TI>Efficacy of single-dose and conventional amoxicillin therapy in urinary-tract infection localized by the antibody-coated bacteria technic</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>298</VL>
<NO>8</NO>
<PG>413-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="340949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferry-2007" NAME="Ferry 2007" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ</AU>
<TI>Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW porject</TI>
<SO>Scand J Prim Health Care</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>1</NO>
<PG>49-57</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17354160"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Fihn-1988" NAME="Fihn 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;E-mail from the editor: None of the partipants were over age 65.&lt;br&gt;Fihn SD, Johnson C, Roberts PL, Running K, Stamm WE. Trimethoprim-sulfamethoxazole for acute dysuria in women: A single-dose or 10-day course. Annals of Internal Medicine 1988;108:350-57.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fihn SD, Johnson C, Roberts PL, Running K, Stamm WE</AU>
<TI>Trimethoprim-sulfamethoxazole for acute dysuria in women: A single-dose or 10-day course</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1988</YR>
<VL>108</VL>
<NO>3</NO>
<PG>350-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3257670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fischer-1982" NAME="Fischer 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Fischer J, Escher J. Vergleichende Studie von Co-siltrim und Amoxicillin bei akuten Harnwegsinfektionen [Comparative study of co-soltrim and amoxicillin in acute urinary tract infections]. Schweizerische Rundschau fur Medizin (Praxis) 1982;71(35):1352-5.&lt;br&gt;Fischer J. Escher J. [Field study: comparative study of Co-soltrim and amoxicillin in acute urinary tract infections]. [German] [Clinical Trial. Journal Article. Randomized Controlled Trial] Schweizerische Rundschau fur Medizin Praxis. 71(35):1352-5, 1982 Aug 31. UI: 6752936&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fischer J, Escher J</AU>
<TI>Comparative study of co-soltrim and amoxicillin in acute urinary tract infections</TI>
<TO>Vergleichende Studie von Co-siltrim und Amoxicillin bei akuten Harnwegsinfektionen</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1982</YR>
<VL>71</VL>
<NO>35</NO>
<PG>1352-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6752936"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flavell_x002d_Matts-1985" NAME="Flavell-Matts 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Flavell Matts SG, Francourt GJ, Mitchell CJ, Gowers E, Boston PF. Further Data on Augmentin and co-trimoxazole in the treatment of urinary tract infection. British Journal of Clinical Practice 1985;39(5):179-84.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flavell Matts SG, Francourt GJ, Mitchell CJ, Gowers E, Boston PF</AU>
<TI>Further data on augmentin and co-trimoxazole in the treatment of urinary tract infection</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1985</YR>
<VL>39</VL>
<NO>5</NO>
<PG>179-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3907682"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-F_x00fc_nfst_x00fc_ck-1990" NAME="Fünfstück 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Funfstuck R. Jansa U. Stein G. Schneider S. [Comparative studies of the effectiveness of 1-day treatment and 7-day treatment with sulfamerazine/trimethoprim (Berlocombin) of patients with urinary tract infection]. [German] [Clinical Trial. Journal Article. Randomized Controlled Trial] Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete. 45(1):1-5, 1990 Jan 1. UI: 2330731&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fünfstück R, Jansa U, Stein G, Scheider S</AU>
<TI>Comparative studies of the effectiveness of 1-day treatment and 7-day treatment with sulfamerazine/trimethoprim (Berlocombin) of patients with urinary tract infection</TI>
<TO>Vergleichende Untersuchungen zur Wirksamkeit einer Ein-Tages-Behandlung und einer Sieben-Tage-Behandlung mit Sulfamerazin/Trimethoprim (Berlocombin) bei Patienten mit einer Harnwegsinfektion</TO>
<SO>Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete</SO>
<YR>1990</YR>
<VL>45</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2330731"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallego-Gomez-1987" NAME="Gallego Gomez 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Gallego Gomez J. Llopis Minguez B. Boronat Tormo F. Martinez Garcia R. Oliver Amoros F. Gobernado Serrano M. Jimenez Cruz JF. [Norfloxacin versus pipemidic acid in acute cystitis]. [Spanish] [Clinical Trial. Controlled Clinical Trial. Journal Article] Archivos Espanoles de Urologia. 40(2):71-4, 1987 Mar. UI: 3592776&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallego Gomez J, Llopis Minguez B, Boronat Tormo F, Martinez Garcia R, Oliver Amoros F, Gobernado Serrano M et al</AU>
<TI>Norfloxacin versus pipemidic acid in acute cystitis</TI>
<TO>Norfloxacina versus acido pipemidico en cistitis agudas</TO>
<SO>Archivos Espanoles de Urologia</SO>
<YR>1987</YR>
<VL>40</VL>
<NO>2</NO>
<PG>71-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3592776"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gippert-1981" NAME="Gippert 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gippert H, Norberg A, Norberg B, Kahlmeter G, Bukh N</AU>
<TI>Symptomatic bacteriuria in non-catheterized geriatric patients with urinary incontinence; the effect of short-term treatment with pivmecillinam or the combination pivmecillinam-pivampicillin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1981</YR>
<VL>7</VL>
<PG>185-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6260728"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordin-1987" NAME="Gordin 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordin A, Kalima S, Mäkela P, Antikainen R</AU>
<TI>Comparison of three- and ten-day regimens with a sulfadiazine-trimethoprim combination and pivmecillinam in acute lower urinary tract infections</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1987</YR>
<VL>19</VL>
<PG>97-102</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3563430"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-1978" NAME="Gordon 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Gordon WE. Efficacy and safety of cefadroxil. The Journal of the Kentucky Medical Association 1978;76(3):121-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon WE</AU>
<TI>Efficacy and safety of cefadroxil</TI>
<SO>Journal of the Kentucky Medical Association</SO>
<YR>1978</YR>
<VL>76</VL>
<NO>3</NO>
<PG>121-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="632656"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gossius-1984a" MODIFIED="2008-05-06 17:17:34 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gossius 1984a" YEAR="1984">
<REFERENCE MODIFIED="2008-05-06 17:17:34 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Gossius G. Single-dose nitrofurantoin therapy for urinary tract infections in women. Current Therapeutic Research 1984;35(6):925-31.&lt;br&gt;Gossius G. Single-dose nitrofurantoin therapy for urinary tract infections in women. [Journal] Current Therapeutic Research, Clinical &amp;amp; Experimental. Vol 35(6) (pp 925-931), 1984. &lt;br&gt;AN: 1984180670&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:17:34 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gossius G</AU>
<TI>Single-dose nitrofurantoin therapy for urinary tract infections in women</TI>
<SO>Current Therapeutic Research, Clinical &amp; Experimental</SO>
<YR>1984</YR>
<VL>35</VL>
<NO>6</NO>
<PG>925-31</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:17:34 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:17:34 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1984180670"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gossius-1984b" NAME="Gossius 1984b" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Gossius G, Vorland L. A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women. Scandinavian Journal of Infectious Diseases 1984;16:373-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gossius G, Vorland L</AU>
<TI>A randomised comparison of single-dose vs. three-day and ten-day therapy with trimethoprim-sulfamethoxazole for acute cystitis in women</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1984</YR>
<VL>16</VL>
<NO>4</NO>
<PG>373-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6396834"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gossius-1986" NAME="Gossius 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Gossius G, Vorland L. Behandling av akutt castitt hos kvinner. Enkeldose versus tredagers og tidagers behandlingsregime med trimethoprim-sulfamethoxazol [Treatment for acute cystitis in women. Single-dose versus a 3-day and 10-day therapeutic regimen with trimethoprim-sulfamethoxazole]. Tidsskrift for den Norske Laegeforening 1986;106(16):1395-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gossius G, Vorland L</AU>
<TI>Treatment for acute cystitis in women. Single-dose versus a 3-day and 10-day therapeutic regimen with trimethoprim-sulfamethoxazole</TI>
<TO>Behandling av akutt castitt hos kvinner. Enkeldose versus tredagers og tidagers behandlingsregime med trimethoprim-sulfamethoxazol</TO>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1986</YR>
<VL>106</VL>
<NO>16</NO>
<PG>1395-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3529490"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goto-1999" NAME="Goto 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goto T, Kitagawa T, Kawahara M, Hayami H, Ohi Y</AU>
<TI>Comparative study of single-dose and three-day therapy for acute uncomplicated cystitis</TI>
<SO>Hinyokika Kiyo - Acta Urologica Japonica</SO>
<YR>1999</YR>
<VL>45</VL>
<NO>2</NO>
<PG>85-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10212779"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Greenberg-1981" NAME="Greenberg 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;E.mail from the author: &amp;quot;I enrolled mostly young adult females who were sexally active. I am nearly certain that most study patients were less than 60 years. I do not have any more data for you than what is in the publications. I do appreciate your interest in these studies.&amp;quot;&lt;br&gt;Greenberg RN, Sanders CV, Lewis AC, Marier RL. Single-dose cefaclor therapy of urinary tract infection. Evaluation of antibody-coated bacteria test and c-reactive protein assay as predictors of care. American Journal of Medicine 71;(841-5).&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Sanders CV, Lewis AC, Marier RL</AU>
<TI>Single-dose cefaclor therapy of urinary tract infection. Evaluation of antibody-coated bacteria test and C-reactive protein assay as predictors of cure</TI>
<SO>American Journal of Medicine</SO>
<YR>1981</YR>
<VL>71</VL>
<NO>5</NO>
<PG>841-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7304657"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenberg-1986" NAME="Greenberg 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;trial included mostly young adult females who were sexally active, most patients were less than 60 years. (e.mail from author)&lt;br&gt;Greenberg RN, Reilly PM, Luppen KL, Weinandt WJ, Ellington LL, Bollinger MR. Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women. The Journal of Infectious Diseases 1986;153(2):277-82.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenberg RN, Reilly PM, Luppen KL, Weinandt WJ, Ellington LL, Bollinger MR</AU>
<TI>Randomized study of single-dose, three-day, and seven-day treatment of cystitis in women</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1986</YR>
<VL>153</VL>
<NO>2</NO>
<PG>277-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3484773"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Greenwood-1994" NAME="Greenwood 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Greenwood D. Fosfomycin trometamol and the single-dose treatment of cystitis. Journal of Medical Microbiology 1994;41:293-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Greenwood D</AU>
<TI>Fosfomycin trometamol and the single-dose treatment of cystitis</TI>
<SO>Journal of Medical Microbiology</SO>
<YR>1994</YR>
<VL>41</VL>
<NO>5</NO>
<PG>293-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7966199"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gr_x00fc_neberg-1967" MODIFIED="2008-05-06 15:52:06 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grüneberg 1967" YEAR="1967">
<REFERENCE MODIFIED="2008-05-06 15:52:06 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grüneberg RN, Brumfitt W</AU>
<TI>Single-dose treatment of acute urinary tract infection: a controlled trial</TI>
<SO>BMJ</SO>
<YR>1967</YR>
<VL>3</VL>
<NO>566</NO>
<PG>649-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6038338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1981" NAME="Hansen 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen PH, Kristensen KH, Lenler-Eriksen HA, Pagh J, Ostergard JE</AU>
<TI>Pivmecillinam (Selexid) in acute cystitis. A comparative study of 3- and 7-day treatments</TI>
<TO>Pivmecillinam (Selexid*) til akut cystitis. En sammenligning af 3 of 7 dages behandling</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1981</YR>
<VL>143</VL>
<NO>11</NO>
<PG>670-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6269263"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heer-1980" NAME="Heer 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Heer H. Tibirox bei Harnwegsinfektionen. Wirksamkeit bei hospitalisierten und ambulanten Patienten. ZFA - Zeitschrift fur Allgemeinmedizin 1980;56:949-52.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heer H</AU>
<TI>Tibirox for urinary tract infections. Effectiveness in hospitalized and ambulatory patients</TI>
<TO>Tibirox bei harnwegsinfektionen. Wirksamkeit bei hospitalisierten und ambulanten patienten</TO>
<SO>ZFA - Zeitschrift fur Allgemeinmedizin</SO>
<YR>1980</YR>
<VL>56</VL>
<NO>13</NO>
<PG>949-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7415463"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henning-1981" NAME="Henning 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Henning C, Kjellberg L. Eingangs- och veckobehandling vid akuta urinv&amp;#228;gsinfektioner. L&amp;#228;kartidningen 1981;78(40):3473-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henning C, Kjellberg L</AU>
<TI>Single-dose and weekly therapy of acute urinary infections</TI>
<TO>Eingangs- och veckobehandling vid akuta urinvägsinfektioner</TO>
<SO>Läkartidningen</SO>
<YR>1981</YR>
<VL>78</VL>
<NO>40</NO>
<PG>3473-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7033696"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henry-1999" NAME="Henry 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Henry DC, Nenad RC, Iravani A, Tice AD, Mansfield DL, Magner DJ, Dorr MB, Talbot GH. Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women. Clinical Therapeutics 1999;21(6):966-81.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henry DC, Nenad RC, Iravani A, Tice AD, Mansfield DL, Magner DJ et al</AU>
<TI>Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women</TI>
<SO>Clinical Therapeutics</SO>
<YR>1999</YR>
<VL>21</VL>
<NO>6</NO>
<PG>966-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10440621"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hill-1985" NAME="Hill 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Hill S, Yeates M, Pathy J, Morgan JR. A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly. Journal of Antimicrobial Chemotherapy 1985;15:505-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hill S, Yeates M, Pathy J, Morgan JR</AU>
<TI>A controlled trial of norfloxacin and amoxycillin in the treatment of uncomplicated urinary tract infection in the elderly</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1985</YR>
<VL>15</VL>
<NO>4</NO>
<PG>505-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3159711"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinnah-1991" NAME="Hinnah 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Hinnah V, Strohmenger P. Perorale Einzeittherapie der akuten Harnwegsinfektion. Ciprofloxacin versus TMP/SMZ. Z Allg Med 1991;67:1179-82.&lt;br&gt;Hinnah V. Strohmenger P. Single-dose oral ciprofloxacin versus trimethoprim sulfamethoxazole in the treatment of acute urinary tract infections. [Journal: Article] Zeitschrift fur Allgemeinmedizin. Vol 67(18) (pp 1179-1182), 1991. AN: 1991215200&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinnah V, Strohmenger P</AU>
<TI>Single-dose oral ciprofloxacin versus trimethoprim sulfamethoxazole in the treatment of acute urinary tract infections</TI>
<SO>Zeitschrift fur Allgemeinmedizin</SO>
<YR>1991</YR>
<VL>67</VL>
<NO>18</NO>
<PG>1179-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1991215200"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoigne-1977" NAME="Hoigne 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Hoign&amp;#233; R, Sturm H, Fahrer H, Spiess J, Patrizzi R. Untersuchungen &amp;#252;ber Therapieschema und Wirkung von Cotrimoxazol bei Harnwegsinfektionen, vergleichend mit hohen Dosen Trimethoprim allein [Choice of the therapeutic schedule of cotrimoxazole in urinary tract infections; comparison of the effect with this of trimethoprim alone]. Schweizerische Rundschau fur Medizin (Praxis) 1977;66:111-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoigné R, Sturm H, Fahrer H, Spiess J, Patrizzi R</AU>
<TI>Choice of the therapeutic schedule of cotrimoxazole in urinary tract infections; comparison of the effect with this of trimethoprim alone</TI>
<TO>Untersuchungen über therapieschema und wirkung von cotrimoxazol bei harnwegsinfektionen, vergleichend mit hohen dosen trimethoprim allein</TO>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1977</YR>
<VL>66</VL>
<NO>4</NO>
<PG>111-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="319450"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hooton-1985" NAME="Hooton 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hooton TM, Running K, Stamm WE</AU>
<TI>Single-dose therapy for cystitis in women. A comparison of trimethoprim-sulfamethoxazole, amoxicillin, and cyclacillin</TI>
<SO>JAMA</SO>
<YR>1985</YR>
<VL>253</VL>
<NO>3</NO>
<PG>387-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3871233"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hooton-1989" NAME="Hooton 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;include? (mean age =24)&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hooton TM, Latham RH, Wong ES, Johnson C, Roberts PL, Stamm WE</AU>
<TI>Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>8</NO>
<PG>1308-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2802557"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hooton-1991" NAME="Hooton 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Hooton TM, Johnson C, Winter C, Kuwamura L, Rogers ME, Roberts PL, Stamm WE. Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women. Antimicrobial Agents and Chemotherapy 1991;35(7):1479-83.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hooton TM, Johnson C, Winter C, Kuwamura L, Rogers ME, Roberts PL et al</AU>
<TI>Single-dose and three-day regimens of ofloxacin versus trimethoprim-sulfamethoxazole for acute cystitis in women</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>7</NO>
<PG>1479-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1929311"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoover-1982" NAME="Hoover 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Hoover DL, Martin RW, Reynolds BH, Krall JM. Rapid diagnosis and single-dose treatment of uncomplicated urinary tract infection. Journal of American College of Health 1982;31:61-66.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoover DL, Martin RW, Reynolds BH, Krall JM</AU>
<TI>Rapid diagnosis and single-dose treatment of uncomplicated urinary tract infection</TI>
<SO>Journal of American College of Health</SO>
<YR>1982</YR>
<VL>31</VL>
<PG>61-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7153433"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoyme-1993" NAME="Hoyme 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoyme UB, Alimi M, Keuter U, Krasemann C, Krolla H, Philipps K et al</AU>
<TI>Single dose therapy of uncomplicated urinary tract infections in women. Remission rates with ciprofloxacin in two prospective randomized comparative studies</TI>
<TO>Einmaltherapie von unkomplizierten Harnwegsinfektionen der Frau. Heilungsraten mit Ciprofloxacin in zwei prospektiven randomisierten Vergleichsstudien</TO>
<SO>Fortschritte der Medizin</SO>
<YR>1993</YR>
<VL>111</VL>
<NO>3</NO>
<PG>35-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8444395"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2002" MODIFIED="2008-05-07 15:59:24 +1000" MODIFIED_BY="Narelle S Willis" NAME="Huang 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-07 15:59:24 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang CK, Chen YS, Lee SS, Lin WR, Tsai HC, Lin HH et al</AU>
<TI>Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections</TI>
<SO>Journal of Microbiology Immunology &amp; Infection</SO>
<YR>2002</YR>
<VL>35</VL>
<NO>3</NO>
<PG>159-67</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:18:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="22267824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Humbert-1987" MODIFIED="2008-05-06 17:18:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Humbert 1987" YEAR="1987">
<REFERENCE MODIFIED="2008-05-06 17:18:16 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Humbert G. Borsa-Lebas F. Lecomte F. Short-course therapy of urinary tract infections. [Journal] Medecine et Maladies Infectieuses. Vol. 17(12 BIS)(pp 791-794), 1987. &lt;br&gt;AN: 1988014375&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:18:16 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Humbert G, Borsa-Lebas F, Lecomte F</AU>
<TI>Short-course therapy of urinary tract infections</TI>
<TO>Les traitements courts de l'infection urinaire</TO>
<SO>Medecine et Maladies Infectieuses</SO>
<YR>1987</YR>
<VL>17</VL>
<NO>12 BIS</NO>
<PG>791-4</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:18:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:18:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1988014375"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1985" NAME="Iravani 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Iravani A, Richard GA. Single-dose ceftriaxone versus multiple-dose trimethoprim-sulfamethoxazole in the treatment of acute urinary tract infections. Antimicrobial Agents and Chemotherapy 1985;27(2):158-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A, Richard GA</AU>
<TI>Single-dose ceftriaxone versus multiple-dose trimethoprim-sulfamethoxazole in the treatment of acute urinary tract infections</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>2</NO>
<PG>158-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3872627"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1989" NAME="Iravani 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Iravani A, Richard GA. Single-dose cefuroxime axetil versus multiple-dose cefaclor in the treatment of acute urinary tract infections. Antimicrobial Agents and Chemotherapy 1989;33(8):1212-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A, Richard GA</AU>
<TI>Single-dose cefuroxime axetil versus multiple-dose cefaclor in the treatment of acute urinary tract infections</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1989</YR>
<VL>33</VL>
<NO>8</NO>
<PG>1212-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2802549"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1991a" NAME="Iravani 1991a" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A</AU>
<TI>Treatment of uncomplicated urinary tract infections with temafloxacin</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91 Suppl</VL>
<NO>6A</NO>
<PG>124-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1662882"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1991b" NAME="Iravani 1991b" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A</AU>
<TI>Comparative, double-blind, prospective, multicenter trial of temafloxacin versus trimethoprim-sulfamethoxazole in uncomplicated urinary tract infections in women</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>9</NO>
<PG>1777-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1952847"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1993" NAME="Iravani 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A</AU>
<TI>Multicenter study of single-dose and multiple-dose fleroxacin versus ciprofloxacin in the treatment of uncomplicated urinary tract infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>94 Suppl</VL>
<NO>3A</NO>
<PG>89-96</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8452189"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1995" NAME="Iravani 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A, Tice AD, McCarty J, Sikes DH, Nolen T, Gallis HA et al</AU>
<TI>Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<NO>5</NO>
<PG>485-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7864704"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iravani-1999" NAME="Iravani 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iravani A, Klimberg I, Briefer C, Munera C, Kowalsky SF, Echols RM et al</AU>
<TI>A trial comparing low-dose, short-course ciprofloxacin and standard 7 day therapy with co-trimoxazole or nitrofurantoin in the treatment of uncomplicated urinary tract infection</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1999</YR>
<VL>43 Suppl</VL>
<NO>A</NO>
<PG>67-75</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10225575"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishihara-1998" NAME="Ishihara 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishihara S, Ban Y, Kawada Y, Ito SI, Yasuhisa I, Doi T et al</AU>
<TI>Fleroxacin treatment for acute uncomplicated cystitis in women: comparison of 3-day and 7-day therapy</TI>
<SO>Hinyokika Kiyo - Acta Urologica Japonica</SO>
<YR>1998</YR>
<VL>44</VL>
<NO>6</NO>
<PG>431-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9719946"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johansen-1981" NAME="Johansen 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Johansen KS, Grosen G, Holm Nielsen E, Jacobsen J, Jensen SH, Juel- Jacobsen T, Skinhoj A, Laursen H. Patienter med symptomer pa akut urinvejsinfektion behandlet med piromidsyre eller sulfametizol i almen praksis. En doggeltblind, klinisk, kontrolleret multicenterundersogelse [Patients with symptoms of acute urinary infections treated with piromidic acid or sulfamethizole in general practice. A double-blind clinical controlled multicentre study]. Ugeskrift for Laeger 1981;143(39):2491-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johansen KS, Grosen G, Holm Nielsen E, Jacobsen J, Jensen SH, Juel- Jacobsen T et al</AU>
<TI>Patients with symptoms of acute urinary infections treated with piromidic acid or sulfamethizole in general practice. A double-blind clinical controlled multicentre study</TI>
<TO>Patienter med symptomer pa akut urinvejsinfektion behandlet med piromidsyre eller sulfametizol i almen praksis. En doggeltblind, klinisk, kontrolleret multicenterundersogelse</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1981</YR>
<VL>143</VL>
<NO>39</NO>
<PG>2491-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7029845"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1983" NAME="Jones 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones RH</AU>
<TI>Single-dose and seven-day trimethoprim and co-trimoxazole in the treatment of urinary tract infection</TI>
<SO>Journal of the Royal College of General Practitioners</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>254</NO>
<PG>585-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6605424"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jordan-1986" NAME="Jordan 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Jordan NS. Single-dose antibiotic therapy for urinary tract infections and type II error. Archives of Internal Medicine 1986;146:413.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jordan NS</AU>
<TI>Single-dose antibiotic therapy for urinary tract infections and type II error</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1986</YR>
<VL>146</VL>
<NO>2</NO>
<PG>413-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3484941"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khatib-1981" NAME="Khatib 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;Khatib A. Comparative efficacy of single- and eight-day treatment of urinary tract infections with carfecillin (Uticillin*). Journal of International Medical Research 1981;9(3):186-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khatib A</AU>
<TI>Comparative efficacy of single- and eight-day treatment of urinary tract infections with carfecillin (Uticillin)</TI>
<SO>Journal of International Medical Research</SO>
<YR>1981</YR>
<VL>9</VL>
<NO>3</NO>
<PG>186-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7238994"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirby-1984" NAME="Kirby 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Kirby CP. Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin. Journal of Antimicrobial Chemotherapy 1984;13 (Suppl. B):107-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirby CP</AU>
<TI>Treatment of simple urinary tract infections in general practice with a 3-day course of norfloxacin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>13 Suppl</VL>
<NO>B</NO>
<PG>107-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6234270"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiyota--1992" NAME="Kiyota  1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;age?&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiyota H, Machida T, Masuda F, Ohishi Y, Onodera S, Suzuki H et al</AU>
<TI>Single-dose treatment of tosufloxacin (TFLX) for acute uncomplicated cystitis</TI>
<SO>Kansenshogaku Zasshi - Journal of the Japanese Association for Infectious Diseases</SO>
<YR>1992</YR>
<VL>66</VL>
<NO>4</NO>
<PG>529-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1624848"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kosmidis-1988" NAME="Kosmidis 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Kosmidis J, Gargalianos P, Adamis G, Petropoulou D, Makris D. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection. Journal of Antimicrobial Chemotherapy 1988;22 (Suppl. D):219-21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kosmidis J, Gargalianos P, Adamis G, Petropoulou D, Makris D</AU>
<TI>Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1988</YR>
<VL>22 Suppl</VL>
<NO>D</NO>
<PG>219-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3144541"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koyama-2000" NAME="Koyama 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koyama Y, Mikami O, Matsuda T, Murota T, Ohara T, Kawamura H et al</AU>
<TI>Efficacy of single-dose therapy with levofloxacin for acute cystitis: comparison to three-day therapy</TI>
<SO>Hinyokika Kiyo - Acta Urologica Japonica</SO>
<YR>2000</YR>
<VL>46</VL>
<NO>1</NO>
<PG>49-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10723666"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumamoto-1992" NAME="Kumamoto 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Kumamoto Y. Single-dose treatment of female acute uncomplicated cystitis. Infection 1992;20(Suppl. 3):S 173-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumamoto Y</AU>
<TI>Single-dose treatment of female acute uncomplicated cystitis</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20 Suppl</VL>
<NO>3</NO>
<PG>173-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1337061"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-K_x00e4_llenius-1979" NAME="Källenius 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Källenius G, Winberg J</AU>
<TI>Urinary tract infections treated with single dose of short-acting sulphonamide</TI>
<SO>BMJ</SO>
<YR>1979</YR>
<VL>1</VL>
<NO>6172</NO>
<PG>1175-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="444997"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lecomte-1991" MODIFIED="2008-05-06 17:18:34 +1000" MODIFIED_BY="Narelle S Willis" NAME="Lecomte 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-06 17:18:34 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Lecomte F, Humbert G. Les traitements courts de l'infection urinaire chez l'adulte. M&amp;#233;d Mal Infect 1991;21(2Bis):109-23.&lt;br&gt;Lecomte F. Humbert G. Short-term treatment of urinary tract infection in adults. [Journal: Conference Paper] Medecine et Maladies Infectieuses, Vol 21(2 BIS) (pp 109-123), 1991. &lt;br&gt;AN: 1991154459&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:18:34 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lecomte F, Humbert G</AU>
<TI>Short-term treatment of urinary tract infection in adults</TI>
<TO>Les traitements courts de l'infection urinaire chez l'adulte</TO>
<SO>Medecine et Maladies Infectieuses</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>2 BIS</NO>
<PG>109-23</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:18:34 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:18:34 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1991154459"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Leelarasamee-1995" NAME="Leelarasamee 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;e.mail from the author: no patients &amp;gt; 60 included&lt;br&gt;Leelarasamee A, Leelarasamee I. Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3-day therapy. Drugs 1995;49 (Suppl. 2):365-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leelarasamee A, Leelarasamee I</AU>
<TI>Comparative efficacies of oral pefloxacin in uncomplicated cystitis. Single dose or 3-day therapy</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49 Suppl</VL>
<NO>2</NO>
<PG>365-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8549364"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leigh-1980" NAME="Leigh 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leigh DA, Marriner J, Fabb S</AU>
<TI>Treatment of domiciliary urinary tract infections with a single dose of amoxycillin</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1980</YR>
<VL>6</VL>
<NO>3</NO>
<PG>403-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7400073"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lewis-1980" NAME="Lewis 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Lewis G. Treatment of acute urinary tract infections with cefadroxil administered once daily. Journal fo International Medical Research 1980;8(Suppl. 1):29-33.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lewis G</AU>
<TI>Treatment of acute urinary tract infections with cefadroxil administered once daily</TI>
<SO>Journal of International Medical Research</SO>
<YR>1980</YR>
<VL>8 Suppl</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7439502"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lightstone-1988" NAME="Lightstone 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lightstone BL, Greaves WE, Humphries JM</AU>
<TI>Comparison of Mictral with amoxycillin, trimethoprim and nitrofurantoin in the treatment of acute cystitis</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1988</YR>
<VL>42</VL>
<NO>7</NO>
<PG>283-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3075504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lockey-1980" NAME="Lockey 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lockey JE, Williams DN, Raij L, Sabath LD</AU>
<TI>Comparison of 4 and 10 days of doxycycline treatment for urinary tract infection</TI>
<SO>Journal of Urology</SO>
<YR>1980</YR>
<VL>124</VL>
<NO>5</NO>
<PG>643-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7005459"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ludwig-1987" NAME="Ludwig 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ludwig G, Pauthner H</AU>
<TI>Clinical experience with ofloxacin in upper and lower urinary tract infections. A comparison with co-trimoxazole and nitrofurantoin</TI>
<SO>Drugs</SO>
<YR>1987</YR>
<VL>34 Suppl</VL>
<NO>1</NO>
<PG>95-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3501751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mabeck-1980a" NAME="Mabeck 1980a" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Mabeck CE, Vejlsgaard. Urinvejsinfektioner i almen praksis. III. Behandling med sulfametizol, trimetoprim eller Co-trimazin* (sulfadiazin-trimtoprim) [Urinary tract infections in general practice. III. Treatment with sulphamethizole, trimethoprim or co-trimazin (sulphadiazine- trimethoprim)]. Ugeskrift for Laeger 1980;142(26):1664-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mabeck CE, Vejlsgaard R</AU>
<TI>Urinary tract infections in general practice. III. Treatment with sulphamethizole, trimethoprim or co-trimazin (sulphadiazine- trimethoprim)</TI>
<TO>Urinvejsinfektioner i almen praksis. III. Behandling med sulfametizol, trimetoprim eller Co-trimazin* (sulfadiazin-trimtoprim)</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1980</YR>
<VL>142</VL>
<NO>26</NO>
<PG>1664-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6996257"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mabeck-1980b" NAME="Mabeck 1980b" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mabeck CE, Vejlsgaard R</AU>
<TI>Treatment of urinary tract infections in general practice with sulfamethizole, trimethoprim or co-trimazine (sulphadiazine-trimethoprim)</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1980</YR>
<VL>6</VL>
<NO>6</NO>
<PG>701-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7440462"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallo-1979" NAME="Mallo 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;Mallo N, Dalet F. Estudio clinico-bacteriologico de la dibekacine en las infecciones urinarias [Clinical--bacteriological study of dibekacine in urinary infections]. Revista Clinica Espanola.1979;155(6):417-21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallo N, Dalet F</AU>
<TI>Clinical bacteriological study of dibekacine in urinary infections</TI>
<TO>Estudio clinico-bacteriologico de la dibekacine en las infecciones urinarias</TO>
<SO>Revista Clinica Espanola</SO>
<YR>1979</YR>
<VL>155</VL>
<NO>6</NO>
<PG>417-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="397556"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marsh-1980" NAME="Marsh 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Marsh BT, Menday AP. Comparative efficacy of 3-day and 7-day chemotherapy with pivmecillinam in urinary tract infections in general practice. Journal of International Medical Research 1980;8:105-11.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marsh BT, Menday AP</AU>
<TI>Comparative efficacy of 3-day and 7-day chemotherapy with pivmecillinam in urinary tract infections in general practice</TI>
<SO>Journal of International Medical Research</SO>
<YR>1980</YR>
<VL>8</VL>
<NO>2</NO>
<PG>105-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6245976"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martin-1983" NAME="Martin 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martin AJ, Lacey RW</AU>
<TI>A blind comparison of the efficacy and incidence of unwanted effects of trimethoprim and co-trimoxazole in the treatment of acute infection of the urinary tract in general practice</TI>
<SO>British Journal of Clinical Practice</SO>
<YR>1983</YR>
<VL>37</VL>
<NO>3</NO>
<PG>105-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6603859"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Masterton-1995" NAME="Masterton 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Masterton RG, Bochsler JA</AU>
<TI>High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>35</VL>
<NO>1</NO>
<PG>129-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7768760"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matsumoto-1991" MODIFIED="2008-05-06 15:52:27 +1000" MODIFIED_BY="Narelle S Willis" NAME="Matsumoto 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-06 15:52:27 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;conference proceeding, abstract presented at the&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 15:52:27 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matsumoto T, Tanaka M, Ogata N, Kumazawa J and Collaborative Research Group</AU>
<TI>Efficacy of single-dose ciprofloxacin therapy for acute uncomplicated cystitis</TI>
<SO>European Journal of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>1991</YR>
<VL>430 - Special Issue</VL>
<PG>430</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menday-2000" NAME="Menday 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menday AP</AU>
<TI>Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2000</YR>
<VL>13</VL>
<NO>3</NO>
<PG>183-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10724022"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Minassian-1998" NAME="Minassian 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Minassian MA, Lewis DA, Chattopadhyay, Bovill B, Duckworth GJ, Williams JD. A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women.. International Journal of Antimicrobial Agents 1998;10:39-47.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Minassian MA, Lewis DA, Chattopadhyay, Bovill B, Duckworth GJ, Williams JD</AU>
<TI>A comparison between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>1998</YR>
<VL>10</VL>
<NO>1</NO>
<PG>39-47</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9624542"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mompo-1986" NAME="Mompo 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Mompo JA, Gallego J, Boronat F, Martinez R, Gobernado M, Jimenez Cruz JF. Tratamiento con dosis unica de antimicrobiano en la cistitis bacteriana no complicada. Estudio comparativo [Treatment with a single-dose antibiotic in non-complicated bacterial cystitis. Comparative study]. Actas Urologicas Espanolas 1986;10(2):95-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mompo JA, Gallego J, Boronat F, Martinez R, Gobernado M, Jimenez Cruz JF</AU>
<TI>Treatment with a single-dose antibiotic in non-complicated bacterial cystitis. Comparative study</TI>
<TO>Tratamiento con dosis unica de antimicrobiano en la cistitis bacteriana no complicada. Estudio comparativo</TO>
<SO>Actas Urologicas Espanolas</SO>
<YR>1986</YR>
<VL>10</VL>
<NO>2</NO>
<PG>95-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3728123"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Musierowicz-1980" NAME="Musierowicz 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Musierowicz A, Borowski J, zaremba M, Prokopowicz, Darewicz J, Gruszecki W, Pachman A. Ocena kliniczna pochodnej kwasu 6-beta-amidynopenicylanowego (preparatu HX) w zakazeniach ukladu moczowego [Clinical evaluation of a derivative of 6-beta-amidino penicillanic acid (preparation HX) in urinary tract infections]. Polski Tygodnik Lekarski 1980;35(27):1017-9.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Musierowicz A, Borowski J, Zaremba M, Prokopowicz, Darewicz J, Gruszecki W et al</AU>
<TI>Clinical evaluation of a derivative of 6-beta-amidino penicillanic acid (preparation HX) in urinary tract infections</TI>
<TO>Ocena kliniczna pochodnej kwasu 6-beta-amidynopenicylanowego (preparatu HX) w zakazeniach ukladu moczowego</TO>
<SO>Polski Tygodnik Lekarski</SO>
<YR>1980</YR>
<VL>35</VL>
<NO>27</NO>
<PG>1017-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6252549"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2004" MODIFIED="2008-05-06 17:18:51 +1000" MODIFIED_BY="Narelle S Willis" NAME="Naber 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-05-06 17:18:51 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naber KG, Allin DM, Clarysse L, Haworth DA, James IG, Raini C et al</AU>
<TI>Gatifloxacin 400 mg as a single shot or 200 mg once daily for 3 days is as effective as ciprofloxacin 250 mg twice daily for the treatment of patients with uncomplicated urinary tract infections</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>6</NO>
<PG>596-605</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:18:51 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="15194131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neringer-1992" NAME="Neringer 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neringer R, Forgren A, Hansson C, Ode B</AU>
<TI>Lomefloxacin versus norfloxacin in the treatment of uncomplicated urinary tract infections: three-day versus seven-day treatment. The South Swedish Lolex Study Group</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>6</NO>
<PG>773-80</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1337623"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Neu-1990" NAME="Neu 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Neu HC. Fosfomycin trometamol versus amoxycillin - Single-dose multicenter study of urinary tract infections. Chemotherapy 1990;36(Suppl. 1):19-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Neu HC</AU>
<TI>Fosfomycin trometamol versus amoxycillin - Single-dose multicenter study of urinary tract infections</TI>
<SO>Chemotherapy</SO>
<YR>1990</YR>
<VL>36 Suppl</VL>
<NO>1</NO>
<PG>19-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2085982"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norrby-1993" NAME="Norrby 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norrby SR, O'Reilly T, Zak O</AU>
<TI>Efficacy of antimicrobial agent treatment in relation to treatment regimen: experimental models and clinical evaluation</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1993</YR>
<VL>31 Suppl</VL>
<NO>D</NO>
<PG>41-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8335523"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ode-1987" NAME="Ode 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ode B, Walder M, Forsgren A</AU>
<TI>Failure of a single dose of 100 mg ofloxacin in lower urinary tract infections in females</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1987</YR>
<VL>19</VL>
<NO>6</NO>
<PG>677-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3327150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olsovsky-1988" NAME="Olsovsky 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olsovsky Z, Nedbalek A, Herboczek K, Konecny J</AU>
<TI>Use of single and short-term therapy of non-complicated infections of the urinary pathways in routine practice</TI>
<TO>Vyuziti jednorazove a kratkokobe terapie nekomplikovanych infekci mocovych cest</TO>
<SO>Rozhledy V Chirurgii</SO>
<YR>1988</YR>
<VL>67</VL>
<NO>10</NO>
<PG>688-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3206315"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Onodera-1980" NAME="Onodera 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Onodera S. Clinical evaluation of cefatrizine for urinary tract infections. The Japanese Journal of Antibiotics 1980;33(4):510-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onodera S</AU>
<TI>Clinical evaluation of cefatrizine for urinary tract infections (author's transl)</TI>
<SO>Japanese Journal of Antibiotics</SO>
<YR>1980</YR>
<VL>33</VL>
<NO>4</NO>
<PG>510-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6997535"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-1980" NAME="Oosterlinck 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Oosterlinck, Welvaert P, Verbaeys A, Schelfout W, Wijndaele JJ, De Maeyer P. L'acide pip&amp;#233;midique: un nouvel antibiotique des voies urinaires. Une &amp;#233;tude comparative, en double-insu, entre l'acide pip&amp;#233;midique et l'amoxycilline [Pipemidic acid: a new antibiotic for the urinary tract. A comparative, double-blind study of pipemidic acid and amoxidillin]. Acta Urologica Belgica 1980;48(4):471-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck, Welvaert P, Verbaeys A, Schelfout W, Wijndaele JJ, De Maeyer P</AU>
<TI>Pipemidic acid: a new antibiotic for the urinary tract. A comparative, double-blind study of pipemidic acid and amoxidillin</TI>
<TO>L'acide pipémidique: un nouvel antibiotique des voies urinaires. Une étude comparative, en double-insu, entre l'acide pipémidique et l'amoxycilline</TO>
<SO>Acta Urologica Belgica</SO>
<YR>1980</YR>
<VL>48</VL>
<NO>4</NO>
<PG>471-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7006346"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Osterberg-1990" NAME="Osterberg 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Österberg E, Aberg H, Hallander HO, Kallner A, Lundin A</AU>
<TI>Efficacy of single-dose versus seven-day trimethoprim treatment of cystitis in women: A randomized double-blind study</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1990</YR>
<VL>161</VL>
<NO>5</NO>
<PG>942-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2182732"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Otieno-1988" NAME="Otieno 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Otieno LS, Kanja C</AU>
<TI>Trimethoprim (monotrim) compared with trimethoprim-sulphonamide in the treatment of bacterial urinary tract infection</TI>
<SO>East African Medical Journal</SO>
<YR>1988</YR>
<VL>65</VL>
<NO>1</NO>
<PG>18-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3046920"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patrick-1991" MODIFIED="2008-05-06 17:20:14 +1000" MODIFIED_BY="Narelle S Willis" NAME="Patrick 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-05-06 17:20:14 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;abstract&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:20:14 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patrick K, Kaplanski M, Trumble B, Pizzuti D, Cerruti R, St. Clair PJ</AU>
<TI>Randomized trial of single dose and multiple dose fleroxacin versus ciprofloxacin for uncomplicated urinary tract infections [abstract]</TI>
<SO>European Journal of Clinical Microbiology &amp; Infectious Diseases</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>Special Issue</NO>
<PG>462-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pawelczyk-2002" MODIFIED="2008-05-06 17:19:18 +1000" MODIFIED_BY="Narelle S Willis" NAME="Pawelczyk 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-05-06 17:19:18 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pawelczyk I, Grzyb M, Zelawski W, Wylezek D, Starzewski JJ, Kozera J</AU>
<TI>[Instillagel in prevention of postoperative urinary tract infection--randomized trial]. [Polish]</TI>
<TO>Instillagel w profilaktyce pooperacyjnych zakazen ukladu moczowego. Badanie randomizowane.</TO>
<SO>Wiadomosci Lekarskie</SO>
<YR>2002</YR>
<VL>55</VL>
<NO>5-6</NO>
<PG>288-95</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:19:18 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:19:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="22221545"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peddie-1981" NAME="Peddie 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peddie BA, Little PJ, Piesse HP</AU>
<TI>Pivmecillinam in uncomplicated urinary tract infections in general practice</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1981</YR>
<VL>93</VL>
<NO>678</NO>
<PG>109-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6267530"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petersen-1990" NAME="Petersen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petersen EE, Wingen F, Fairchild KL, Halfhide A, Hendrischk A, Links M et al</AU>
<TI>Single dose pefloxacin compared with multiple dose co-trimoxazole in cystitis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>26 Suppl</VL>
<NO>B</NO>
<PG>147-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2258341"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pfau-1984" NAME="Pfau 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pfau A, Sacks TG, Shapiro A, Shapiro M</AU>
<TI>A randomized comparison of 1-day versus 10-day antibacterial treatment of documented lower urinary tract infection</TI>
<SO>Journal of Urology</SO>
<YR>1984</YR>
<VL>132</VL>
<NO>5</NO>
<PG>931-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6387183"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pitk_x00e4_j_x00e4_rvi-1990" NAME="Pitkäjärvi 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Pitk&amp;#228;j&amp;#228;rvi T, Pyyk&amp;#246;nen ML, Kannisto K, Piippo T, Viita P. Pivmecillinam treatment in acute cystitis. Three versus seven days study. Arzneimittelforschung 1990;40(10):1156-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitkäjärvi T, Pyykönen ML, Kannisto K, Piippo T, Viita P</AU>
<TI>Pivmecillinam treatment in acute cystitis. Three versus seven days study</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1990</YR>
<VL>40</VL>
<NO>10</NO>
<PG>1156-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2291755"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polubiec-1988" NAME="Polubiec 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Polubiec A, Weuta H, Stepka K, Ktos K, Strazynska R, Jorasz J. Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin - a comparative study. Infection 1988;16(Suppl. 1):S 62-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polubiec A, Weuta H, Stepka K, Ktos K, Strazynska R, Jorasz J</AU>
<TI>Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin - a comparative study</TI>
<SO>Infection</SO>
<YR>1988</YR>
<VL>16 Suppl</VL>
<NO>1</NO>
<PG>62-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3286518"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pontzer-1983" NAME="Pontzer 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Pontzer RE, Krieger RE, Boscia JA, McNamee W, Levison ME, Kaye D. Single-dose cefonicid therapy for urinary tract infections. Antimicrobial Agents and Chemotherapy 1983;23(6):814-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontzer RE, Krieger RE, Boscia JA, McNamee W, Levison ME, Kaye D</AU>
<TI>Single-dose cefonicid therapy for urinary tract infections</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1983</YR>
<VL>23</VL>
<NO>6</NO>
<PG>814-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6555015"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porpaczy-1984" NAME="Porpaczy 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porpaczy P</AU>
<TI>Cefotaxime in the treatment of urinary tract infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>14 Suppl</VL>
<NO>B</NO>
<PG>311-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6094458"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prat-1986" NAME="Prat 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Prat V, Horcickova M, Milotova Z, Matousovic K, Hatala M. Lecebny ucinek jednorazoveho podani 1g cefotaximu pri infekci mocovych cest [The therapeutic effect of a single administration of 1g of cefotaxime in urinary tract infections]. Casopis Lekaru Ceskych 1986;125(35):1097-99.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prat V, Horcickova M, Milotova Z, Matousovic K, Hatala M</AU>
<TI>The therapeutic effect of a single administration of 1g of cefotaxime in urinary tract infections</TI>
<TO>Lecebny ucinek jednorazoveho podani 1g cefotaximu pri infekci mocovych cest</TO>
<SO>Casopis Lekaru Ceskych</SO>
<YR>1986</YR>
<VL>125</VL>
<NO>35</NO>
<PG>1097-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3757001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prentice-1985" NAME="Prentice 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prentice RD, Wu LR, Gehlbach SH, Hanlon JT, Clapp-Channing NE, Finn AL</AU>
<TI>Treatment of lower urinary tract infections with single-dose trimethoprim-sulfamethoxazole</TI>
<SO>Journal of Family Practice</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>6</NO>
<PG>551-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3873511"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ranno-1986" MODIFIED="2008-05-06 17:20:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Ranno 1986" YEAR="1986">
<REFERENCE MODIFIED="2008-05-06 17:20:37 +1000" MODIFIED_BY="Narelle S Willis" NOTES="&lt;p&gt;Ranno S, Bellotti MG, Raimondi A, Minaldi G. Sutdio sull'attivita terapeutica dell'aztreoanm nel trattamento delle infezioni urinarie acute e croniche [Therapeutic activity of aztreonam in the treatment of acute and chronic urinary tract infections]. Minerva Urologica e Nefrologica 1986;38(1):65-9.&lt;/p&gt;" NOTES_MODIFIED="2008-05-06 17:20:37 +1000" NOTES_MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ranno S, Bellotti MG, Raimondi A, Minaldi G</AU>
<TI>Investigation of the therapeutic action of aztreonam in the treatment of acute and chronic urinary infections</TI>
<TO>Sutdio sull'attivita terapeutica dell'aztreoanm nel trattamento delle infezioni urinarie acute e croniche</TO>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>1986</YR>
<VL>38</VL>
<NO>1</NO>
<PG>65-9</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:20:37 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:20:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1986233148"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Rapoport-1981" NAME="Rapoport 1981" YEAR="1981">
<REFERENCE NOTES="&lt;p&gt;letter from Dr Slack: elderly patients were excluded and the majority of patients were under 65 years&lt;br&gt;Rapoport J, Rees GA, Willmott NJ, Slack RCB, O'Grady FW. Treatment of acute urinary tract infection with three doses of co-trimoxazole. BMJ 1981;283:1302-3.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rapoport J, Rees GA, Willmott NJ, Slack RCB, O'Grady FW</AU>
<TI>Treatment of acute urinary tract infection with three doses of co-trimoxazole</TI>
<SO>British Medical Journal Clinical Research Ed</SO>
<YR>1981</YR>
<VL>283</VL>
<NO>6302</NO>
<PG>1302-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6794832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raz-1991" NAME="Raz 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raz R, Rottensterich E, Boger S, Potasman I</AU>
<TI>Comparison of single-dose administration and three-day course of amoxicillin with those of clavulanic acid for treatment of uncomplicated urinary tract infection in women</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1991</YR>
<VL>35</VL>
<NO>8</NO>
<PG>1688-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1929343"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reeves-1981" NAME="Reeves 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reeves DS</AU>
<TI>Single dose treatment of urinary tract infections</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<NO>8217</NO>
<PG>444</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6110075"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reynaert-1990" NAME="Reynaert 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reynaert J, Van Eyck D, Vandepitte J</AU>
<TI>Single dose fosfomycin trometamol versus multiple dose norfloxacin over three days for uncomplicated UTI in general practice</TI>
<SO>Infection</SO>
<YR>1990</YR>
<VL>18 Suppl</VL>
<NO>2</NO>
<PG>77-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2286466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richard-2002" NAME="Richard 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richard GA, Mathew CP, Kirstein JM, Orchard D, Yang JY</AU>
<TI>Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens</TI>
<SO>Urology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>3</NO>
<PG>334-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21874689"/>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00408507"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richards-1984" NAME="Richards 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Richards HH. Comparative efficacy of 3-day and 7-day chemotherapy with twice-daily pivmecillinam in urinary tract infections seen in general practice. Current Medical Research and Opinion 1984;9(3):197-203.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richards HH</AU>
<TI>Comparative efficacy of 3-day and 7-day chemotherapy with twice-daily pivmecillinam in urinary tract infections seen in general practice</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>3</NO>
<PG>197-203</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6499513"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenstock-1985" NAME="Rosenstock 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenstock J, Smith LP, Gurney M, Lee K, Weinberg WG, Longfield JN et al</AU>
<TI>Comparison of single-dose tetracycline hydrochloride to conventional therapy of urinary tract infections</TI>
<SO>Antimicrobial Agents &amp; Chemotherapy</SO>
<YR>1985</YR>
<VL>27</VL>
<NO>4</NO>
<PG>652-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3890732"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubin-1980" NAME="Rubin 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Rubin RH, Fang LST, Jones SR. Munford RS, Slepack JM, Varga PA, Onheiber L, Hall CL, Tolkoff-Rubin NE. Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique. JAMA 1980;244(6):561-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubin RH, Fang LST, Jones SR. Munford RS, Slepack JM, Varga PA et al</AU>
<TI>Single-dose amoxicillin therapy for urinary tract infection. Multicenter trial using antibody-coated bacteria localization technique</TI>
<SO>JAMA</SO>
<YR>1980</YR>
<VL>244</VL>
<NO>6</NO>
<PG>561-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6993706"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Russ-1980" NAME="Russ 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;letter from Russ: no information on age, raw data no more available&lt;br&gt;Russ GR, Mathew TH, Caon A. Single day or single dose treatment of urinary tract infection with co-trimoxazole. Austalian and New Zealand Journal of Medicine 1980;10(6):604-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russ GR, Mathew TH, Caon A</AU>
<TI>Single day or single dose treatment of urinary tract infection with co-trimoxazole</TI>
<SO>Australian &amp; New Zealand Journal of Medicine</SO>
<YR>1980</YR>
<VL>10</VL>
<NO>6</NO>
<PG>604-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7011293"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saginur-1992" NAME="Saginur 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saginur R, Nicolle LE</AU>
<TI>Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1992</YR>
<VL>152</VL>
<NO>6</NO>
<PG>1233-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1599352"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sanchez-1988" NAME="Sanchez 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Sanchez IM. Tratamiento de la infeccion urinaria aguda con esquema habitual y con dosis unica de antibiotico [Treatment of acute urinary infection with the usual regimen and a single dose of antibiotic].Revista Medica de Chile 1988;116(2):184-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sanchez IM</AU>
<TI>Treatment of acute urinary infection with the usual regimen and a single dose of antibiotic</TI>
<TO>Tratamiento de la infeccion urinaria aguda con esquema habitual y con dosis unica de antibiotico</TO>
<SO>Revista Medica de Chile</SO>
<YR>1988</YR>
<VL>116</VL>
<NO>2</NO>
<PG>184-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3068759"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sandberg-1985" NAME="Sandberg 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sandberg T, Henning C, Iwarson S, Paulsen O</AU>
<TI>Cefadroxil once daily for three or seven days versus amoxycillin for seven days in uncomplicated urinary tract infections in women</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1985</YR>
<VL>17</VL>
<NO>1</NO>
<PG>83-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3887560"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Savard_x002d_Fenton-1982" NAME="Savard-Fenton 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Savard-Fenton M, Fenton BW, Reller LB, Lauer BA, Byyny RL</AU>
<TI>Single-dose amoxicillin therapy with follow-up urine culture. Effective initial management for acute uncomplicated urinary tract infections</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73</VL>
<NO>6</NO>
<PG>808-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6924538"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schultz-1984" NAME="Schultz 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Schultz JH, McCaffrey LA, Keys TF, Nobrega FT. Acute cystitis: A prospective study of laboratory tests and duration of therapy. Mayo Clinic Proceedings 1984;59:391-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schultz JH, McCaffrey LA, Keys TF, Nobrega FT</AU>
<TI>Acute cystitis: A prospective study of laboratory tests and duration of therapy</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1984</YR>
<VL>59</VL>
<NO>6</NO>
<PG>391-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6427533"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sigurdsson-1983" NAME="Sigurdsson 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Sigudsson JAm Ahlmen J, Berglund L, Jerneck M, Larsson L, Lincoln K, Wohrm A, Bucht H. Three-day treatment of acute lower urinary tract infections in women. A double-blind study with amoxycillin and co-trimazine. Acta Medica Scandinavica 1983;213:55-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sigudsson Jam Ahlmen J, Berglund L, Jerneck M, Larsson L, Lincoln K, Wohrm A et al</AU>
<TI>Three-day treatment of acute lower urinary tract infections in women. A double-blind study with amoxycillin and co-trimazine</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1983</YR>
<VL>213</VL>
<NO>1</NO>
<PG>55-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6829321"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slade-1972" NAME="Slade 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slade N, Crowther ST</AU>
<TI>Multicentre survey of urinary tract infections in general practice. Clinical trial of single dose treatment with sulfametopyrazine (Kelfizine-W)</TI>
<SO>British Journal of Urology</SO>
<YR>1972</YR>
<VL>44</VL>
<NO>1</NO>
<PG>105-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4556420"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staszewska-1995" NAME="Staszewska 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Staszewska Pistoni M, Dontas AS, Giamarellou H, Petrikkos G, Zorbas P. Effectiveness of ofloxacin therapy in preventing functional impairment and increased mortality in elderly patients with bacteriuria. Drugs 1995;49 (Suppl. 2):374-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staszewska Pistoni M, Dontas AS, Giamarellou H, Petrikkos G, Zorbas P</AU>
<TI>Effectiveness of ofloxacin therapy in preventing functional impairment and increased mortality in elderly patients with bacteriuria</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49 Suppl</VL>
<NO>2</NO>
<PG>374-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8549366"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Stein-1987" NAME="Stein 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stein GE, Mummaw N, Goldstein EJC, Boyko EJ, Reller LB, Kurtz TO et al</AU>
<TI>A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<NO>10</NO>
<PG>1760-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3310941"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sturm-1984" NAME="Sturm 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Sturm AW. Trimethoprim bij acute ongecompliceerde urineweginfecties; eenmaal toedienen of een kuur van zeven dagen [Trimethoprim in acute uncomplicated urinary tract infections; a single-dose administration or a 7-day course]. Nederlands Tijdschrift voor Geneeskunde 1984;128(12):534-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sturm AW</AU>
<TI>Trimethoprim in acute uncomplicated urinary tract infections; a single-dose administration or a 7-day course</TI>
<TO>Trimethoprim bij acute ongecompliceerde urineweginfecties; eenmaal toedienen of een kuur van zeven dagen</TO>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1984</YR>
<VL>128</VL>
<NO>12</NO>
<PG>534-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6717617"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutlieff-1982" NAME="Sutlieff 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Sutlieff PA. A comparison between a 3-day and a 5-day course of pivmecillinam as a treatment for acute lower urinary tract infections in general practice. Current Medical Research Opinion 1982;7(9):563-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutlieff PA</AU>
<TI>A comparison between a 3-day and a 5-day course of pivmecillinam as a treatment for acute lower urinary tract infections in general practice</TI>
<SO>Current Medical Research &amp; Opinion</SO>
<YR>1982</YR>
<VL>7</VL>
<NO>9</NO>
<PG>563-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="1982133536"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tolkoff_x002d_Rubin-1982" NAME="Tolkoff-Rubin 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tolkoff-Rubin NE, Weber D, Fang LST, Kelly M, Wilkinson R, Rubin RH</AU>
<TI>Single-dose therapy with trimethoprim-sulfamethoxazole for urinary tract infection in women</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>2</NO>
<PG>444-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6981162"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trienekens-1993" NAME="Trienekens 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Trienekens TAM, London NHHJ, Houben AW, Dejong RAM, Stobberingh EE. Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin. Canadian Family Physician 1993;39:514-18.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trienekens TAM, London NHHJ, Houben AW, Dejong RAM, Stobberingh EE</AU>
<TI>Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin</TI>
<SO>Canadian Family Physician</SO>
<YR>1993</YR>
<VL>39</VL>
<PG>514-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8471899"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-UTI-Study-Group-1987" NAME="UTI Study Group 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;The Urinary Tract Infection Study Group. Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment or symptomatic urinary tract infections. The Journal of Infectious Diseases 1987;155(2):170-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment or symptomatic urinary tract infections. The Urinary Tract Infection Study Group</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1987</YR>
<VL>155</VL>
<NO>2</NO>
<PG>170-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2879872"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Balen-1990" NAME="van Balen 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Balen FAM, Touw-Otten FWMM, de Melker RA</AU>
<TI>Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1990</YR>
<VL>26 Suppl</VL>
<NO>B</NO>
<PG>153-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2258342"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Pienbroek-1993" NAME="van Pienbroek 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Pienbroek E, Hermans J, Kaptein AA, Mulder JD</AU>
<TI>Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women</TI>
<SO>Pharmacy World &amp; Science</SO>
<YR>1993</YR>
<VL>15</VL>
<NO>6</NO>
<PG>257-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8298585"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vogel-1984" NAME="Vogel 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Vogel R, Deaney NB, Round EM, VandenBurg MJ, Currie WJC. Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections. Journal of Antimicrobial Chemotherapy 1984;13 (Suppl. B):113-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vogel R, Deaney NB, Round EM, VandenBurg MJ, Currie WJC</AU>
<TI>Norfloxacin, amoxycillin, cotrimoxazole and nalidixic acid. A summary of 3-day and 7-day therapy studies in the treatment of urinary tract infections</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1984</YR>
<VL>13 Suppl</VL>
<NO>B</NO>
<PG>113-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6234271"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winwick-1981" NAME="Winwick 1981" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Winwick JG, Savage SJ</AU>
<TI>A comparison of a 3-day course of Mictral with a 7-day course of ampicillin in the treatment of urinary tract infection</TI>
<SO>Journal of International Medical Research</SO>
<YR>1981</YR>
<VL>9</VL>
<NO>1</NO>
<PG>58-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7202832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zorbas-1995" NAME="Zorbas 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Zorbas P, Giamarellou H, Staszewska-Pistoni M, Petrikkos G, Grammatikou M, Dontas AJ. Comparison of 2 oral ofloxacin regimens for the treatment of bacteriuria in elderly subjects. Drugs 1995;49 (Suppl. 2):384-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zorbas P, Giamarellou H, Staszewska-Pistoni M, Petrikkos G, Grammatikou M, Dontas AJ</AU>
<TI>Comparison of 2 oral ofloxacin regimens for the treatment of bacteriuria in elderly subjects</TI>
<SO>Drugs</SO>
<YR>1995</YR>
<VL>49 Suppl</VL>
<NO>2</NO>
<PG>384-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8549370"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-05-07 16:06:53 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_REFERENCES MODIFIED="2008-05-07 16:06:53 +1000" MODIFIED_BY="Narelle S Willis">
<REFERENCE ID="REF-Abrutyn-1991" NAME="Abrutyn 1991" TYPE="JOURNAL_ARTICLE">
<AU>Abrutyn E, Mossey J, Boscia J, Pitsakis P, Kaye D</AU>
<TI>Epidemiology of asymptomatic bacteriuria in elderly women</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1991</YR>
<VL>39</VL>
<NO>4</NO>
<PG>388-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2010589"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baldassarre-1991" NAME="Baldassarre 1991" TYPE="JOURNAL_ARTICLE">
<AU>Baldassarre JS, Kaye D</AU>
<TI>Special problems of urinary tract infection in the elderly</TI>
<SO>Medical Clinics of North America</SO>
<YR>1991</YR>
<VL>75</VL>
<NO>2</NO>
<PG>375-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996040"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1997" NAME="Berlin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA</AU>
<TI>Does blinding of readers affect the results of meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>350</VL>
<NO>9072</NO>
<PG>185-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9250191"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Borrego-1997" NAME="Borrego 1997" TYPE="JOURNAL_ARTICLE">
<AU>Borrego F, Gleckman R</AU>
<TI>Principles of antibiotic prescribing in the elderly</TI>
<SO>Drugs &amp; Aging</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>1</NO>
<PG>7-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="9237037"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Childs-1996" NAME="Childs 1996" TYPE="JOURNAL_ARTICLE">
<AU>Childs SJ, Egan RJ</AU>
<TI>Bacteriuria and urinary infections in the elderly</TI>
<SO>Urologic Clinics of North America</SO>
<YR>1996</YR>
<VL>23</VL>
<NO>1</NO>
<PG>43-54</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8677536"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Compendium-1998" NAME="Compendium 1998" TYPE="BOOK">
<AU>Anonymous</AU>
<SO>Compendium Suisse des Médicaments</SO>
<YR>1998</YR>
<PB>Documed</PB>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Emori-1991" NAME="Emori 1991" TYPE="JOURNAL_ARTICLE">
<AU>Emori TG, Banerjee SN, Culver DH, Gaynes RP, Horan TC, Edwards JR et al</AU>
<TI>Nosocomial Infections in elderly patients in the United States, 1986-1990</TI>
<SO>American Journal of Medicine</SO>
<YR>1991</YR>
<VL>91 Suppl</VL>
<NO>3B</NO>
<PG>289-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1928180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ewer-1988" NAME="Ewer 1988" TYPE="JOURNAL_ARTICLE">
<AU>Ewer TC, Bailey RR, Gilchrist NL, Aitken JM, Sainsbury R</AU>
<TI>Comparative study of norfloxacin and trimethoprim for the treatment of elderly patients with urinary tract infection</TI>
<SO>New Zealand Medical Journal</SO>
<YR>1988</YR>
<VL>1101</VL>
<NO>852</NO>
<PG>537-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3045717"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gallacher-1986" NAME="Gallacher 1986" TYPE="JOURNAL_ARTICLE">
<AU>Gallacher G, Erwin L, Scott PJ, Sleigh JD</AU>
<TI>Augmentin (amoxycillin-clavulanic acid) compared with amoxycillin alone in the treatment of urinary tract infections in the elderly</TI>
<SO>Journal of Infection</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>3</NO>
<PG>229-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3522749"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Goessens-2007" NAME="Goessens 2007" TYPE="JOURNAL_ARTICLE">
<AU>Goessens WH, Verbrugh HA</AU>
<TI>Antibiotic resistance: epidemiological developments and preventive measures</TI>
<SO>Ned Tijdschr Geneeskd</SO>
<YR>2007</YR>
<VL>151</VL>
<NO>13</NO>
<PG>748-52</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="17471776"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Harding-1991" NAME="Harding 1991" TYPE="JOURNAL_ARTICLE">
<AU>Harding GK, Nicolle LE, Ronald AR, Preiksaitis JK, Forward KR, Low DE et al</AU>
<TI>How long should catheter-acquired urinary tract infection in women be treated? A randomized controlled study</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1991</YR>
<VL>114</VL>
<NO>9</NO>
<PG>713-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2012351"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2008-05-07 16:06:53 +1000" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2008-05-07 16:06:47 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hooton-1995" NAME="Hooton 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hooton TM, Winter C, Tiu F, Stamm WE</AU>
<TI>Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>1</NO>
<PG>41-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7654268"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Humbert-1992" NAME="Humbert 1992" TYPE="JOURNAL_ARTICLE">
<AU>Humbert G</AU>
<TI>French consensus on antibiotherapy of urinary tract infections</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20 Suppl</VL>
<NO>3</NO>
<PG>171-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1490744"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jonsson-1990" NAME="Jonsson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson M, Englund G, Norgard K</AU>
<TI>Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients</TI>
<SO>Scandinavian Journal of Infectious Diseases</SO>
<YR>1990</YR>
<VL>22</VL>
<NO>3</NO>
<PG>339-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2196670"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kasviki_x002d_Charvati1982" NAME="Kasviki-Charvati1982" TYPE="JOURNAL_ARTICLE">
<AU>Kasviki-Charvati P, Drolette-Kefakis B, Papanayiotou PC, Dontas AS</AU>
<TI>Turnover of bacteriuria in old age</TI>
<SO>Age &amp; Ageing</SO>
<YR>1982</YR>
<VL>11</VL>
<NO>3</NO>
<PG>169-74</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6981920"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kaye-1980" NAME="Kaye 1980" TYPE="JOURNAL_ARTICLE">
<AU>Kaye D</AU>
<TI>Urinary tract infections in the elderly</TI>
<SO>Bulletin of the New York Academy of Medicine</SO>
<YR>1980</YR>
<VL>56</VL>
<NO>2</NO>
<PG>209-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6929194"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kunin-1987" NAME="Kunin 1987" TYPE="BOOK">
<AU>Kunin MC</AU>
<SO>Detection, prevention and management of urinary tract infections</SO>
<YR>1987</YR>
<PB>Lea &amp; Febiger</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lutters-2000" NAME="Lutters 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lutters M, Vogt N</AU>
<TI>What's the basis for treating infections your way? Quality assessment of review articles on the treatment of urinary and respiratory tract infections in older people</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2000</YR>
<VL>48</VL>
<NO>11</NO>
<PG>1454-61</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="11083323"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McCue-1992" NAME="McCue 1992" TYPE="JOURNAL_ARTICLE">
<AU>McCue JD</AU>
<TI>Antimicrobial therapy</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>1992</YR>
<VL>8</VL>
<NO>4</NO>
<PG>925-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1423144"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Michel-1991" NAME="Michel 1991" TYPE="JOURNAL_ARTICLE">
<AU>Michel JP, Lesourd B, Conne P, Richard D, Rapin CH</AU>
<TI>Prevalence of infections and their risk factors in geriatric institutions: a one-day multicentre survey</TI>
<SO>Bulletin of the World Health Organization</SO>
<YR>1991</YR>
<VL>69</VL>
<NO>1</NO>
<PG>35-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1905207"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1994" NAME="Mulrow 1994" TYPE="BOOK">
<AU>Mulrow CD, Oxman AD</AU>
<SO>The Cochrane Handbook</SO>
<YR>1997</YR>
<VL>Issue 4</VL>
<PB>The Cochane Collaboration</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naber-1990" MODIFIED="2008-05-06 17:21:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Naber 1990" TYPE="CONFERENCE_PROC">
<AU>Naber KG, Kumamoto Y</AU>
<TI>Summary of discussion for acute uncomplicated cystitis. Clincal evaluation of drug efficacy in UTI. Proceedings of the First International Symposium, 27-28 October 1989, Tokyo, Japan</TI>
<SO>International Congress Series 938</SO>
<YR>1990</YR>
<PG>230</PG>
<ED>Ohkoschi M, Kawada Y</ED>
<PB>Excerpta Medica</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicolle-1983" NAME="Nicolle 1983" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE, Bjornson J, Harding GK, MacDonell JA</AU>
<TI>Bacteriuria in elderly institutionalized men</TI>
<SO>New England Journal of Medicine</SO>
<YR>1983</YR>
<VL>309</VL>
<NO>23</NO>
<PG>1420-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6633618"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nicolle-1992" NAME="Nicolle 1992" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE</AU>
<TI>Urinary tract infection in the elderly. How to treat and when?</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20 Suppl</VL>
<NO>4</NO>
<PG>261-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicolle-1993" NAME="Nicolle 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE</AU>
<TI>Urinary tract infections in long-term care facilities</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>1993</YR>
<VL>14</VL>
<NO>4</NO>
<PG>220-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8478544"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nicolle-1994" NAME="Nicolle 1994" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE</AU>
<TI>Urinary tract infection in the elderly</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>1994</YR>
<VL>33 Suppl</VL>
<NO>A</NO>
<PG>99-109</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="7928842"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nolan-1988" NAME="Nolan 1988" TYPE="JOURNAL_ARTICLE">
<AU>Nolan L, O'Malley K</AU>
<TI>Prescribing for the elderly. Part I: Sensitivity of the elderly to adverse drug reactions</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1988</YR>
<VL>36</VL>
<NO>2</NO>
<PG>142-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3276767"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Norrby-1990" NAME="Norrby 1990" TYPE="JOURNAL_ARTICLE">
<AU>Norrby SR</AU>
<TI>Short-term treatment of uncomplicated lower urinary tract infections in women</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1990</YR>
<VL>12</VL>
<NO>3</NO>
<PG>458-67</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2193352"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Norrby-1992" NAME="Norrby 1992" TYPE="JOURNAL_ARTICLE">
<AU>Norrby SR</AU>
<TI>Design of clinical trials in patients with urinary tract infections</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20 Suppl</VL>
<NO>3</NO>
<PG>181-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1490745"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nygaard-1996" NAME="Nygaard 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nygaard IE, Johnson JM</AU>
<TI>Urinary tract infections in elderly women</TI>
<SO>American Family Physician</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>1</NO>
<PG>175-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8546044"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Reid-1984" MODIFIED="2008-05-06 17:22:01 +1000" MODIFIED_BY="Narelle S Willis" NAME="Reid 1984" TYPE="JOURNAL_ARTICLE">
<AU>Reid G, Zorzotto ML, Bruce AW et al</AU>
<TI>Pathogenesis of urinary tract infection in the elderly: The role of bacterial adherence to uroepithelial cells</TI>
<SO>Current Microbiology</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>2</NO>
<PG>67-72</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:22:01 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:22:01 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1985159608"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Rubin-1992" NAME="Rubin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE</AU>
<TI>Evaluation of new anti-infective drugs for the treatment of urinary tract infection</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1992</YR>
<VL>15 Suppl</VL>
<NO>1</NO>
<PG>216-27</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1477233"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sant-1987" NAME="Sant 1987" TYPE="JOURNAL_ARTICLE">
<AU>Sant GR</AU>
<TI>Urinary tract infection in the elderly</TI>
<SO>Seminars in Urology</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>2</NO>
<PG>126-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="3296082"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Smith-1994" NAME="Smith 1994" TYPE="JOURNAL_ARTICLE">
<AU>Smith MA, Duke WM</AU>
<TI>A retrospective review of nosocomial infections in an acute rehabilitative and chronic population at a large skilled nursing facility</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1994</YR>
<VL>42</VL>
<NO>1</NO>
<PG>45-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8277114"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sobel-1990" NAME="Sobel 1990" TYPE="BOOK_SECTION">
<AU>Sobel JD, Kaye D</AU>
<TI>Urinary tract infections</TI>
<SO>Principles and practice of infectious diseases</SO>
<YR>1990</YR>
<PG>582-611</PG>
<ED>Mandell Gl, Douglas RG Jr, Bennett JE</ED>
<PB>Churchill Livingstone</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sourander-1972" NAME="Sourander 1972" TYPE="JOURNAL_ARTICLE">
<AU>Sourander LB, Kasanen A</AU>
<TI>A 5-year follow-up of bacteriuria in the aged</TI>
<SO>Gerontologia Clinica</SO>
<YR>1972</YR>
<VL>14</VL>
<NO>5</NO>
<PG>274-81</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="4571598"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stamm-1992" NAME="Stamm 1992" TYPE="JOURNAL_ARTICLE">
<AU>Stamm WE</AU>
<TI>Criteria for the diagnosis of urinary tract infection and for the assessment of therapeutic effectiveness</TI>
<SO>Infection</SO>
<YR>1992</YR>
<VL>20 Suppl</VL>
<NO>3</NO>
<PG>151-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1490740"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Stamm-1993" NAME="Stamm 1993" TYPE="JOURNAL_ARTICLE">
<AU>Stamm WE, Hooton TM</AU>
<TI>Management of urinary tract infections in adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>18</NO>
<PG>1328-34</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8413414"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tam-2007" MODIFIED="2008-05-06 17:26:16 +1000" MODIFIED_BY="Narelle S Willis" NAME="Tam 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tam VH, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L et al</AU>
<TI>Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2007</YR>
<VL>195</VL>
<NO>12</NO>
<PG>1818-27</PG>
<IDENTIFIERS MODIFIED="2008-05-06 17:26:16 +1000" MODIFIED_BY="Narelle S Willis">
<IDENTIFIER MODIFIED="2008-05-06 17:26:16 +1000" MODIFIED_BY="Narelle S Willis" TYPE="MEDLINE" VALUE="17492598"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Warren-1999" NAME="Warren 1999" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE</AU>
<TI>Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>29</VL>
<NO>4</NO>
<PG>745-58</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="10589881"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Winickoff-1981" NAME="Winickoff 1981" TYPE="JOURNAL_ARTICLE">
<AU>Winickoff RN, Wilner SI, Gall G, Laage T, Barnett GO</AU>
<TI>Urine culture after treatment of uncomplicated cystitis in women</TI>
<SO>Southern Medical Journal</SO>
<YR>1981</YR>
<VL>74</VL>
<NO>2</NO>
<PG>165-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6781071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wood-1996" NAME="Wood 1996" TYPE="JOURNAL_ARTICLE">
<AU>Wood CA, Abrutyn E</AU>
<TI>Optimal treatment of urinary tract infections in elderly patients</TI>
<SO>Drugs &amp; Aging</SO>
<YR>1996</YR>
<VL>9</VL>
<NO>5</NO>
<PG>352-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8922562"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-05-09 15:25:01 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-05-09 15:25:01 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-05-07 15:22:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Andersen-1986">
<CHAR_METHODS MODIFIED="2008-05-07 15:22:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre, double-blind RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:05:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ambulatory patients &gt;15 years old with symptoms of lower UTI and significant bacteriuria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:05:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>Sulfamethizole 3 g single dose versus 2 x 1 g for 6 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:05:38 +1000" MODIFIED_BY="Narelle S Willis">
<P>For subgroup &#8805; 60: bacterial eradication after 8 days</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:05:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &gt; 60 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:07:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ferraro-1990">
<CHAR_METHODS MODIFIED="2008-05-07 15:06:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>Open RCT<BR/>Method of randomisation not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:06:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age: &gt; 50<BR/>Uncomplicated symptomatic lower UTI with &#8805;100,000 bacteria/mL of germs susceptible to study drugs.<BR/>Gender: 5/60 (25%) men</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:06:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Fosfomycin trometamol single dose 3 g versus norfloxacin 2 x 400 mg for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:07:12 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication</LI>
<LI>Side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:22:45 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Flanagan-1991">
<CHAR_METHODS MODIFIED="2008-05-07 15:22:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>Open, single centre RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:07:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Hospitalised elderly women, with significant bacteriuria, without catheter</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:08:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>single dose versus 7-10 days<BR/>Various AB, if resistance &#8805; other antibiotic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:08:47 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication rate for subgroup with urinary symptoms available</LI>
<LI>No clinical outcome</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:22:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gellermann-1988">
<CHAR_METHODS MODIFIED="2008-05-07 15:22:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre, open RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:09:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>Women, outpatients, with acute lower uncomplicated UTI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:09:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ciprofloxacin single dose 1 x 250 mg versus 2 x 250 mg for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:09:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Bacterial eradication and clinical cure after 1 week and 4 weeks</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:09:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &gt; 65 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:22:54 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Guibert-1993">
<CHAR_METHODS MODIFIED="2008-05-07 15:22:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre, open RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:09:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ambulatory women age &gt; 50 with acute uncomplicated bacterial cystitis and positive dipstick test</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:10:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>Pefloxacin 1 x 800 mg single dose versus 10 days norfloxacin 2 x 400 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:10:30 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication rate</LI>
<LI>Clinical cure</LI>
<LI>Side effects</LI>
<LI>Acceptability</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:10:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Also data for patients over 75 years available, resistant bacteria excluded from efficacy evaluation</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:23:05 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Guibert-1996">
<CHAR_METHODS MODIFIED="2008-05-07 15:23:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre, open RCT<BR/>Concealment by telephone</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:10:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ambulatory women &gt; 18, with acute uncomplicated cystitis + positive dipstick test and urinary culture</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:11:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Pefloxacin 800 mg single dose versus 3-day lomefloxacin, 1 x 400 mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:11:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>For subgroup &#8805; 50</P>
<OL>
<LI>Bacterial eradication</LI>
<LI>acceptability</LI>
<LI>Side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:12:06 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &#8805; 50 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:22:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Guibert-1997">
<CHAR_METHODS MODIFIED="2008-05-07 15:22:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre, open RCT<BR/>Concealment by telephone</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:12:17 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ambulatory women &gt; 18, with acute recurrent uncomplicated cystitis + positive dipstick test</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:12:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Lomefloxacin 1x 400mg 3 days versus norfloxacin 2x 400mg, 10 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:12:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>for subgroup &#8805; 50: acceptability</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:12:46 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &#8805; 50 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:22:32 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jardin-1990">
<CHAR_METHODS MODIFIED="2008-05-07 15:22:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre, open RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:12:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Women, outpatients, with symptoms of uncomplicated lower UTI and significant bacteriuria</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:13:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Fosfomycin trometamol 3 g single dose versus pipemidic acid 2 x 400 mg 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:13:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>Bacterial eradication at 5-10 days and 28 days post treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:13:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &#8805; 58 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-08 14:05:07 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lacey-1981">
<CHAR_METHODS MODIFIED="2008-05-07 15:23:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre single-blind RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:13:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Elderly patients (age 63-97, men: 33/96), with UTI: 2 urine cultures with significant bacteriuria, susceptible to trimethoprim, and significant pyuria (&gt; 100 pus cells /mm³)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-08 14:05:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>Trimethoprim 2 x 100 mg single dose versus 2 x 200 mg for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:14:38 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication rate</LI>
<LI>Side effects</LI>
<LI>Selection of resistance</LI>
</OL>
<P>Time points: 1 and 2 weeks post treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-08 14:05:01 +1000" MODIFIED_BY="Narelle S Willis">
<P>Catheter 35% symptoms ?<BR/>Complicated UTI?</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-07 15:15:19 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Matsumoto-1994">
<CHAR_METHODS MODIFIED="2008-05-07 15:14:58 +1000" MODIFIED_BY="Narelle S Willis">
<P>Open RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:15:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>Women, 18-69, with acute uncomplicated cystitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:15:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Isepamicin 400mg single dose versus ofloxacin 2x 200mg for 3 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:15:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Clinical cure at 5 days post treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:15:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &#8805; 50 or postmenopausal women</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-08 14:06:21 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Piipo-1990">
<CHAR_METHODS MODIFIED="2008-05-07 15:15:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Double blind RCT, 2 centres</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-08 14:06:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Female outpatients, 18-80 years old, with acute lower uncomplicated UTI (&#8805; 100,000 cfu/mL)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:16:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>Norfloxacin 2 x 400 mg for 3 days versus 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:16:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>Accumulated bacterial eradication rate (day 3 to day 45)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:16:26 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients &gt; 65 years<BR/>All initial bacteria sensitive to norfloxacin.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-08 14:06:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Raz-1996">
<CHAR_METHODS MODIFIED="2008-05-07 15:16:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>Single centre, open RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-08 14:06:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Postmenopausal ambulatory women with lower UTI: pyuria (&gt; 8 WBC/field) + positive urine culture (&#8805; 100,000 cfu/mL) sensitive to antibiotics.<BR/>Mean age: 66</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:17:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ofloxacin 1 x 200 mg 3 days versus cefalexin 4 x 500 mg 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:18:17 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication</LI>
<LI>Short/long term</LI>
<LI>Resolution of symptoms</LI>
<LI>Adverse drug reactions</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:18:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age range unknown</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-09 15:25:01 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stein-1992">
<CHAR_METHODS MODIFIED="2008-05-09 15:22:51 +1000" MODIFIED_BY="[Empty name]">
<P>Multicentre double-blind RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-09 15:25:01 +1000" MODIFIED_BY="[Empty name]">
<P>Ambulatory women &#8805; 18 years, with symptoms of lower UTI, pyuria (&gt; 5 WBC/field), &#8805; 10,000 cfu/mL susceptible to both drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:19:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Temafloxacin 1 x 400 mg 3 days versus ciprofloxacin 2 x 250 mg for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:19:46 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication</LI>
<LI>Clinical cure</LI>
<LI>Side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:19:56 +1000" MODIFIED_BY="Narelle S Willis">
<P>Clinical cure rate subgroup of patients &#8805; 65 years, no raw data available, resistant bacteria excluded from efficacy analysis</P>
<P>Clinical cure rate subgroup of patients 65 years, no raw data available, resistant bacteria excluded from efficacy analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-08 14:07:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-van-Merode-2005">
<CHAR_METHODS MODIFIED="2008-05-08 14:07:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre single-blind (physicians) RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-07 15:20:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ambulatory women (GPs) 13-77 years with symptoms of lower UTI</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:20:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Trimethoprim (dosage?) 3 days versus 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:20:48 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial cure</LI>
<LI>Self-stated clinical cure rate</LI>
<LI>Trimethoprim-resistant bacteria</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-05-07 15:20:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Subgroup of patients 60 years old</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-05-08 14:08:13 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Vogel-2004">
<CHAR_METHODS MODIFIED="2008-05-07 15:21:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Multicentre double-blind RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-05-08 14:08:13 +1000" MODIFIED_BY="Narelle S Willis">
<P>Hospitalised and ambulatory women &#8805; 65 years with at least 1 symptom of lower UTI and bacteriuria &#8805; 100,000 cfu/mL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-05-07 15:21:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Ciprofloxacin 2 x 250 mg P.O. 3 days versus 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-05-07 15:22:14 +1000" MODIFIED_BY="Narelle S Willis">
<OL>
<LI>Bacterial eradication at 2 days after end of treatment and at 6 weeks</LI>
<LI>Clinical cure</LI>
<LI>Side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-05-07 15:43:30 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Abadi-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Abadi-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:24:33 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Abbas-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:24:33 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:24:37 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Allgulander-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:24:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 14-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:24:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ancill-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:24:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Anderson-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:24:48 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Anderson-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:24:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>Leading article, no trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:24:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Andrewes-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:24:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aragones-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arredondo-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Pre-menopausal women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Auquer-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Two different antibiotics, two different treatment durations, population ranged from 18-65 years and unable to separate data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Backhouse-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:25:41 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bailey-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:25:41 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 16-56</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:25:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bailey-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:25:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 17-55, not only symptomatic lower UTI, but also asymptomatic and upper UTI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:25:44 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bailey-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:25:44 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 17-64, majority &lt; 21 years old</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bailey-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:25:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bailey-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:25:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-55</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:26:11 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bailey-1985a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:26:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bailey-1985b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Basista-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:26:23 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bergan-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:26:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Healthy volunteers, no control</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bitsch-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:26:35 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Boerema-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:26:35 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 16-50</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:26:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bordier-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:26:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 10-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brosof-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:26:50 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Brouhard-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:26:50 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:26:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Brumfitt-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:26:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>The trial included only 10 patients over 50 years old. Details on these patients were not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:27:05 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Buckwold-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:27:05 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups single dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:27:16 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Capalbi-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:27:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 7-day treatment, age 16-63</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:27:22 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Capri-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:27:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carmignani-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Complicated UTI, mixed population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:27:39 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Charlton-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:27:39 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT, treatment assigned according to the month (odd- or even-numbered) the patient attended the doctor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:27:51 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Charlton-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:27:51 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT, treatment assigned according to the month (odd- or even-numbered) the patient attended the doctor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:28:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Cheung-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:28:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT, both groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:28:09 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Compton-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:28:09 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT "Treatment was alternated from one woman to the next as the woman entered the study".</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1990a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cooper-1990b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cosmi-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Counts-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cox-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Craft-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crocchiolo-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Daengsvang-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Almeida-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Jong-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-del-Rio-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:28:43 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Dickie-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:28:43 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dickreuter-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:28:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Dubois-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:28:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-45</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Elhanan-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fair-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:07 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fairley-1970">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:07 +1000" MODIFIED_BY="Narelle S Willis">
<P>Recurrent UTI, age 18-65</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:11 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Falck-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:11 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 3 days, not different duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falck-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:21 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fang-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-54</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:27 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ferry-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Different durations with different doses (200mg x 3 x 7days versus 200mg x 2 x 7 days versus 400mg x 2 x 3 days versus placebo), no separate outcome data for elderly patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fihn-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>None of the participants were over age of 65 (email from the author)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:47 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Fischer-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:47 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 10-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Flavell_x002d_Matts-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:29:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-F_x00fc_nfst_x00fc_ck-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:29:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Chronic pyelonephritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gallego-Gomez-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 10-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gippert-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:17 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gordin-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:17 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 17-63, mostly young women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:25 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gordon-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:25 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups same treatment duration (&#8805; 5 days)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gossius-1984a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 16-60</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:42 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gossius-1984b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 16-60</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:30:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Gossius-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:30:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 16-60</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goto-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:31:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Greenberg-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:31:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>Trial included mostly young adult females who were sexually active, most patients were less than 60 years (author's information)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:31:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Greenberg-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:31:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Trial included mostly young adult females who were sexally active, most patients were less than 60 years (author's information)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:31:22 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Greenwood-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:31:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gr_x00fc_neberg-1967">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hansen-1981">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:31:31 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Heer-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:31:31 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:10 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Henning-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 16-65, inclusion criteria: significant bacteriuria &#8805; 10<SUP>8</SUP>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:19 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Henry-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age range 18-64, mean age 34</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:24 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hill-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:24 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 10-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hinnah-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups single dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hoigne-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups &#8805; 14-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:48 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hooton-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:48 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-56, all groups single dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hooton-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:32:55 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hooton-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:32:55 +1000" MODIFIED_BY="Narelle S Willis">
<P>Students, mean age 25</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:01 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Hoover-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:01 +1000" MODIFIED_BY="Narelle S Willis">
<P>Only young women</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoyme-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huang-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Study is not on uncomplicated UTI or treatment duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Humbert-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:16 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Iravani-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>College women, mean age 22</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:21 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Iravani-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:21 +1000" MODIFIED_BY="Narelle S Willis">
<P>College women, mean age 22 and 23 respectively</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iravani-1991a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iravani-1991b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iravani-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iravani-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Iravani-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishihara-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Johansen-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 10-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Jordan-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:33:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Khatib-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:33:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 14-57</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:34:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kirby-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:34:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kiyota--1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:34:16 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kosmidis-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:34:16 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups single dose, age 18-50</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koyama-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:34:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kumamoto-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:34:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control groups, 5 trials, all single dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:04 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-K_x00e4_llenius-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:04 +1000" MODIFIED_BY="Narelle S Willis">
<P>Girls 6-14 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lecomte-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:15 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Leelarasamee-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:15 +1000" MODIFIED_BY="Narelle S Willis">
<P>No patients &gt; 60 included (email from the author)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leigh-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:23 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Lewis-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>Dose comparison, same treatment duration, also patients with upper UTI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lightstone-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lockey-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ludwig-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mabeck-1980a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups same duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:43:03 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mabeck-1980b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:43:03 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 1-week treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:45 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mallo-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:52 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Marsh-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 15-55</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:35:57 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Martin-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:35:57 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Masterton-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Matsumoto-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Menday-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:10 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Minassian-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:10 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-65, mean age 40</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Mompo-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups single dose</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:23 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Musierowicz-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:23 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:28 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Naber-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:28 +1000" MODIFIED_BY="Narelle S Willis">
<P>Population of women &gt; 18 years, no separation based on age</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:37 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Neringer-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-65, mean age 39</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:42 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Neu-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups single dose, no duration trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Norrby-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ode-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Olsovsky-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:36:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Onodera-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:36:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group (7-day treatment)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:37:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Oosterlinck-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:37:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 15-day treatment, recurrent UTI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Osterberg-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:37:19 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Otieno-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:37:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 7-day treatment, age 20-57</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patrick-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pawelczyk-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Does not look at duration of antibiotics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:37:32 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Peddie-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:37:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 5-day treatment, age ?</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Petersen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pfau-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:37:49 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Pitk_x00e4_j_x00e4_rvi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:37:49 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age range 18-65, mean age 35</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:37:54 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Polubiec-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:37:54 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 10-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:38:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Pontzer-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:38:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 19-49 and 18-62 respectively</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Porpaczy-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:38:19 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Prat-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:38:19 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:38:27 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Prentice-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:38:27 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-65, mean 27.2 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:38:32 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Ranno-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:38:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:38:36 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Rapoport-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:38:36 +1000" MODIFIED_BY="Narelle S Willis">
<P>Letter from Dr Slack: elderly patients were excluded and the majority of patients were under 65 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raz-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:38:52 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Reeves-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:38:52 +1000" MODIFIED_BY="Narelle S Willis">
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reynaert-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:39:02 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Richard-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:39:02 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age group 18-88 years, unable to separate/obtain data on women over 60 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:39:12 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Richards-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:39:12 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-55</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rosenstock-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:39:22 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Rubin-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:39:22 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-55</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:39:42 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Russ-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:39:42 +1000" MODIFIED_BY="Narelle S Willis">
<P>Patients included without symptoms of UTI and with renalkidney transplantation, mean age unknown, raw data not available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saginur-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:39:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sanchez-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:39:59 +1000" MODIFIED_BY="Narelle S Willis">
<P>Probably not randomised (randomisation not mentioned, both groups same size), very small subgroup of elderly patients (11)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sandberg-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Savard_x002d_Fenton-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:40:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Schultz-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:40:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-55<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:40:20 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sigurdsson-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:40:20 +1000" MODIFIED_BY="Narelle S Willis">
<P>Both groups 3-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Slade-1972">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:40:32 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Staszewska-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:40:32 +1000" MODIFIED_BY="Narelle S Willis">
<P>Duration &gt; 14 days (3, 6, and 18 months), no information if patients had symptoms of UTI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Stein-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:40:45 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sturm-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:40:45 +1000" MODIFIED_BY="Narelle S Willis">
<P>Only 2 patients &gt; 60 years</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:40:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Sutlieff-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:40:53 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-55</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:41:00 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Tolkoff_x002d_Rubin-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:41:00 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-55</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:41:08 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Trienekens-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:41:08 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-65</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:41:14 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-UTI-Study-Group-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:41:14 +1000" MODIFIED_BY="Narelle S Willis">
<P>All groups 7-day treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Balen-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Pienbroek-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unable to separate/determine population group/s included in this study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:43:30 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Vogel-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:43:30 +1000" MODIFIED_BY="Narelle S Willis">
<P>Four trials: one: no control group, others: both groups same treatment duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:41:34 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Winwick-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:41:34 +1000" MODIFIED_BY="Narelle S Willis">
<P>Age 18-65, mean age 38 and 30 respectively</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-05-07 15:41:40 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Zorbas-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-05-07 15:41:40 +1000" MODIFIED_BY="Narelle S Willis">
<P>Only patients with asymptomatic bacteriuria included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andersen-1986">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Ferraro-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Flanagan-1991">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Gellermann-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Guibert-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Guibert-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Guibert-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jardin-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lacey-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Matsumoto-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Piipo-1990">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Raz-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Stein-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vogel-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-van-Merode-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-05-07 13:34:43 +1000" MODIFIED_BY="Narelle S Willis"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-05-08 14:11:48 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2008-05-08 14:11:00 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Single dose versus short-course treatment</NAME>
<DICH_OUTCOME CHI2="6.263888711535383" CI_END="3.83524914405639" CI_START="1.0522945263583843" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.008932970885594" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="19" I2="36.14190506555897" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.5837935816811737" LOG_CI_START="0.022137311367191492" LOG_EFFECT_SIZE="0.30296544652418267" METHOD="MH" MODIFIED="2008-05-06 17:27:28 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.180288837890771" P_Q="0.0" P_Z="0.03447554040676212" Q="0.0" RANDOM="YES" SCALE="23.502270613739245" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1952551907439476" TOTALS="YES" TOTAL_1="172" TOTAL_2="184" WEIGHT="100.0" Z="2.114465359446771">
<NAME>Persistent UTI: short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="251" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="17.787727239224026"/>
<DICH_DATA CI_END="2.7683950533929873" CI_START="0.4298817985422692" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4422280645659553" LOG_CI_START="-0.3666509427871559" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="252" O_E="0.0" SE="0.47513953293487987" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.22575757575757577" WEIGHT="25.853608150146105"/>
<DICH_DATA CI_END="3.3168948797303766" CI_START="0.4103570238022596" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5207317079148834" LOG_CI_START="-0.3868381286536571" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="253" O_E="0.0" SE="0.5331110145435066" STUDY_ID="STD-Guibert-1996" TOTAL_1="79" TOTAL_2="79" VAR="0.284207353827607" WEIGHT="22.701875703483488"/>
<DICH_DATA CI_END="18.24276690710383" CI_START="0.8962300800849514" EFFECT_SIZE="4.043478260869565" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.261090709066648" LOG_CI_START="-0.0475804839939634" LOG_EFFECT_SIZE="0.6067551125363423" ORDER="254" O_E="0.0" SE="0.7687199368306851" STUDY_ID="STD-Jardin-1990" TOTAL_1="23" TOTAL_2="31" VAR="0.5909303412809724" WEIGHT="13.844949630788076"/>
<DICH_DATA CI_END="16.423049750251263" CI_START="1.5934821510078825" EFFECT_SIZE="5.115646258503402" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2154538084910487" LOG_CI_START="0.2023472031958836" LOG_EFFECT_SIZE="0.7089005058434662" ORDER="255" O_E="0.0" SE="0.5951038349089564" STUDY_ID="STD-Lacey-1981" TOTAL_1="49" TOTAL_2="47" VAR="0.35414857432334634" WEIGHT="19.811839276358302"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9409391647587264" CI_END="2.3248878037585072" CI_START="0.5946499862839235" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1757952630524828" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.3664019992112264" LOG_CI_START="-0.22573858679802744" LOG_EFFECT_SIZE="0.07033170620659944" METHOD="MH" NO="2" P_CHI2="0.37890515397216507" P_Q="0.0" P_Z="0.641508415130267" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="57" WEIGHT="100.0" Z="0.465590822156659">
<NAME>Persistent UTI: long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="256" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="29.035954290669224"/>
<DICH_DATA CI_END="1.9089738099007443" CI_START="0.2770732720854939" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.28079997014662067" LOG_CI_START="-0.5574053664791835" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="257" O_E="0.0" SE="0.4923659639173309" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.24242424242424238" WEIGHT="49.90554643708773"/>
<DICH_DATA CI_END="7.795656103172191" CI_START="0.39947719730015485" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8918526724429063" LOG_CI_START="-0.3985080057601291" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="258" O_E="0.0" SE="0.7579642497648346" STUDY_ID="STD-Jardin-1990" TOTAL_1="17" TOTAL_2="30" VAR="0.5745098039215686" WEIGHT="21.058499272243036"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 17:27:54 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="15" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (persistence of symptoms): short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="37.259844059993256" CI_START="0.0764269502957366" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.57124103295351" LOG_CI_START="-1.116753469947385" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="259" O_E="0.0" SE="1.578941276791368" STUDY_ID="STD-Matsumoto-1994" TOTAL_1="15" TOTAL_2="8" VAR="2.4930555555555554" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 10:49:39 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (persistence of symptoms): long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours short course</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 10:50:15 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Adverse drug reactions</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 10:50:44 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Discontinuation due to adverse reactions</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:01:09 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.4156221297341105" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="47" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection rate: short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6172710608825287" CI_START="0.2787512479723753" EFFECT_SIZE="0.6714285714285714" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.20878281544122282" LOG_CI_START="-0.5547831795983016" LOG_EFFECT_SIZE="-0.1730001820785394" ORDER="95" O_E="0.0" SE="0.44852244519885054" STUDY_ID="STD-Lacey-1981" TOTAL_1="49" TOTAL_2="47" VAR="0.20117238384715588" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:01:16 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="36" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection rate: long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.786840599121604" CI_START="0.8095750984655955" EFFECT_SIZE="2.814814814814815" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9906425149066082" LOG_CI_START="-0.09174285866300014" LOG_EFFECT_SIZE="0.449449828121804" ORDER="96" O_E="0.0" SE="0.6357985263287981" STUDY_ID="STD-Lacey-1981" TOTAL_1="36" TOTAL_2="38" VAR="0.4042397660818713" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 17:28:55 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="59.81544835673608" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="79" TOTAL_2="79" WEIGHT="0.0" Z="0.0">
<NAME>Acceptability (little or not satisfied with treatment)</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0491472458011475" CI_START="0.0857839548835439" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.020836444867742415" LOG_CI_START="-1.0665939354284175" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="262" O_E="0.0" SE="0.6387619882531606" STUDY_ID="STD-Guibert-1996" TOTAL_1="79" TOTAL_2="79" VAR="0.4080168776371308" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-05-08 14:11:09 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Single dose versus long-course treatment</NAME>
<DICH_OUTCOME CHI2="7.221047273218629" CI_END="3.696658936991165" CI_START="1.0097702764803682" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.932039419074878" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="18" I2="30.757966111869035" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.5678093833251892" LOG_CI_START="0.004222582688891518" LOG_EFFECT_SIZE="0.2860159830070403" METHOD="MH" MODIFIED="2008-05-06 17:29:10 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.20471309083841227" P_Q="0.0" P_Z="0.04666441441953861" Q="0.0" RANDOM="YES" SCALE="20.02759406554014" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.20077011785275614" TOTALS="YES" TOTAL_1="311" TOTAL_2="317" WEIGHT="100.0" Z="1.9893334090284411">
<NAME>Persistent UTI: short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="263" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="17.750244149303814"/>
<DICH_DATA CI_END="2.288930488946035" CI_START="0.15727869489202628" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35963260406574094" LOG_CI_START="-0.8033301032984537" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="264" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.4666666666666667" WEIGHT="16.420511913906825"/>
<DICH_DATA CI_END="3.95905904500969" CI_START="0.44904048097454585" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5975919788248678" LOG_CI_START="-0.34771450560826794" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="265" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Flanagan-1991" TOTAL_1="10" TOTAL_2="8" VAR="0.30833333333333335" WEIGHT="21.52736078776812"/>
<DICH_DATA CI_END="8.733537076697276" CI_START="0.2495138341840693" EFFECT_SIZE="1.4761904761904763" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9411901683084671" LOG_CI_START="-0.6029053701077601" LOG_EFFECT_SIZE="0.16914239910035345" ORDER="266" O_E="0.0" SE="0.9070093626618781" STUDY_ID="STD-Guibert-1993" TOTAL_1="189" TOTAL_2="186" VAR="0.8226659839563064" WEIGHT="10.708683866641175"/>
<DICH_DATA CI_END="18.24276690710383" CI_START="0.8962300800849514" EFFECT_SIZE="4.043478260869565" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.261090709066648" LOG_CI_START="-0.0475804839939634" LOG_EFFECT_SIZE="0.6067551125363423" ORDER="267" O_E="0.0" SE="0.7687199368306851" STUDY_ID="STD-Jardin-1990" TOTAL_1="23" TOTAL_2="31" VAR="0.5909303412809724" WEIGHT="13.843182160046739"/>
<DICH_DATA CI_END="16.423049750251263" CI_START="1.5934821510078825" EFFECT_SIZE="5.115646258503402" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2154538084910487" LOG_CI_START="0.2023472031958836" LOG_EFFECT_SIZE="0.7089005058434662" ORDER="268" O_E="0.0" SE="0.5951038349089564" STUDY_ID="STD-Lacey-1981" TOTAL_1="49" TOTAL_2="47" VAR="0.35414857432334634" WEIGHT="19.750017122333333"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5592521569825295" CI_END="1.8397111997574989" CI_START="0.8852841342368838" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2761924371830513" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="41" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.26474965225094194" LOG_CI_START="-0.05291731898959078" LOG_EFFECT_SIZE="0.1059161666306756" METHOD="MH" NO="2" P_CHI2="0.8160965369532209" P_Q="0.0" P_Z="0.19122018202543337" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="255" TOTAL_2="268" WEIGHT="100.0" Z="1.3069780038257848">
<NAME>Persistent UTI: long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="269" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="8.356618391295285"/>
<DICH_DATA CI_END="2.1076971966517677" CI_START="0.36325189463469976" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3238082178928757" LOG_CI_START="-0.43979211184824923" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="270" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="17.306606135818637"/>
<DICH_DATA CI_END="4.112396705829642" CI_START="0.5884045872786459" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6140950025929032" LOG_CI_START="-0.2303239501150769" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="271" O_E="0.0" SE="0.4960158727618966" STUDY_ID="STD-Flanagan-1991" TOTAL_1="9" TOTAL_2="7" VAR="0.24603174603174605" WEIGHT="14.152337598161369"/>
<DICH_DATA CI_END="2.022362051596334" CI_START="0.748278726942704" EFFECT_SIZE="1.2301587301587302" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" LOG_CI_END="0.3058589074048354" LOG_CI_START="-0.1259366012993781" LOG_EFFECT_SIZE="0.08996115305272862" ORDER="272" O_E="0.0" SE="0.253638819235095" STUDY_ID="STD-Guibert-1993" TOTAL_1="189" TOTAL_2="186" VAR="0.0643326506229732" WEIGHT="54.12375047489451"/>
<DICH_DATA CI_END="7.795656103172191" CI_START="0.39947719730015485" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8918526724429063" LOG_CI_START="-0.3985080057601291" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="273" O_E="0.0" SE="0.7579642497648346" STUDY_ID="STD-Jardin-1990" TOTAL_1="17" TOTAL_2="30" VAR="0.5745098039215686" WEIGHT="6.060687399830199"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 17:29:22 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="197" TOTAL_2="191" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (persistence of symptoms): short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.568481126012345" CI_START="0.6752390054135892" EFFECT_SIZE="1.9390862944162437" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7457367519877737" LOG_CI_START="-0.17054247848754206" LOG_EFFECT_SIZE="0.2875971367501158" ORDER="274" O_E="0.0" SE="0.5382269556365414" STUDY_ID="STD-Guibert-1993" TOTAL_1="197" TOTAL_2="191" VAR="0.2896882557737795" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 10:57:55 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (persistence of symptoms): long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5423603738981617" CI_END="1.4087393861326312" CI_START="0.4544158442447838" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8000959301673382" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.1488306569608925" LOG_CI_START="-0.3425465343654441" LOG_EFFECT_SIZE="-0.09685793870227578" METHOD="MH" MODIFIED="2008-05-06 17:29:34 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.46246708179509843" P_Q="0.0" P_Z="0.43971322028604665" Q="0.0" RANDOM="YES" SCALE="641.8858927322408" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="290" WEIGHT="100.00000000000001" Z="0.772677587906893">
<NAME>Adverse drug reactions</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="275" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="5.812433408906293"/>
<DICH_DATA CI_END="2.8549046903241697" CI_START="0.007238091894988489" EFFECT_SIZE="0.14375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.45559161410298366" LOG_CI_START="-2.1403759073796476" LOG_EFFECT_SIZE="-0.842392146638332" ORDER="276" O_E="0.0" SE="1.524884172365375" STUDY_ID="STD-Flanagan-1991" TOTAL_1="31" TOTAL_2="22" VAR="2.3252717391304345" WEIGHT="3.5828735250879657"/>
<DICH_DATA CI_END="1.5989478589174517" CI_START="0.48708928053212686" EFFECT_SIZE="0.8825136612021858" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.2038343017989909" LOG_CI_START="-0.31239142792560654" LOG_EFFECT_SIZE="-0.054278563063307785" ORDER="277" O_E="0.0" SE="0.30323354899880295" STUDY_ID="STD-Guibert-1993" TOTAL_1="244" TOTAL_2="238" VAR="0.09195058523840942" WEIGHT="90.60469306600575"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.8959675020363438" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="290" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Discontinuation due to adverse reactions</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363438" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="278" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="279" O_E="0.0" SE="0.0" STUDY_ID="STD-Flanagan-1991" TOTAL_1="31" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="280" O_E="0.0" SE="0.0" STUDY_ID="STD-Guibert-1993" TOTAL_1="244" TOTAL_2="238" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="89" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 17:30:03 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="197" TOTAL_2="191" WEIGHT="0.0" Z="0.0">
<NAME>Acceptability (little or not satisfied with treatment)</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8762311412776923" CI_START="0.6000696871880676" EFFECT_SIZE="0.7251205050548138" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="119" LOG_CI_END="-0.057381316046307154" LOG_CI_START="-0.2217983112766595" LOG_EFFECT_SIZE="-0.13958981366148335" ORDER="281" O_E="0.0" SE="0.09657935687556143" STUDY_ID="STD-Guibert-1993" TOTAL_1="197" TOTAL_2="191" VAR="0.009327572174497055" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:00:44 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection rate: short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:00:52 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection rate: long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-6 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-6 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-05-08 14:11:23 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<NAME>Short-course versus long-course treatment</NAME>
<DICH_OUTCOME CHI2="13.374549205788922" CI_END="2.1881238004771446" CI_START="0.3926032176556412" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9268572946771348" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="56" I2="70.09244993267754" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.34007189003025046" LOG_CI_START="-0.40604614537696204" LOG_EFFECT_SIZE="-0.03298712767335581" METHOD="MH" MODIFIED="2008-05-08 11:03:23 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.009583551187078432" P_Q="0.0" P_Z="0.8624104525744211" Q="0.0" RANDOM="YES" SCALE="18.5" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.620485677748465" TOTALS="SUB" TOTAL_1="329" TOTAL_2="310" WEIGHT="200.0" Z="0.17330657918734158">
<NAME>Persistent UTI: short-term</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.011973658187289" CI_END="2.473147884881314" CI_START="0.29032293262099546" DF="2.0" EFFECT_SIZE="0.8473556199991565" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="47" I2="71.47736004876788" ID="CMP-003.01.01" LOG_CI_END="0.39325008630373554" LOG_CI_START="-0.5371186578734849" LOG_EFFECT_SIZE="-0.07193428578487472" NO="1" P_CHI2="0.030017173679727227" P_Z="0.7618280277966522" STUDIES="3" TAU2="0.6219262561537311" TOTAL_1="224" TOTAL_2="207" WEIGHT="100.0" Z="0.3030811391168358">
<NAME>All trials</NAME>
<DICH_DATA CI_END="0.9425462877325487" CI_START="0.40910087051487287" EFFECT_SIZE="0.6209641751437417" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" LOG_CI_END="-0.02569731272619267" LOG_CI_START="-0.38816959637695386" LOG_EFFECT_SIZE="-0.20693345455157325" ORDER="284" O_E="0.0" SE="0.21291801368319876" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.045334080550798815" WEIGHT="44.779775228079465"/>
<DICH_DATA CI_END="8.270075778187493" CI_START="0.8960611759696125" EFFECT_SIZE="2.7222222222222223" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9175094889839736" LOG_CI_START="-0.04766233913355835" LOG_EFFECT_SIZE="0.4349235749252076" ORDER="285" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-van-Merode-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.3214285714285714" WEIGHT="31.653899646496733"/>
<DICH_DATA CI_END="1.5389737765819895" CI_START="0.06612114827615725" EFFECT_SIZE="0.31899641577060933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18723121971272166" LOG_CI_START="-1.1796596129700911" LOG_EFFECT_SIZE="-0.49621419662868477" ORDER="286" O_E="0.0" SE="0.8029184413366303" STUDY_ID="STD-Vogel-2004" TOTAL_1="93" TOTAL_2="89" VAR="0.6446780234384438" WEIGHT="23.56632512542381"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.991169861773326" CI_END="8.571199688859691" CI_START="0.11697359794886575" DF="1.0" EFFECT_SIZE="1.001301186628737" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="79.9646169596659" ID="CMP-003.01.02" LOG_CI_END="0.9330416132636029" LOG_CI_START="-0.9319121515789974" LOG_EFFECT_SIZE="5.647308423027053E-4" NO="2" P_CHI2="0.025477147239990505" P_Z="0.9990529094924381" STUDIES="2" TAU2="1.9279477623468422" TOTAL_1="105" TOTAL_2="103" WEIGHT="100.0" Z="0.0011870022010606364">
<NAME>Trials comparing the same antibiotic in each group</NAME>
<DICH_DATA CI_END="8.270075778187493" CI_START="0.8960611759696125" EFFECT_SIZE="2.7222222222222223" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9175094889839736" LOG_CI_START="-0.04766233913355835" LOG_EFFECT_SIZE="0.4349235749252076" ORDER="287" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-van-Merode-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.3214285714285714" WEIGHT="57.32301847237812"/>
<DICH_DATA CI_END="1.5389737765819895" CI_START="0.06612114827615725" EFFECT_SIZE="0.31899641577060933" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="6" LOG_CI_END="0.18723121971272166" LOG_CI_START="-1.1796596129700911" LOG_EFFECT_SIZE="-0.49621419662868477" ORDER="288" O_E="0.0" SE="0.8029184413366303" STUDY_ID="STD-Vogel-2004" TOTAL_1="93" TOTAL_2="89" VAR="0.6446780234384438" WEIGHT="42.67698152762188"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.0224454634166635" CI_END="1.2424621873339352" CI_START="0.6511375683583004" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8994519483762063" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="101" I2="33.581797887619004" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.09428318043788188" LOG_CI_START="-0.18632724665891703" LOG_EFFECT_SIZE="-0.04602203311051754" METHOD="MH" MODIFIED="2008-05-08 11:03:47 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.19747842202737909" P_Q="0.0" P_Z="0.5202922049088123" Q="0.0" RANDOM="YES" SCALE="20.68" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.042642035175392036" TOTALS="SUB" TOTAL_1="375" TOTAL_2="342" WEIGHT="200.0" Z="0.6428950508015764">
<NAME>Persistent UTI: long-term</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6305417065493737" CI_END="1.3189684011435894" CI_START="0.5447013235703274" DF="2.0" EFFECT_SIZE="0.8476106617134731" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="71" I2="44.91180210402023" ID="CMP-003.02.01" LOG_CI_END="0.12023439116929369" LOG_CI_START="-0.2638415694329607" LOG_EFFECT_SIZE="-0.07180358913183352" NO="1" P_CHI2="0.16279387889118024" P_Z="0.4636581388652343" STUDIES="3" TAU2="0.06579673043887184" TOTAL_1="247" TOTAL_2="223" WEIGHT="100.0" Z="0.732836538055797">
<NAME>All trials</NAME>
<DICH_DATA CI_END="11.806565876375348" CI_START="0.5600481094329152" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0721235946650947" LOG_CI_START="-0.25177466448699626" LOG_EFFECT_SIZE="0.4101744650890493" ORDER="289" O_E="0.0" SE="0.7776643908280131" STUDY_ID="STD-Piipo-1990" TOTAL_1="35" TOTAL_2="30" VAR="0.6047619047619047" WEIGHT="6.290455161325064"/>
<DICH_DATA CI_END="0.9713210736672019" CI_START="0.4495371819969961" EFFECT_SIZE="0.6607911457265833" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="41" LOG_CI_END="-0.012637188760246477" LOG_CI_START="-0.34723438119818006" LOG_EFFECT_SIZE="-0.17993578497921325" ORDER="290" O_E="0.0" SE="0.19654404712085694" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.03862956245864563" WEIGHT="50.10933184528842"/>
<DICH_DATA CI_END="1.4351370954792944" CI_START="0.5933790262761043" EFFECT_SIZE="0.9228110599078341" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.15689339024506865" LOG_CI_START="-0.22666780842957712" LOG_EFFECT_SIZE="-0.034887209092254255" ORDER="291" O_E="0.0" SE="0.2253057467600415" STUDY_ID="STD-Vogel-2004" TOTAL_1="93" TOTAL_2="89" VAR="0.05076267952309996" WEIGHT="43.600212993386506"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6336840066008016" CI_END="2.8148038040552255" CI_START="0.49613928150706765" DF="1.0" EFFECT_SIZE="1.1817507084522185" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="30" I2="38.78865215307487" ID="CMP-003.02.02" LOG_CI_END="0.44944812928127686" LOG_CI_START="-0.3043963866175224" LOG_EFFECT_SIZE="0.07252587133187723" NO="2" P_CHI2="0.20119431678611055" P_Z="0.7060781722672773" STUDIES="2" TAU2="0.20769772249752338" TOTAL_1="128" TOTAL_2="119" WEIGHT="100.0" Z="0.37712842041010014">
<NAME>Trials comparing the same antibiotic in each group</NAME>
<DICH_DATA CI_END="11.806565876375348" CI_START="0.5600481094329152" EFFECT_SIZE="2.5714285714285716" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0721235946650947" LOG_CI_START="-0.25177466448699626" LOG_EFFECT_SIZE="0.4101744650890493" ORDER="292" O_E="0.0" SE="0.7776643908280131" STUDY_ID="STD-Piipo-1990" TOTAL_1="35" TOTAL_2="30" VAR="0.6047619047619047" WEIGHT="12.608480491418327"/>
<DICH_DATA CI_END="1.4351370954792944" CI_START="0.5933790262761043" EFFECT_SIZE="0.9228110599078341" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.15689339024506865" LOG_CI_START="-0.22666780842957712" LOG_EFFECT_SIZE="-0.034887209092254255" ORDER="293" O_E="0.0" SE="0.2253057467600415" STUDY_ID="STD-Vogel-2004" TOTAL_1="93" TOTAL_2="89" VAR="0.05076267952309996" WEIGHT="87.39151950858168"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8762741559325689" CI_END="1.4990382675586251" CI_START="0.639236478710955" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9788973100418378" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.1758127196911177" LOG_CI_START="-0.19433844950941004" LOG_EFFECT_SIZE="-0.009262864909146202" METHOD="MH" MODIFIED="2008-05-08 11:12:20 +1000" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.9279397497226721" P_Q="0.0" P_Z="0.9218573205571755" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="242" TOTAL_2="244" WEIGHT="200.0" Z="0.09809441723390096">
<NAME>Clinical failure (persistence of symptoms): short-term</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.4366906766846125" CI_END="1.5410023013423118" CI_START="0.624218347441412" DF="2.0" EFFECT_SIZE="0.9807761772939383" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="28" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="0.18780328729695317" LOG_CI_START="-0.2046634704104203" LOG_EFFECT_SIZE="-0.008430091556733563" NO="1" P_CHI2="0.8038479191201113" P_Z="0.9328981258548938" STUDIES="4" TAU2="0.0" TOTAL_1="199" TOTAL_2="196" WEIGHT="100.00000000000001" Z="0.08419910992763611">
<NAME>All trials</NAME>
<DICH_DATA CI_END="1.593406510812461" CI_START="0.6066681753776078" EFFECT_SIZE="0.9831932773109243" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="24" LOG_CI_END="0.20232658740225307" LOG_CI_START="-0.21704878669499134" LOG_EFFECT_SIZE="-0.007361099646369138" ORDER="294" O_E="0.0" SE="0.24634317068630351" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.06068495774378126" WEIGHT="87.57898450585286"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="295" O_E="0.0" SE="0.0" STUDY_ID="STD-Stein-1992" TOTAL_1="37" TOTAL_2="44" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.74198727314598" CI_START="0.28703390218255653" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6759603840559419" LOG_CI_START="-0.5420668047947156" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="296" O_E="0.0" SE="0.7154752000627009" STUDY_ID="STD-van-Merode-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.5119047619047619" WEIGHT="10.382257344520935"/>
<DICH_DATA CI_END="8.632242794173337" CI_START="0.015398200689415801" EFFECT_SIZE="0.3645833333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9361236470000188" LOG_CI_START="-1.8125300243786044" LOG_EFFECT_SIZE="-0.4382031886892928" ORDER="297" O_E="0.0" SE="1.6145727726229122" STUDY_ID="STD-Vogel-2004" TOTAL_1="31" TOTAL_2="34" VAR="2.606845238095238" WEIGHT="2.0387581496262137"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.44737665538011717" CI_END="3.473971939001094" CI_START="0.2674476963833913" DF="1.0" EFFECT_SIZE="0.9639013395500525" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="0.5408263061127492" LOG_CI_START="-0.5727611384767233" LOG_EFFECT_SIZE="-0.015967416181987035" NO="2" P_CHI2="0.5035834047927599" P_Z="0.9551771109631465" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="48" WEIGHT="99.99999999999999" Z="0.056206741185725016">
<NAME>Trials comparing the same antibiotic in each group</NAME>
<DICH_DATA CI_END="4.74198727314598" CI_START="0.28703390218255653" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6759603840559419" LOG_CI_START="-0.5420668047947156" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="298" O_E="0.0" SE="0.7154752000627009" STUDY_ID="STD-van-Merode-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.5119047619047619" WEIGHT="83.58622005916594"/>
<DICH_DATA CI_END="8.632242794173337" CI_START="0.015398200689415801" EFFECT_SIZE="0.3645833333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9361236470000188" LOG_CI_START="-1.8125300243786044" LOG_EFFECT_SIZE="-0.4382031886892928" ORDER="299" O_E="0.0" SE="1.6145727726229122" STUDY_ID="STD-Vogel-2004" TOTAL_1="31" TOTAL_2="34" VAR="2.606845238095238" WEIGHT="16.413779940834047"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="29" EVENTS_2="34" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:05:11 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="2.43" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="104" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (persistence of symptoms): long-term</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1342823656698207" CI_START="0.48988003165126925" EFFECT_SIZE="0.7454275827978251" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="34" LOG_CI_END="0.05472118029535089" LOG_CI_START="-0.3099102627694497" LOG_EFFECT_SIZE="-0.1275945412370494" ORDER="300" O_E="0.0" SE="0.21418631461101703" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.04587577736664957" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:05:29 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="104" WEIGHT="0.0" Z="0.0">
<NAME>Adverse drug reactions</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9347314049685482" CI_START="0.26025818471677054" EFFECT_SIZE="0.8739495798319328" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.46756835952642567" LOG_CI_START="-0.5845956037139264" LOG_EFFECT_SIZE="-0.0585136220937504" ORDER="301" O_E="0.0" SE="0.6180463203029992" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.38198125404007754" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9695982130783247" CI_START="0.005874412197919592" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.10756501182033097" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.294377641572936" LOG_CI_START="-2.231035583008796" LOG_EFFECT_SIZE="-0.9683289707179299" METHOD="MH" MODIFIED="2008-05-08 11:05:39 +1000" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.13283049357418117" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="194" WEIGHT="100.0" Z="1.5030331585502954">
<NAME>Discontinuation due to adverse reactions</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-4 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="302" O_E="0.0" SE="0.0" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.9695982130783247" CI_START="0.005874412197919592" EFFECT_SIZE="0.10756501182033097" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.294377641572936" LOG_CI_START="-2.231035583008796" LOG_EFFECT_SIZE="-0.9683289707179299" ORDER="303" O_E="0.0" SE="1.4834402291163844" STUDY_ID="STD-Vogel-2004" TOTAL_1="93" TOTAL_2="90" VAR="2.200594913360871" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:05:56 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="119" TOTAL_2="104" WEIGHT="0.0" Z="0.0">
<NAME>Reinfection rate: short-term</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="19.49029563699354" CI_START="0.9797027740291235" EFFECT_SIZE="4.369747899159663" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2898184267287642" LOG_CI_START="-0.008905662244227437" LOG_EFFECT_SIZE="0.6404563822422683" ORDER="304" O_E="0.0" SE="0.7628769586506579" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.5819812540400776" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5909679143334388" CI_END="4.00717711291725" CI_START="0.42237246168632664" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.300969354595244" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="72.15235491220974" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.6028385382057815" LOG_CI_START="-0.3743044051701319" LOG_EFFECT_SIZE="0.11426706651782474" METHOD="MH" MODIFIED="2008-05-08 11:06:14 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.05809456532401869" P_Q="0.0" P_Z="0.6466677801417173" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.48042278835369534" TOTALS="YES" TOTAL_1="212" TOTAL_2="193" WEIGHT="100.0" Z="0.45839625924171595">
<NAME>Reinfection rate: long-term</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.563534912029699" CI_START="0.9123280314755575" EFFECT_SIZE="2.447058823529412" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.8171377996365092" LOG_CI_START="-0.03984898113957136" LOG_EFFECT_SIZE="0.3886444092484689" ORDER="305" O_E="0.0" SE="0.5033982771808511" STUDY_ID="STD-Raz-1996" TOTAL_1="119" TOTAL_2="104" VAR="0.253409825468649" WEIGHT="44.89462981127021"/>
<DICH_DATA CI_END="1.5220404613417124" CI_START="0.3972232476054453" EFFECT_SIZE="0.7775537634408602" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="16" LOG_CI_END="0.18242619770647817" LOG_CI_START="-0.40096534222269886" LOG_EFFECT_SIZE="-0.10926957225811032" ORDER="306" O_E="0.0" SE="0.3426870783890956" STUDY_ID="STD-Vogel-2004" TOTAL_1="93" TOTAL_2="89" VAR="0.11743443369485415" WEIGHT="55.1053701887298"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:06:33 +1000" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="49" TOTAL_2="43" WEIGHT="0.0" Z="0.0">
<NAME>Acceptability (little or not satisfied with treatment)</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.717630012070631" CI_START="0.07173566255899738" EFFECT_SIZE="0.3510204081632653" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.23492961990210523" LOG_CI_START="-1.1442648861440348" LOG_EFFECT_SIZE="-0.4546676331209648" ORDER="307" O_E="0.0" SE="0.8101456799744139" STUDY_ID="STD-Guibert-1997" TOTAL_1="49" TOTAL_2="43" VAR="0.6563360227812054" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.10" MODIFIED="2008-05-08 11:07:38 +1000" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.2" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="91" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean number of adverse events/patient (day 5)</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.3106646416457541" CI_START="-1.089335358354246" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="1.6" ORDER="308" SD_1="1.1" SD_2="1.5" SE="0.1986441390889188" STUDY_ID="STD-Vogel-2004" TOTAL_1="91" TOTAL_2="86" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.11" MODIFIED="2008-05-08 11:08:01 +1000" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="1.48" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="91" TOTAL_2="86" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean number of adverse events/patient (day 9)</NAME>
<GROUP_LABEL_1>3-6 days</GROUP_LABEL_1>
<GROUP_LABEL_2>7-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3-6 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 7-14 days</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.4690803088706802" CI_START="-1.3309196911293202" EFFECT_SIZE="-0.9000000000000001" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.1" ORDER="309" SD_1="1.3" SD_2="1.6" SE="0.21986102526799445" STUDY_ID="STD-Vogel-2004" TOTAL_1="91" TOTAL_2="86" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2008-05-08 14:11:48 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Single dose versus short-course or long-course treatment (3 to 14 days)</NAME>
<DICH_OUTCOME CHI2="19.982571176604772" CI_END="2.3380425747307796" CI_START="1.208464513272572" CI_STUDY="95" CI_TOTAL="95" DF="15.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6809049592652712" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="59" I2="24.93458490686261" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.3688524152100377" LOG_CI_START="0.0822339018134385" LOG_EFFECT_SIZE="0.22554315851173812" METHOD="MH" MODIFIED="2008-05-08 11:21:52 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.17260243988862867" P_Q="0.0" P_Z="0.0020380343995729127" Q="0.0" RANDOM="YES" SCALE="26.31" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1118266090560049" TOTALS="SUB" TOTAL_1="561" TOTAL_2="572" WEIGHT="400.0" Z="3.0846330364621894">
<NAME>Persistent UTI: short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.7128497643535" CI_END="2.4893890689016707" CI_START="0.9187196036669787" DF="7.0" EFFECT_SIZE="1.5122997516214343" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="31" I2="27.93052327762501" ID="CMP-004.01.01" LOG_CI_END="0.39609277819642463" LOG_CI_START="-0.03681701653695061" LOG_EFFECT_SIZE="0.17963788082973697" NO="1" P_CHI2="0.20543845130112226" P_Z="0.1038238067530641" STUDIES="8" TAU2="0.14307233302709366" TOTAL_1="401" TOTAL_2="408" WEIGHT="99.99999999999997" Z="1.6265918718805037">
<NAME>All trials</NAME>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="310" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="11.455178144424131"/>
<DICH_DATA CI_END="2.288930488946035" CI_START="0.15727869489202628" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.35963260406574094" LOG_CI_START="-0.8033301032984537" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="311" O_E="0.0" SE="0.6831300510639732" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.4666666666666667" WEIGHT="10.465090737607348"/>
<DICH_DATA CI_END="3.95905904500969" CI_START="0.44904048097454585" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5975919788248678" LOG_CI_START="-0.34771450560826794" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="312" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Flanagan-1991" TOTAL_1="10" TOTAL_2="8" VAR="0.30833333333333335" WEIGHT="14.408762023114479"/>
<DICH_DATA CI_END="2.7683950533929873" CI_START="0.4298817985422692" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4422280645659553" LOG_CI_START="-0.3666509427871559" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="313" O_E="0.0" SE="0.47513953293487987" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.22575757575757577" WEIGHT="17.93325900286641"/>
<DICH_DATA CI_END="3.2527942700046193" CI_START="0.1674820278437384" EFFECT_SIZE="0.7380952380952381" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.5122565962584349" LOG_CI_START="-0.7760317893856904" LOG_EFFECT_SIZE="-0.13188759656362778" ORDER="314" O_E="0.0" SE="0.7567469748577171" STUDY_ID="STD-Guibert-1993" TOTAL_1="189" TOTAL_2="186" VAR="0.5726659839563064" WEIGHT="8.844485219176908"/>
<DICH_DATA CI_END="3.3168948797303766" CI_START="0.4103570238022596" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.5207317079148834" LOG_CI_START="-0.3868381286536571" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="315" O_E="0.0" SE="0.5331110145435066" STUDY_ID="STD-Guibert-1996" TOTAL_1="79" TOTAL_2="79" VAR="0.284207353827607" WEIGHT="15.28652890639239"/>
<DICH_DATA CI_END="18.24276690710383" CI_START="0.8962300800849514" EFFECT_SIZE="4.043478260869565" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.261090709066648" LOG_CI_START="-0.0475804839939634" LOG_EFFECT_SIZE="0.6067551125363423" ORDER="316" O_E="0.0" SE="0.7687199368306851" STUDY_ID="STD-Jardin-1990" TOTAL_1="23" TOTAL_2="31" VAR="0.5909303412809724" WEIGHT="8.614620771278792"/>
<DICH_DATA CI_END="16.423049750251263" CI_START="1.5934821510078825" EFFECT_SIZE="5.115646258503402" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2154538084910487" LOG_CI_START="0.2023472031958836" LOG_EFFECT_SIZE="0.7089005058434662" ORDER="317" O_E="0.0" SE="0.5951038349089564" STUDY_ID="STD-Lacey-1981" TOTAL_1="49" TOTAL_2="47" VAR="0.35414857432334634" WEIGHT="12.992075195139531"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.070157599865128" CI_END="3.833508569065911" CI_START="0.914078138802075" DF="3.0" EFFECT_SIZE="1.8719311894120398" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="14" I2="40.83024164614127" ID="CMP-004.01.02" LOG_CI_END="0.583596438374536" LOG_CI_START="-0.03901667757025327" LOG_EFFECT_SIZE="0.27228988040214136" NO="2" P_CHI2="0.16673155998390798" P_Z="0.08647038443309502" STUDIES="4" TAU2="0.21803660879405004" TOTAL_1="80" TOTAL_2="82" WEIGHT="100.00000000000003" Z="1.7143177529534734">
<NAME>Trials comparing the same antibiotic in each group</NAME>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="318" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="20.17137614875789"/>
<DICH_DATA CI_END="3.95905904500969" CI_START="0.44904048097454585" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5975919788248678" LOG_CI_START="-0.34771450560826794" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="319" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Flanagan-1991" TOTAL_1="10" TOTAL_2="8" VAR="0.30833333333333335" WEIGHT="25.372329870544412"/>
<DICH_DATA CI_END="2.7683950533929873" CI_START="0.4298817985422692" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4422280645659553" LOG_CI_START="-0.3666509427871559" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="320" O_E="0.0" SE="0.47513953293487987" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.22575757575757577" WEIGHT="31.57860212728297"/>
<DICH_DATA CI_END="16.423049750251263" CI_START="1.5934821510078825" EFFECT_SIZE="5.115646258503402" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2154538084910487" LOG_CI_START="0.2023472031958836" LOG_EFFECT_SIZE="0.7089005058434662" ORDER="321" O_E="0.0" SE="0.5951038349089564" STUDY_ID="STD-Lacey-1981" TOTAL_1="49" TOTAL_2="47" VAR="0.35414857432334634" WEIGHT="22.877691853414742"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.056047911645211" CI_END="10.3689391188324" CI_START="0.6381020349603754" DF="1.0" EFFECT_SIZE="2.572244380323766" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="6" I2="67.27799992305572" ID="CMP-004.01.03" LOG_CI_END="1.0157343245273334" LOG_CI_START="-0.1951098703742349" LOG_EFFECT_SIZE="0.4103122270765491" NO="3" P_CHI2="0.08043732838260731" P_Z="0.18407082978583042" STUDIES="2" TAU2="0.681047271370126" TOTAL_1="59" TOTAL_2="55" WEIGHT="100.0" Z="1.3283248016097258">
<NAME>Hospital setting</NAME>
<DICH_DATA CI_END="3.95905904500969" CI_START="0.44904048097454585" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.5975919788248678" LOG_CI_START="-0.34771450560826794" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="322" O_E="0.0" SE="0.5552777082985894" STUDY_ID="STD-Flanagan-1991" TOTAL_1="10" TOTAL_2="8" VAR="0.30833333333333335" WEIGHT="52.58511595228042"/>
<DICH_DATA CI_END="16.423049750251263" CI_START="1.5934821510078825" EFFECT_SIZE="5.115646258503402" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="3" LOG_CI_END="1.2154538084910487" LOG_CI_START="0.2023472031958836" LOG_EFFECT_SIZE="0.7089005058434662" ORDER="323" O_E="0.0" SE="0.5951038349089564" STUDY_ID="STD-Lacey-1981" TOTAL_1="49" TOTAL_2="47" VAR="0.35414857432334634" WEIGHT="47.41488404771959"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5791746783827831" CI_END="2.857656313158783" CI_START="0.6376482226925201" DF="1.0" EFFECT_SIZE="1.3498812796508282" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.45600999552772237" LOG_CI_START="-0.19541884647810848" LOG_EFFECT_SIZE="0.1302955745248069" NO="4" P_CHI2="0.44663613462543805" P_Z="0.43301394668638626" STUDIES="2" TAU2="0.0" TOTAL_1="21" TOTAL_2="27" WEIGHT="99.99999999999999" Z="0.7840446014863135">
<NAME>Ambulatory patients</NAME>
<DICH_DATA CI_END="7.087257777399769" CI_START="0.564393186424715" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8504782291868461" LOG_CI_START="-0.24841823785888384" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="324" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Andersen-1986" TOTAL_1="10" TOTAL_2="15" VAR="0.41666666666666663" WEIGHT="38.9785209979437"/>
<DICH_DATA CI_END="2.7683950533929873" CI_START="0.4298817985422692" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.4422280645659553" LOG_CI_START="-0.3666509427871559" LOG_EFFECT_SIZE="0.037788560889399754" ORDER="325" O_E="0.0" SE="0.47513953293487987" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.22575757575757577" WEIGHT="61.02147900205629"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2156514127611735" CI_END="1.5404021700376183" CI_START="0.8198684908114013" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1238003392023646" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.18763412176236532" LOG_CI_START="-0.08625580407394492" LOG_EFFECT_SIZE="0.05068915884421019" METHOD="MH" MODIFIED="2008-05-08 11:21:16 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7813342904839057" P_Q="0.0" P_Z="0.4681661509481778" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="276" TOTAL_2="284" WEIGHT="199.99999999999997" Z="0.7254660823170084">
<NAME>Persistent UTI: long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.9981082601316096" CI_END="1.6282221768628133" CI_START="0.8001610821009237" DF="4.0" EFFECT_SIZE="1.1414201763326555" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="44" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.21171366566498084" LOG_CI_START="-0.09682257547619365" LOG_EFFECT_SIZE="0.057445545094393584" NO="1" P_CHI2="0.7361069588639841" P_Z="0.46548738503176434" STUDIES="5" TAU2="0.0" TOTAL_1="256" TOTAL_2="265" WEIGHT="100.0" Z="0.7298410004662341">
<NAME>All trials</NAME>
<DICH_DATA CI_END="2.1076971966517677" CI_START="0.36325189463469976" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.3238082178928757" LOG_CI_START="-0.43979211184824923" LOG_EFFECT_SIZE="-0.057991946977686754" ORDER="326" O_E="0.0" SE="0.4485426135725302" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="0.2011904761904762" WEIGHT="16.326013602350923"/>
<DICH_DATA CI_END="4.112396705829642" CI_START="0.5884045872786459" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6140950025929032" LOG_CI_START="-0.2303239501150769" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="327" O_E="0.0" SE="0.4960158727618966" STUDY_ID="STD-Flanagan-1991" TOTAL_1="9" TOTAL_2="7" VAR="0.24603174603174605" WEIGHT="13.350465961922449"/>
<DICH_DATA CI_END="1.9089738099007443" CI_START="0.2770732720854939" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.28079997014662067" LOG_CI_START="-0.5574053664791835" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="328" O_E="0.0" SE="0.4923659639173309" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.24242424242424238" WEIGHT="13.549133610165347"/>
<DICH_DATA CI_END="2.022362051596334" CI_START="0.748278726942704" EFFECT_SIZE="1.2301587301587302" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="24" LOG_CI_END="0.3058589074048354" LOG_CI_START="-0.1259366012993781" LOG_EFFECT_SIZE="0.08996115305272862" ORDER="329" O_E="0.0" SE="0.253638819235095" STUDY_ID="STD-Guibert-1993" TOTAL_1="189" TOTAL_2="186" VAR="0.0643326506229732" WEIGHT="51.057098054284566"/>
<DICH_DATA CI_END="7.795656103172191" CI_START="0.39947719730015485" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.8918526724429063" LOG_CI_START="-0.3985080057601291" LOG_EFFECT_SIZE="0.2466723333413885" ORDER="330" O_E="0.0" SE="0.7579642497648346" STUDY_ID="STD-Jardin-1990" TOTAL_1="17" TOTAL_2="30" VAR="0.5745098039215686" WEIGHT="5.71728877127672"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.1887008061800906" CI_END="2.2390445487522435" CI_START="0.5028849042493093" DF="1.0" EFFECT_SIZE="1.0611228503378909" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" I2="15.87454178537017" ID="CMP-004.02.02" LOG_CI_END="0.3500627345280271" LOG_CI_START="-0.29853140096611636" LOG_EFFECT_SIZE="0.025765666780955356" NO="2" P_CHI2="0.27559183500782336" P_Z="0.8762531495664503" STUDIES="2" TAU2="0.046086019402569" TOTAL_1="20" TOTAL_2="19" WEIGHT="99.99999999999997" Z="0.15572073863991504">
<NAME>Trials comparing the same antibiotic in each group</NAME>
<DICH_DATA CI_END="4.112396705829642" CI_START="0.5884045872786459" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6140950025929032" LOG_CI_START="-0.2303239501150769" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="331" O_E="0.0" SE="0.4960158727618966" STUDY_ID="STD-Flanagan-1991" TOTAL_1="9" TOTAL_2="7" VAR="0.24603174603174605" WEIGHT="49.63072378138846"/>
<DICH_DATA CI_END="1.9089738099007443" CI_START="0.2770732720854939" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.28079997014662067" LOG_CI_START="-0.5574053664791835" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="332" O_E="0.0" SE="0.4923659639173309" STUDY_ID="STD-Gellermann-1988" TOTAL_1="11" TOTAL_2="12" VAR="0.24242424242424238" WEIGHT="50.36927621861152"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006940127064486483" CI_END="5.187428596538023" CI_START="0.7041681414878702" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9112357138577152" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.7149521318227136" LOG_CI_START="-0.15232362750355652" LOG_EFFECT_SIZE="0.2813142521595785" METHOD="MH" NO="3" P_CHI2="0.9336070967135875" P_Q="0.0" P_Z="0.20355475661103262" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="212" TOTAL_2="199" WEIGHT="100.0" Z="1.2714890198220534">
<NAME>Clinical failure (persistence of symptoms): short-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.568481126012345" CI_START="0.6752390054135892" EFFECT_SIZE="1.9390862944162437" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7457367519877737" LOG_CI_START="-0.17054247848754206" LOG_EFFECT_SIZE="0.2875971367501158" ORDER="333" O_E="0.0" SE="0.5382269556365414" STUDY_ID="STD-Guibert-1993" TOTAL_1="197" TOTAL_2="191" VAR="0.2896882557737795" WEIGHT="89.58983379661552"/>
<DICH_DATA CI_END="37.259844059993256" CI_START="0.0764269502957366" EFFECT_SIZE="1.6875" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.57124103295351" LOG_CI_START="-1.116753469947385" LOG_EFFECT_SIZE="0.22724378150306254" ORDER="334" O_E="0.0" SE="1.578941276791368" STUDY_ID="STD-Matsumoto-1994" TOTAL_1="15" TOTAL_2="8" VAR="2.4930555555555554" WEIGHT="10.410166203384476"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-08 11:26:38 +1000" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="0" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (persistence of symptoms): long-term</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5423603738981617" CI_END="1.4087393861326312" CI_START="0.4544158442447838" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8000959301673382" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.1488306569608925" LOG_CI_START="-0.3425465343654441" LOG_EFFECT_SIZE="-0.09685793870227578" METHOD="MH" NO="5" P_CHI2="0.46246708179509843" P_Q="0.0" P_Z="0.43971322028604665" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="290" WEIGHT="100.0" Z="0.772677587906893">
<NAME>Adverse drug reactions</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.224499169520386" CI_START="0.047851476646507" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7180446644790353" LOG_CI_START="-1.3201046558069978" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="335" O_E="0.0" SE="1.1972189997378646" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="1.4333333333333331" WEIGHT="5.812433408906293"/>
<DICH_DATA CI_END="2.8549046903241697" CI_START="0.007238091894988489" EFFECT_SIZE="0.14375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.45559161410298366" LOG_CI_START="-2.1403759073796476" LOG_EFFECT_SIZE="-0.842392146638332" ORDER="336" O_E="0.0" SE="1.524884172365375" STUDY_ID="STD-Flanagan-1991" TOTAL_1="31" TOTAL_2="22" VAR="2.3252717391304345" WEIGHT="3.5828735250879657"/>
<DICH_DATA CI_END="1.5989478589174517" CI_START="0.48708928053212686" EFFECT_SIZE="0.8825136612021858" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.2038343017989909" LOG_CI_START="-0.31239142792560654" LOG_EFFECT_SIZE="-0.054278563063307785" ORDER="337" O_E="0.0" SE="0.30323354899880295" STUDY_ID="STD-Guibert-1993" TOTAL_1="244" TOTAL_2="238" VAR="0.09195058523840942" WEIGHT="90.60469306600575"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.8698689779204765" CI_START="0.01411854649967386" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.8959675020363438" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.4771212547196625" METHOD="MH" NO="6" P_CHI2="1.0" P_Q="0.0" P_Z="0.49584060533880536" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="305" TOTAL_2="290" WEIGHT="99.99999999999999" Z="0.6810488185180525">
<NAME>Discontinuationsdue to adverse reactions</NAME>
<GROUP_LABEL_1>Single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.8698689779204765" CI_START="0.01411854649967386" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8959675020363438" LOG_CI_START="-1.850210011475669" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="338" O_E="0.0" SE="1.613118265234886" STUDY_ID="STD-Ferraro-1990" TOTAL_1="30" TOTAL_2="30" VAR="2.6021505376344085" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="339" O_E="0.0" SE="0.0" STUDY_ID="STD-Flanagan-1991" TOTAL_1="31" TOTAL_2="22" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="340" O_E="0.0" SE="0.0" STUDY_ID="STD-Guibert-1993" TOTAL_1="244" TOTAL_2="238" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.9411410917841365" CI_END="1.2489656302562406" CI_START="0.2689120347282623" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5795359254937282" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="129" I2="48.48390958119986" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.09655048737698867" LOG_CI_START="-0.5703897611864441" LOG_EFFECT_SIZE="-0.23691963690472784" METHOD="MH" MODIFIED="2008-05-06 17:34:55 +1000" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.16354496680411257" P_Q="0.0" P_Z="0.16377393870014326" Q="0.0" RANDOM="YES" SCALE="24.269953307837905" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.19639000557288264" TOTALS="YES" TOTAL_1="276" TOTAL_2="270" WEIGHT="100.0" Z="1.3924904264325813">
<NAME>Acceptability (little or not satisfied with treatment)</NAME>
<GROUP_LABEL_1>single dose</GROUP_LABEL_1>
<GROUP_LABEL_2>3-14 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours single dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 3-14 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8762311412776923" CI_START="0.6000696871880676" EFFECT_SIZE="0.7251205050548138" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="119" LOG_CI_END="-0.057381316046307154" LOG_CI_START="-0.2217983112766595" LOG_EFFECT_SIZE="-0.13958981366148335" ORDER="341" O_E="0.0" SE="0.09657935687556143" STUDY_ID="STD-Guibert-1993" TOTAL_1="197" TOTAL_2="191" VAR="0.009327572174497055" WEIGHT="74.60667000422804"/>
<DICH_DATA CI_END="1.0491472458011475" CI_START="0.0857839548835439" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.020836444867742415" LOG_CI_START="-1.0665939354284175" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="342" O_E="0.0" SE="0.6387619882531606" STUDY_ID="STD-Guibert-1996" TOTAL_1="79" TOTAL_2="79" VAR="0.4080168776371308" WEIGHT="25.393329995771968"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-05-06 17:35:33 +1000" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>3 days versus 5 days</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 17:35:25 +1000" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Persistent UTI: short term (3 days after treatment)</NAME>
<GROUP_LABEL_1>3 days</GROUP_LABEL_1>
<GROUP_LABEL_2>5 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.270075778187493" CI_START="0.8960611759696125" EFFECT_SIZE="2.7222222222222223" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.9175094889839736" LOG_CI_START="-0.04766233913355835" LOG_EFFECT_SIZE="0.4349235749252076" ORDER="343" O_E="0.0" SE="0.5669467095138409" STUDY_ID="STD-van-Merode-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.3214285714285714" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-05-06 17:35:33 +1000" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="12" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>Clinical failure (not recovered): short term (3 days after treatment)</NAME>
<GROUP_LABEL_1>3 days</GROUP_LABEL_1>
<GROUP_LABEL_2>5 days</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 3 days</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 5 days</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.74198727314598" CI_START="0.28703390218255653" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6759603840559419" LOG_CI_START="-0.5420668047947156" LOG_EFFECT_SIZE="0.06694678963061322" ORDER="344" O_E="0.0" SE="0.7154752000627009" STUDY_ID="STD-van-Merode-2005" TOTAL_1="12" TOTAL_2="14" VAR="0.5119047619047619" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-05-09 10:31:37 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-05-09 10:31:37 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-05-07 13:13:29 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-09 10:31:37 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database searched</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>1. elderly<BR/>2. explode "AGED"/ all subheadings<BR/>3. explode "AGED, 80 AND OVER"/ all subheadings<BR/>4. old*<BR/>5. geriatric*<BR/>6. nursing home<BR/>7. #1 or #2 or #3 or #4 or #5 or #6<BR/>8. urinary tract infection*<BR/>9. explode "URINARY TRACT INFECTIONS"/ all subheadings<BR/>10. cystitis<BR/>11. explode "CYSTITIS"/ all subheadings<BR/>12. UTI<BR/>13. bacteriuria<BR/>14. explode "BACTERIURIA"/ all subheadings<BR/>15. #8 or #9 or #10 or #11 or #12 or #13 or #14<BR/>16. explode "ANTI-INFECTIVE AGENTS" / all subheadings<BR/>17. explode "ANTIBIOTICS"/ all subheadings<BR/>18. antibiotic*<BR/>19. #16 or #17 or #18<BR/>20. #7 and #15 and #19</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>1. RANDOMIZED ADJ CONTROLLED ADJ TRIAL$1<BR/>2. RANDOM ADJ ALLOCAT$5<BR/>3. (SINGL$ DOUBL$ TREBL$ TRIPL$) WITH (BLIND$4 MASK$4)<BR/>4. PLACEBO$1.TI,DE,AB.<BR/>5. 1 2 3 4<BR/>6. ELDERLY AGED# AGED GERIATRIC$ OLD<BR/>7. NURSING WITH HOME<BR/>8. 5 AND (6 7)<BR/>9. URINARY-TRACT-INFECTION#<BR/>10URINARY WITH INFECTION$1<BR/>11 CYSTITIS<BR/>12. BACTERIURIA<BR/>13. 8 AND (9 10 11 12)<BR/>14. ANTI ADJ INFECTI$5<BR/>15. ANTIBIOTIC$4<BR/>16. 13 AND (14 15)</P>
</TD>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1. AGED<BR/>#2. elderly<BR/>#3. old*<BR/>#4. geriatric<BR/>#5. GERIATRICS<BR/>#6. NURSING HOMES<BR/>#7. HOMES FOR THE AGED<BR/>#8. (#1 or #2 or #3 or #4 or #5 or #6 or #7)<BR/>#9. URINARY TRACT INFECTIONS<BR/>#10. (urinary next tract next infection*)<BR/>#11. uti*<BR/>#12. CYSTITIS<BR/>#13. cystitis<BR/>#14. BACTERIURIA<BR/>#15. bacteriuria<BR/>#16. (#9 or #10 or #11 or #12 or #13 or #14 or #15)<BR/>#17. ANTI-INFECTIVE AGENTS<BR/>#18. anti-infective*<BR/>#19. antibiotic*<BR/>#20. (#17 or #18 or #19)<BR/>#21. (#8 and #16 and #20)<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-05-09 10:31:37 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-05-07 13:17:58 +1000" MODIFIED_BY="Narelle S Willis">Results of initial literature search</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-09 10:31:37 +1000" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="18">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>System</P>
</TH>
<TH>
<P>Identified reference</P>
</TH>
<TH>
<P>Included references</P>
</TH>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>Knowledge Finder</P>
</TD>
<TD>
<P>2923</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>Ovid</P>
</TD>
<TD>
<P>4115</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>Grateful Med</P>
</TD>
<TD>
<P>5533</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>PubMed</P>
</TD>
<TD>
<P>3098</P>
</TD>
<TD>
<P>10</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
</TD>
<TD>
<P>Datastar</P>
</TD>
<TD>
<P>110</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE Geriatrics</P>
</TD>
<TD>
<P>1989-99</P>
</TD>
<TD>
<P>219</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Gerolit</P>
</TD>
<TD>
<P>DIMDI</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Healthstar</P>
</TD>
<TD>
<P>DIMDI</P>
</TD>
<TD>
<P>1128</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Bioethics Line</P>
</TD>
<TD>
<P>DIMDI</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Popline</P>
</TD>
<TD>
<P>GratefulMed</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Cochrane CCRT</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>377</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>ISTP 1978-95 (Index to Scientific &amp; Technical Proceedings)</P>
</TD>
<TD>
<P>Printed index</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>DAI 1991-1995 (Dissertation abstracts international)</P>
</TD>
<TD>
<P>Printed index</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Authors and investigators</P>
</TD>
<TD>
<P>13 were contacted by letter or e-mail, 6 responded</P>
</TD>
<TD>
<P>17</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>Pharmaceutical companies</P>
</TD>
<TD>
<P>17 were contacted by letter of e-mail, 5 responded</P>
</TD>
<TD>
<P>106</P>
</TD>
<TD>
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>References</P>
</TD>
<TD>
<P>Trial articles</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>References</P>
</TD>
<TD>
<P>Review articles</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>3</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-05-07 13:57:53 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<TITLE MODIFIED="2008-05-07 13:33:55 +1000" MODIFIED_BY="Narelle S Willis">Inter-individual variability of study selection</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-07 13:53:10 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="4" ROWS="4">
<TR>
<TH>
<P>Abstract/articles</P>
</TH>
<TH>
<P>Total number</P>
</TH>
<TH>
<P>% of screened record</P>
</TH>
<TH>
<P>Different selections</P>
</TH>
</TR>
<TR>
<TD>
<P>Abstracts</P>
</TD>
<TD>
<P>262</P>
</TD>
<TD>
<P>ca. 5%</P>
</TD>
<TD>
<P>17 (6.5%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Articles</P>
</TD>
<TD>
<P>166</P>
</TD>
<TD>
<P>79%</P>
</TD>
<TD>
<P>10 (6.1%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Total</P>
</TD>
<TD>
<P>427</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>27 (6.3%)</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-05-07 17:09:31 +1000" MODIFIED_BY="Narelle S Willis" NO="4">
<TITLE MODIFIED="2008-05-07 13:26:44 +1000" MODIFIED_BY="Narelle S Willis">Sources of included studies</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-07 17:09:31 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="7" ROWS="16">
<TR>
<TH>
<P>Trials</P>
</TH>
<TH>
<P>MEDLINE</P>
</TH>
<TH>
<P>EMBASE</P>
</TH>
<TH>
<P>Industry</P>
</TH>
<TH>
<P>Theses</P>
</TH>
<TH>
<P>References - reviews</P>
</TH>
<TH>
<P>References - trials</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>+</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-05-07 17:18:57 +1000" MODIFIED_BY="Narelle S Willis" NO="5">
<TITLE MODIFIED="2008-05-07 13:23:15 +1000" MODIFIED_BY="Narelle S Willis">Quality of included studies</TITLE>
<APPENDIX_BODY MODIFIED="2008-05-07 17:18:57 +1000" MODIFIED_BY="Narelle S Willis">
<TABLE COLS="10" ROWS="16">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Allocation concealment</P>
</TH>
<TH>
<P>Blinding</P>
</TH>
<TH>
<P>Randomization method</P>
</TH>
<TH>
<P>Baseline characteristics</P>
</TH>
<TH>
<P>Power calculation</P>
</TH>
<TH>
<P>Sample size (old pt)</P>
</TH>
<TH>
<P>Excluded patients</P>
</TH>
<TH>
<P>Intention to treat</P>
</TH>
<TH>
<P>Overall quality</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Andersen-1986" TYPE="STUDY">Andersen 1986</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>Double</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Yes ?</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>287</P>
</TD>
<TD>
<P>23, not described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ferraro-1990" TYPE="STUDY">Ferraro 1990</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>60</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Flanagan-1991" TYPE="STUDY">Flanagan 1991</LINK>
</P>
</TD>
<TD>
<P>C (open lists)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Yes (random lists)</P>
</TD>
<TD>
<P>Yes, difference in mean number of drugs</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>81</P>
</TD>
<TD>
<P>30, reason described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gellermann-1988" TYPE="STUDY">Gellermann 1988</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Yes (random list)</P>
</TD>
<TD>
<P>Yes (in detail), no difference</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>90</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>Yes (2 analyses)</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guibert-1993" TYPE="STUDY">Guibert 1993</LINK>
</P>
</TD>
<TD>
<P>B (NS)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Yes (random number table)</P>
</TD>
<TD>
<P>Yes, no difference</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>482</P>
</TD>
<TD>
<P>94 / 110, reasons described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guibert-1996" TYPE="STUDY">Guibert 1996</LINK>
</P>
</TD>
<TD>
<P>A (telephone)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Yes, no difference</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>595</P>
</TD>
<TD>
<P>213 /219, reasons described</P>
</TD>
<TD>
<P>No (efficacy), yes (ADRs)</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guibert-1997" TYPE="STUDY">Guibert 1997</LINK>
</P>
</TD>
<TD>
<P>A (telephone)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Yes, no difference</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>421</P>
</TD>
<TD>
<P>81, reasons described</P>
</TD>
<TD>
<P>No (efficacy), yes (ADRs)</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jardin-1990" TYPE="STUDY">Jardin 1990</LINK>
</P>
</TD>
<TD>
<P>B (NS)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Yes, difference in biochemical parameters</P>
</TD>
<TD>
<P>Yes (200)</P>
</TD>
<TD>
<P>386</P>
</TD>
<TD>
<P>90, reasons only partially described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lacey-1981" TYPE="STUDY">Lacey 1981</LINK>
</P>
</TD>
<TD>
<P>B (NS)</P>
</TD>
<TD>
<P>Single (outcome assessment)</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Yes, no difference</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>100</P>
</TD>
<TD>
<P>4, reasons described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Matsumoto-1994" TYPE="STUDY">Matsumoto 1994</LINK>
</P>
</TD>
<TD>
<P>B (NS)</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Piipo-1990" TYPE="STUDY">Piipo 1990</LINK>
</P>
</TD>
<TD>
<P>A (numbered boxes)</P>
</TD>
<TD>
<P>Double</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>400</P>
</TD>
<TD>
<P>73, reasons described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Raz-1996" TYPE="STUDY">Raz 1996</LINK>
</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>NS</P>
</TD>
<TD>
<P>Yes (difference ?)</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>223</P>
</TD>
<TD>
<P>27, reasons described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Stein-1992" TYPE="STUDY">Stein 1992</LINK>
</P>
</TD>
<TD>
<P>A (numbered boxes)</P>
</TD>
<TD>
<P>Double</P>
</TD>
<TD>
<P>Yes (computer random number generator)</P>
</TD>
<TD>
<P>Yes (difference ?)</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>404</P>
</TD>
<TD>
<P>184, reasons described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-van-Merode-2005" TYPE="STUDY">van Merode 2005</LINK>
</P>
</TD>
<TD>
<P>B (not specified envelopes)</P>
</TD>
<TD>
<P>Single (Physician)</P>
</TD>
<TD>
<P>Yes (computer generated)</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>26</P>
</TD>
<TD>
<P>205/324 (all patients), reasons described</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>C</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Vogel-2004" TYPE="STUDY">Vogel 2004</LINK>
</P>
</TD>
<TD>
<P>A (numbered sealed envelopes)</P>
</TD>
<TD>
<P>Double</P>
</TD>
<TD>
<P>Yes (computer generated randomization list, stratified by hospital laboratories)</P>
</TD>
<TD>
<P>Yes (only significant difference for suprapubic pain)</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>183</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>